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Abstract
Background & Introduction: Heart transplantation is the most effective treat-
ment for end-stage heart failure (HF) but is hindered due to an inadequate
availability of donor organs. Left ventricular assist devices (LVADs) have been
shown to be a suitable alternative and primarily used as a ‘bridge to transplan-
tation’ wherein the failing heart can be supported by mechanical circulatory
assistance until a suitable donor organ becomes available. In 4-9% of patients,
the LVAD also acts as ‘bridge to recovery’, since it induces substantial func-
tional improvement that allows LVAD explantation, without the need of trans-
plantation. The rate for explantation of the LVAD remains low and the func-
tional improvement observed, a transient phenomenon. LVADs cause mechan-
ical unloading, which produces functional, structural, signalling and molecular
changes in HF. Development of myocardial unloading-induced atrophy, time-
dependent myocyte contractile dysfunction and excitation-contraction (EC)
coupling changes may have detrimental consequences.
However, when mechanical unloading is combined with pharmacological ther-
apy, including the β2-AR agonist clenbuterol, an improved ‘bridge to recov-
ery’ rate of 75% can be achieved. The effects of clenbuterol on functional,
structural, signalling and molecular changes in a normal and failing hearts,
during mechanical unloading, are unknown. This thesis investigates some of
the key effects of mechanical unloading and β2-AR agonist stimulation with
clenbuterol for HF treatment, based on the following hypotheses which have
been individually addressed in Chapters 3, 4 and 5 respectively.
• Chronic administration of clenbuterol alters myocardial structure and
function and affects calcium handling in normal rat hearts.
• Mechanical left ventricular unloading and the consequent left ventricu-
lar atrophy results in altered whole-heart and cellular function in non-
failing/normal rat hearts.
• Clenbuterol treatment during mechanical unloading of a normal rat heart
normalises whole-heart and cellular function.
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• Clenbuterol has an additional benefit when combined with mechanical
unloading in the treatment of failing rat hearts.
Methods: Clenbuterol was administered by osmotic minipumps. Mechanical un-
loading was achieved by heterotopic abdominal heart transplantation. Heart
failure was induced by left coronary artery ligation in rats. In-vivo whole heart
function was assessed by echocardiography and ex-vivo function by pressure-
volume relationship. Only LV myocytes were isolated and studied using op-
tical, fluorescence and electrophysiological techniques. Calcium handling pro-
tein expression was assessed by Western blotting. Theory and methodology
of the single-cell studies is outlined, together with validation experiments and
the necessary assumptions.
Results: Data obtained and their interpretations are presented in three chapters
according to the proposed hypotheses. The results show that clenbuterol with,
without mechanical unloading, or on its own can affect both whole-heart and
cellular function in normal hearts. The treatment of failing hearts with clen-
buterol, alone or in combination with mechanical unloading, improves LV func-
tion at whole-heart and cellular level by effects on cell morphology, EC coupling
and myofilament sensitivity to calcium. The details of individual experiments
and their interpretation are discussed in the respective chapter.
General Discussion: This thesis supports the use of clenbuterol in the strategy to
improve recovery in HF patients treated with LVADs and also begins to eluci-
date some of the possible cellular mechanisms responsible for the improvement
in LV function. The questions remaining unanswered are discussed and possi-
ble future experiments that could be performed to address them are described.
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Glossary of Abbreviations
ANOVA analysis of variance
ANP atrial natriuretic peptide
AP action potential
APD action potential duration
APD50 action potential duration at 50% repolarisation
APD90 action potential duration at 90% repolarisation
AR adrenoceptor
BNP brain/B-type natriuretic peptide
bpm beats per minute
BTR Bridge to Recovery
BTT Bridge to Transplantation
Ca2+ calcium
[Ca2+] calcium concentration
[Ca2+]i intracellular calcium concentration
∆[Ca2+]i change in intracellular calcium concentration
[Ca2+]o extracellular calcium concentration
CICR calcium induced calcium release
DCM dilated cardiomyopathy
DTT dithiothreitol
EC Coupling excitation-contraction coupling
ECG Electrocardiography
ECL enhanced chemiluminescence
EGTA ethylene glycol bis(2-aminoethyl ether)-N,N,N’N’ -tetraacetic acid
ESHF end-stage heart failure
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FBS fœtal bovine serum
g grammes
g gravity
G gauge
GFP green fluorescent protein
GPCR G-protein coupled receptor
HEPES N -2-hydroxyethylpiperazine-N’ -2-ethansulphonic acid
HRP horseradish peroxidase
I Ca,L L-type calcium current
INCX sodium-calcium exchanger current
INa,K sodium-potassium pump current
IGF-1 insulin-like growth factor-1
ICM ischæmic cardiomyopathy
IU International Units
IVC inferior vena cava
LCA left coronary artery
LDS buffer lithium dodecyl sulfate buffer
LVAD left ventricular assist device
LVEF left ventricular ejection fraction
LV left ventricle
L/W myocyte length/width ratio
MHC myosin heavy chain
MLC myosin light chain
[Na+]i intracellular sodium concentration
Na+/K+ ATPase sodium-potassium ATPase pump
NCX sodium-calcium exchange
NHE sodium-hydrogen exchange
PC personal computer
PCR polymerase chain reaction
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PI3-K phosphoinositide-3 kinase
PKA protein kinase-A
PKC protein kinase-C
PVDF polyvinylidene difluoride
RyR ryanodine receptor
S.E.M standard error of mean
SDS sodium dodecyl sulphate
SERCA sarcoplasmic & endoplasmic reticulum calcium ATPase
SR sarcoplasmic reticulum
SVC superior vena cava
TBS Tris-buffered saline
TBS-T Tris-buffered saline with 0.05% Tween 20
Tn-C Troponin-C
Tn-I Troponin-I
Tn-T Troponin-T
VPB ventricular premature beats
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Chapter 1
Introduction
1.1 Heart failure
“A state in which the heart fails to maintain an adequate circulation for the needs
of the body despite a satisfactory filling pressure” – Paul Wood (1950)
“A pathophysiological state in which an abnormality of cardiac function is re-
sponsible for the failure of the heart to pump blood at a rate commensurate with the
requirements of the metabolizing tissues.” – Eugene Braunwald (1980)
“The traditional view that heart failure is a constellation of signs and symptoms
caused by inadequate performance of the heart focuses on only one aspect of the
pathophysiology involved in the syndrome. Currently, a complex blend of structural,
functional, and biologic alterations are evoked to account for the progressive nature
of heart failure and to explain the efficacy or failure of therapies used in clinical
trials.’ – Jessup & Brozena (2003)
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1.1.1 Epidemiology
Heart failure is a serious health problem and increasingly more common in both
men and women (Cowie et al. 1999; Eriksson 1995; Cowie et al. 1997). Risk factors
for the development of heart failure are broadly similar to those for coronary heart
disease (Eriksson et al. 1989; Ho et al. 1993b; Chen et al. 1999). Data from the
Framingham Heart Study, USA (McKee et al. 1971) which was established in 1948
indicates that the lifetime risk for developing heart failure is presently a striking
1 in 5 for both men and women (Lloyd-Jones et al. 2004). Despite current medical
management, long-term survival is poor. About one third of patients diagnosed with
heart failure will die within the first year and approximately half will not survive
for 5 years (Levy et al. 2002). The prognosis for congestive heart failure has been
found to correlate closely with decreasing left ventricular ejection fraction, and is
poor in the end stages of the disease (McKee et al. 1971; Ho et al. 1993a).
In the United Kingdom, the incidence rate of heart failure ranges from 1-5 cases
per 1000 person-years (Cowie et al. 1997). The incidence increases steeply with age
(Kannel 1996). For those aged >75 years the incidence rate has been reported to
be as high as 40 per 1000 person-years (Cowie et al. 1997). At least 24,000 people
die from the disease annually (Cowie et al. 2000). About 2% of the National Health
Service budget is spent on management of heart failure, and it also accounts for
5% of admissions to general medical and geriatric wards in British hospitals (Davis
et al. 2000).
Coronary heart disease has been shown to be the most frequent underlying cause
of heart failure ranging from 32-45%, followed by hypertension (6-18%), valve disease
(9-19%), and cor pulmonale (4-7%) (Cowie et al. 1999; Parameshwar et al. 1992a,b;
Mair et al. 1996). In addition to these factors, there are numerous other pathologies
that are recognized as causes of heart failure and are summarized in Table 1.1.
Also in many patients these causative factors often co-exist.
Cardiomyopathies are disorders affecting the heart muscle that frequently re-
sult in congestive heart failure. Dilated cardiomyopathy (DCM) is the most fre-
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quent form of primary myocardial diseases and one common cause of heart failure.
Myocarditis, immunological abnormalities, toxic myocardial damage, and genetic
factors are all assumed to be causes. Familial occurrence of DCM, mostly as an au-
tosomal dominant trait, is more common than generally believed and is responsible
for 20-30% of all cases of DCM (Osterziel et al. 2005).
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Table 1.1: The causes of heart failure
Ischæmic heart disease
Hypertension
Rheumatic heart disease
Valvular heart diease
Arrhythmias
Excessive consumption of alcohol
Connective tissue disorders (SLE, scleroderma)
Structural abnormalities within the heart (septal defects)
Cardiomyopathies
• Familial dilated
• Familial hypertrophic
• Restrictive (amyloidosis, sarcoidosis)
• Right ventricular
• Obstructive
• Non-classifiable
Infection
• Viral (coxsackie B, cytomegalovirus, HIV)
• Rickettsia
• Bacteria (diphtheria)
• Mycobacteria
• Fungus
• Parasites (Chagas’ disease, toxoplasmosis)
Muscular dystrophy
Cardiotoxic drugs (adriamycin, doxorubicin)
Endocrine disease (myxœdema, thyrotoxicosis, acromegaly)
Idiopathic
List compiled from Oakley (1997), Cowie et al. (1999), Lip et al. (2000), Jessup & Brozena (2003).
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1.1.2 Clinical manifestations of heart failure
The term heart failure is a clinical diagnosis of a functional state in which cardiac
output is unable to meet the needs of the peripheral organs’ blood flow. It is usually
accompanied by numerous compensatory mechanisms to meet these demands and
maitain homeostasis (Remes et al. 1991).
The pattern of symptoms due to heart failure depends on the side of the heart
affected (Braunwald 2004). Reduced left ventricular performance results in stagna-
tion of blood in the lungs, leading to worsening shortness of breath (dyspnœa) and
fatigue. In comparison, symptoms of right-sided heart failure are due to systemic
venous congestion and include peripheral œdema, ascites, and sequelæ of congestive
liver failure. It is common for patients to have deteriorating function on both sides
of the heart, either because of shared underlying pathology, or because failure of
one side of the heart can impose a mechanical burden on the other, hence termed
as congestive cardiac failure (Braunwald 2004).
The clinical features of heart failure are progressive (Pfeffer & Braunwald 1990),
and in its advanced stages can be extremely debilitating. About one third of pa-
tients suffer from dyspnœa and fatigue of such severity that exercise tolerance is
limited to walking only a few yards. Patients may end up severely dyspnœic even
at rest, and find that they cannot maintain a supine position (orthopnœa) and may
even wake from sleep with breathlessness (paroxysmal nocturnal dyspnœa) due to
orthostatic increase in venous return to the failing heart. Other symptoms of heart
failure include lack of appetite and weight loss, nocturia, impaired cognition, and
an increased susceptibility to chest infections. The symptoms lead to a poor overall
quality of life, when compared to other chronic diseases (Hobbs et al. 2002).
1.1.3 Diastolic & systolic heart failure
Diastolic heart failure and systolic heart failure are distinct subtypes of the clinical
condition of chronic heart failure with characteristic morphological and functional
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changes (Chatterjee & Massie 2007). However the signs, symptoms, neurohormonal
abnormalities, prognosis and rates of hospitalization appear to be similar (Senni &
Redfield 2001; Jessup & Brozena 2003). The differences in stimuli and signalling
pathways underlying their pathogenesis are unclear.
Fig. 1.1: Key morphological difference of the left ventricle in a normal and failing heart
due to diastolic (usually normal or hypertrophied) and systolic heart failure (dilated). Figure
reproduced from Jessup & Brozena (2003).
In diastolic heart failure the left ventricle is non-dilated, usually normal or hy-
pertrophied (Fig 1.1). The systolic function and ejection fraction are preserved.
Diastolic heart failure accounts for 20-50% of patients with heart failure (Jessup &
Brozena 2003). Cardiac output, especially during exercise, is limited by the abnor-
mally low ventricular compliance and relaxation leading to pulmonary congestion,
dyspnœa, and peripheral œdema, identical to those seen in patients with a dilated,
poorly contracting heart (Banerjee et al. 2002; Brutsaert & Sys 1997; Vasan & Levy
2000).
In contrast, the LV is dilated and ejection fraction reduced (<40%) in systolic
heart failure. Impaired contractile function and increased wall stress are the prin-
cipal functional derangements, and are the major mechanisms for reduced ejection
fraction (Aurigemma et al. 2006; Aurigemma & Gaasch 2004).
The major functional and morphological features of systolic heart failure are
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summarized in Table 1.2.
Table 1.2: Major functional and morphologic features of remodelling in systolic heart failure.
Table reproduced from Chatterjee & Rame (2008).
Reduced ejection fraction
Altered ventricular shape and geometry
Disproportionate increase in ventricular cavity size
Usually eccentric hypertrophy
Increased ventricular mass
Cavity-mass ratio increased
Wall thickness - decreased or unchanged
Increased wall stress
Frequent mechanical dyssynchrony with or with-
out electrical dyssynchrony
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1.2 Ventricular remodelling in heart failure
The adaptability of the heart, termed cardiac plasticity,1 is increasingly being stud-
ied as it may offer new therapeutic options for heart failure treatment. The heart is
capable of ‘physiological’ and ‘pathological’ growth (see Page 32) in response to ap-
propriate stimuli, as well as undergo ‘atrophy’ (see Section 1.6, Page 82) in response
to ventricular unloading.
The process of ‘ventricular remodelling’ refers to the changes in size, shape, and
function of the heart after injury to the left ventricle and the most obvious and
constant feature observed is the increase in LV dimensions and cardiomyocyte size
(hence the name ‘remodelling’). In medical terms, ‘ventricular remodelling’ implies
a decline in function (even though the word ‘remodelling’ usually implies improve-
ment). The current concept of ‘remodelling’ is a complex series of anatomical, func-
tional, cellular and molecular changes that the myocardium undergœs in response
to injury (Jessup & Brozena 2003; Sutton & Sharpe 2000), involving numerous lo-
cal and systemic pathophysiological mechanisms (Braunwald & Pfeffer 1991). Some
of the key mechanisms are summarized in Table 1.3. The injury is typically due
to acute myocardial infarction (usually transmural), but may be from a number of
causes that result in increased pressure or volume overload on the heart. Cardiac
remodelling is a major determinant of the clinical course of heart failure, irrespective
of ætiology (Udelson & Konstam 2002).
The tissue necrosis and inflammation that occurs during the first few hours of a
myocardial infarction is followed by a phase of scar formation that is completed over
several weeks. During the period of resorption of necrotic tissue, but before there
has been extensive deposition of collagen, the transient decrease in tensile strength
can result in the infarcted region becoming thinner and longer. This phenomenon
is called infarct expansion (Hutchins & Bulkley 1978; Jugdutt & Michorowski 1987)
and is not accompanied by additional cardiomyocyte death (Fig 1.2). This phe-
1ability of the heart to undergo structural changes (‘grow’ or ‘shrink’) in response to environ-
mental demands and a variety of stimuli
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Fig. 1.2: Ventricular remodelling after acute infarction. Schematic showing infarct expansion
(middle) and progression to global left ventricular remodelling (right). Figure reproduced from
Jessup & Brozena (2003).
nomenon directly increases LV dimensions over a period of hours to days. In addition
to infarct expansion, the non-infarcted region also undergœs gradual lengthening,
even at sites remote to the infarcted area, over a period of weeks to months (Fig 1.2)
(Erlebacher et al. 1982, 1984). These two changes both contribute towards LV di-
lation, and can initially enable the LV to maintain a normal stroke volume despite
a decreased ejection fraction (Pfeffer & Braunwald 1990). However, this dilation
substantially increases the LV wall stress throughout the cardiac cycle (by the Law
of LaPlace), which then stimulates further ventricular enlargement. A vicious cycle
can be entered in which initial dilatation promotes further dilatation. The ventricle
also often becomes more spherical in its shape as it dilates (Fig 1.1 & 1.2).
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Table 1.3: Pathophysiological mechanisms important in the syndrome of heart failure. (Table reproduced from Jessup & Brozena (2003).)
Cardiac abnormalities Biologically active tissue and circulating substances Other factors
Structural abnormalities Renin-angiotensin-aldosterone system Genetic background
Myocardium or myocyte Sympathetic nervous system (norepinephrine) Effects of sex
• Abnormal EC coupling Vasodilators (bradykinin, nitric oxide, and prostaglandins) Age
• β-AR desensitization Natriuretic peptides Alcohol, tobacco, toxic drugs
• Hypertrophy Cytokines (endothelin, TNF, interleukins) Coexisting conditions
• Fibrosis Vasopressin Diabetes mellitus
• Apoptosis Matrix metalloproteinases Hypertension
Left ventricular chamber Renal disease
remodelling Coronary artery disease
• Dilatation Anæmia
• Increased sphericity Obesity
• Aneurysmal dilatation or wall thinning Sleep apnœa
Coronary artery obstruction/inflammation Depression
Functional abnormalities
Mitral regurgitation
Hibernating myocardium
Induced atrial and ventricular arrhythmias
Altered ventricular interaction
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Ventricular structure and contractile function are known to be coupled in the normal
and failing hearts. This relationship is often reflected at the cellular level by changes
in size and shape of the individual myocytes (Spotnitz 2000). The key mechanisms
and changes underlying the ventricular remodelling process, based on the principal
components of the myocardium, are described below.
• Changes involving cardiomyocytes, which make up one third of the total cell
number but account for 70∼80% of the heart’s mass (Zak 1984)
• Changes involving non-cardiomyocytes and extra-cellular matrix.
1.2.1 Changes involving cardiomyocytes
Cardiomyocyte morphology: Data from many mammalian species suggests that
myocyte length/width ratio (L/W) is normally regulated within a rather nar-
row range (approximately 7-9:1) (Gerdes 2002). Myocyte L/W declines slightly
in concentric hypertrophy and remains normal during volume overloading due
to proportional myocyte growth (Gerdes 2002).
In ischæmic and dilated cardiomyopathy, L/W increases (Gerdes et al. 1992;
Zafeiridis et al. 1998). Cardiomyocytes change their phenotype with marked
enlargement in their size which is more pronounced in the long axis as com-
pared to the width or depth (Onodera et al. 1998; Gerdes et al. 1996, 1992).
With hypertrophy and failure, the pattern of sarcomere formation and re-
organization has important effects on cell shape and morphology (Gerdes &
Capasso 1995; Gerdes 2002). Transverse growth of myocytes due to parallel
addition of myofibrils is thought to be responsible for changes in wall thick-
ness, while lengthening of myocytes by the series addition of sarcomeres is seen
as an increase in the longitudinal and transverse diameters of the ventricular
chamber (Gerdes & Capasso 1995).
Whether left ventricular hypertrophy is adaptive or maladaptive is contro-
versial. It is currently thought that maladaptive myocyte growth may be an
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important cellular event leading to elevated wall stress and pump failure or a
response to counterbalance the increase in wall stress (Gerdes 2002; Zak 1984).
Pathological vs Physiological cardiac hypertrophy: Cardiac hypertrophy, usu-
ally considered a poor prognostic sign (McKee et al. 1971; The Framingham
Study), is associated with nearly all forms of heart failure (Levy et al. 1990)
and coronary artery disease (Levy et al. 1989). However, the striking excep-
tions to the association between cardiac enlargement and incidence of heart
failure are the athlete’s heart (Pluim et al. 2000; Fagard 1997) and ventricu-
lar hypertrophy in pregnancy (Duvekot & Peeters 1994; Moll 2001). Despite
morphological differences based on strength-training compared to endurance-
training of the athletes, overall the systolic and diastolic cardiac function are
normal or even enhanced (Pluim et al. 2000; Fagard 1997). During pregnancy
there is a temporary dilatation of the left ventricle with cardiomyocyte hyper-
trophy and increased contractility, which are normalized postpartum (Duvekot
& Peeters 1994). Based on the above observations it is apparent that in adult,
the growth of the heart is usually closely matched to its functional load and un-
der normal circumstances, mainly compensatory in nature. Therefore cardiac
hypertrophic response can broadly be classified as either physiological or patho-
logical variants and some key differences have been proposed by McMullen &
Jennings (2007), shown in Table 1.4.
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Table 1.4: Differences between pathological and physiological forms of cardiac hypertrophy. Table modified from McMullen & Jennings (2007).
Pathological hypertrophy Physiological hypertrophy
Stimuli Usually chronic Usually transient
Pressure overload (e.g. hypertension, aortic coarc-
tion); Volume load (valvular disease); Cardiomyopa-
thy (familial, viral, toxic, metabolic)
Regular physical activity or chronic exercise training;
Volume load (running, walking, swimming); Pressure
load (strength training, weight lifting)
Cardiac morphology Increased myocyte volume Increased myocyte volume
Formation of new sarcomeres Formation of new sarcomeres
Interstitial fibrosis
Myocyte necrosis and apoptosis
Fœtal gene expression Usually upregulated* Relatively normal*
Cardiac function Depressed over time Normal or enhanced
Completely reversible Not usually Usually
Association with heart failure and in-
creased mortality
Yes No
*Biological significance not clear.
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Fig. 1.3: Current concept of distinct signalling pathways involved in the induction of
pathological and physiological cardiac hypertrophy. Figure reproduced from McMullen
& Jennings (2007). (Abbreviations used: RTK, receptor tyrosine kinase; mTOR, mam-
malian target of rapamycin; NA, noradrenaline; PLC, phospholipase C; DAG, diacyl-
glycerol; IP3, inositol 1,4,5-trisphosphate; MAPK, mitogen activated protein kinase;
JNK, c-jun amino-terminal kinase; PKC, protein kinase C; PI3-K, phosphoinositide-3
kinase; ERK, extracellular signal regulated kinase; AngII, angiotensin II; ET-1, en-
dothelin 1; GPCR, G-protein coupled receptor; NFAT, nuclear factor of activated T
cells; IGF1, insulin-like growth factor 1; S6Ks, ribosomal S6 kinases.)
Pathological (eg. produced by aortic banding) and physiological (eg. pro-
duced by chronic swim-training) cardiac hypertrophy in rodents is associated
with distinct histological and molecular features (Kaplan et al. 1994; Iemitsu
et al. 2001; McMullen et al. 2003). Until recently, it was unclear whether
these two forms of cardiac hypertrophy are induced by distinct molecular sig-
nalling pathways. Using transgenic and gene-knockout techniques in combi-
nation with surgical and exercise models of hypertrophy, distinct signalling
cascades that play a role in regulating physiological (insulin-like growth fac-
tor (IGF) 1–phosphoinositide-3 kinase (PI3-K; isoform p110α) and patholog-
ical (Gαq) cardiac hypertrophy have been proposed by McMullen & Jennings
(2007) (Fig 1.3).
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Cardiomyocyte excitation-contraction (EC) coupling: In normal cardiomy-
ocyte, the action potential triggers Ca2+ entry into the cell through depolarization-
activated Ca2+ channels as inward Ca2+ current (I Ca) (Fig 1.4). This Ca
2+
entry leads to Ca2+-induced Ca2+-release (CICR) from the sarcoplasmic retic-
ulum (SR) (Fabiato 1983). The combination of Ca2+ influx and release raises
the cytoplasmic Ca2+ concentration ([Ca2+]), allowing Ca2+ to bind to the my-
ofilament protein troponin-C (Tn-C), which then switches on the contractile
machinery. For relaxation to occur cytoplasmic [Ca2+] must decline, allowing
Ca2+ to dissociate from Tn-C. This requires Ca2+ transport out of the cy-
tosol by four pathways involving SERCA, sarcolemmal Na+/Ca2+ exchanger
(NCX), sarcolemmal Ca2+–ATPase or mitochondrial Ca2+ uniporter. The
SERCA and NCX are the major contributors to Ca2+ extrusion from the cell
in most mammalian species, including humans (Bers 2001). The waveform de-
scribing the rise and fall of cytoplasmic [Ca2+] with each heartbeat is termed
the Ca2+ transient. The interplay between the numerous mechanisms involved
in regulating the fine balance between [Ca2+]i homeostasis and contractile ap-
paratus is complex and perturbation (due to disease states) can lead to altered
regulation (Bers 2001, 2002).
During the last few decades, there has been an accumulation of substantial
evidence that altered cardiomyocyte EC coupling is of significant relevance
for the pathophysiology of heart failure. Study of cardiomyocytes from failing
hearts isolated from humans (Beuckelmann et al. 1992) as well as numerous
animal models of heart failure (Hasenfuss 1998a) indicate that the intrinsic
contractile ability of individual cardiomyocytes is impaired during the heart
failure process. This contractile dysfunction is secondary to important cellular
changes that include altered expression of membrane and contractile proteins,
altered energy metabolism, and impaired EC coupling.
Contractile function: In heart failure the amplitude of contraction is re-
duced and the time course of cell shortening and relaxation is prolonged result-
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Fig. 1.4: Schematic illustration of EC coupling and Ca2+ cycling in normal ventricular
myocytes. Inset shows the time course of an action potential, Ca2+ transient and
contraction measured in a rabbit ventricular myocyte at 37℃. Figure reproduced from
Bers (2002).
ing in systolic and diastolic dysfunction. Studies on myocardial tissue strips
(Pieske et al. 1996) or isolated cardiomyocytes (Davies et al. 1995; Hasenfuss
et al. 1997) from failing human myocardium obtained in the setting of cardiac
transplantation have also demonstrated depressed contractility (Fig 1.5). De-
terioration in contractile function, both contraction and relaxation (Houser &
Lakatta 1999; Davies et al. 1995), and a diminished catecholamine sensitivity
(Bristow et al. 1982) are key features. Frequency-dependent augmentation of
contractile force is an important compensatory mechanism for the regulation
of myocardial function during increased demand such as exercise (Fig 1.5). In
most large mammals, including humans, contractile force correlates positively
with increasing stimulation rate (Davies et al. 1995; Pieske et al. 1992). How-
ever, in heart failure the force-frequency relationship is blunted (Hasenfuss
& Pieske 2002; Pieske et al. 1992; Hasenfuss et al. 1992; Mulieri et al. 1992)
(Fig 1.5) and has been shown to be due to reduced loading of Ca2+ into the
SR during increasing rates of stimulation (Pieske et al. 1999)
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Fig. 1.5: Cardiomyocytes isolated from heart failure patients have impaired contrac-
tions. Figure reproduced from Davies et al. (1995).
Cytoplasmic Ca2+ cycling : Following the work from Gwathmey et al.
(1987), several changes in cytoplasmic [Ca2+] regulation in human and ex-
perimental heart failure have been described. In the end-stage failing human
myocardium, unchanged basal and peak Ca2+ levels and a prolonged transient
were found in papillary muscle preparations (Gwathmey et al. 1987; Vahl et al.
1994; Gwathmey et al. 1990, 1991). Beuckelmann et al. (1992) found differ-
ent results, i.e. an increased diastolic cytoplasmic [Ca2+] level, a significantly
depressed peak cytoplasmic [Ca2+], and a slower rate of diastolic Ca2+ decay
in isolated ventricular myocytes. Similarly, in experimental heart failure dias-
tolic Ca2+ concentration may be unchanged (Perreault et al. 1992) or elevated
(Baartscheer et al. 2003) with prolonged transients. Changes of several cellular
mechanisms such as altered sarcolemmal L-type Ca2+ current (I Ca,L), SR Ca
2+
release, storage and reuptake can explain the altered [Ca2+] regulation in heart
failure and are described below.
• SR Ca2+ release: SR Ca2+ release channels are among the largest
proteins identified to date. Two different types of channels are known
termed ryanodine receptor (RyR) and inositol 1,4,5-trisphosphate recep-
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tor (IP3R). In the cardiac sarcoplasmic reticulum, the density of the RyR
is significantly higher than that of the IP3R, and the former is far more
relevant for EC coupling (Marks 1997). The Ca2+-sensitive RyR, which
is coupled to sarcolemmal I Ca,L, is activated by a local increase in [Ca
2+]
subsequent to trans-sarcolemmal Ca2+ influx. RyR is a macromolecular
signaling complex that includes kinases and phosphatases associated with
the cytoplasmic channel region. These kinases and phosphatases modu-
late the channel activity upon extracellular signals via second messengers,
and thereby regulate SR Ca2+ release (Hasenfuss & Pieske 2002).
RyR expression and function has been shown to be reduced in human
(Brillantes et al. 1992; Go et al. 1995), and several animal models of heart
failure (Finkel et al. 1992; Vatner et al. 1994; Dodd et al. 1993). RyR
high affinity binding sites for [3H] ryanodine (which may reflect channel
activity) have been shown to be decreased (Go et al. 1995), unchanged
(Schumacher et al. 1995) or increased (Sainte-Beuve et al. 1997) in human
heart failure.
Marx et al. (2000) have proposed that modifications in protein kinase-A
(PKA)-dependent phosphorylated state of the RyR complex is a con-
tributing factor in the progression of heart failure and leads to less effi-
cient CICR during systole. They suggest that hyperphosphorylation (at
serine 2808-9 position) of the RyR channel leads to dissociation of the reg-
ulatory subunit FKBP12.6 from the channel, resulting in pronouncedly
altered channel functions and increased SR Ca2+ leak. This increased
SR Ca2+ leak may occur due to reduced RyR threshold for spontaneous
Ca2+ release (Jiang et al. 2004). It is conceivable that Ca2+ released in
such a manner, if it becomes substantial, may cause acute depolarization
of the cardiomyocyte by ‘forward-mode’ sarcolemmal NCX - a plausible
explanation for the arrhythmias seen in failing hearts.
Increased phosphorylation of RyR in the failing human heart is puz-
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zling in the presence of down regulation of the β-adrenoceptor (β-AR)
adenylyl cyclase system (Wang & Dhalla 2000). However, it has been
suggested that hyperphosphorylation may result from decreased levels
of RyR complex-associated phosphatases (PP1 and PP2a) in the fail-
ing human myocardium (Marx et al. 2000). Studies from other groups
suggest that hyperphosphorylation of RyR alone may not be responsible
(Obayashi et al. 2006) but an enhanced sensitivity to luminal Ca2+ and
an increased propensity for spontaneous Ca2+ release or store-overload-
induced Ca2+ release (SOICR) may underly arrhythmogenesis in heart
failure (Jiang et al. 2007). Recent evidence suggests that there is a loss
of close spatial coupling between L-type Ca2+ channels and RyR clus-
ters (essential for synchronous Ca2+ release from SR), due to increased
spatial dispersion of the cardiomyocyte t-tubules, which in turn results
in uncoupled RyRs (termed ‘orphaned RyRs’) in failing hearts. These
orphaned RyRs have been implicated in the loss of local control and
Ca2+ release instability in heart failure (Song et al. 2006; Sobie et al.
2006; Brette & Orchard 2003). Iribe et al. (2009) have recently shown
that axial stretch of rat cardiomyocytes acutely and transiently increases
sarcoplasmic reticulum Ca2+ spark rate via microtubule-mediated mod-
ulation of RyR function. The mechanism of increased spark rate in this
study was shown to be independent of sarcolemmal stretch-activated ion
channels, nitric oxide synthesis, or availability of extracellular Ca2+ but
requires cytoskeletal integrity.
IP3Rs are expressed in cardiac myocytes and when activated by the sec-
ond messenger IP3, Ca2+ release from the SR occurs (Kentish et al. 1990).
IP3R mRNA levels may be increased in failing human myocardium, rel-
ative to RyR density (Go et al. 1995), but the functional relevance of
this alteration is unclear. It is possible that IP3Rs could be involved in
regulation of diastolic tone and/or regulation of Ca2+-mediated nuclear
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signaling pathways in the heart (Marks 1997; Wu et al. 2006).
Sarcolemmal Ca2+ regulatory mechanisms are also involved but their role
is less clear. Sarcolemmal L-type Ca2+ currrent (I Ca,L), the major trigger
source for cardiac myocytes, has been found to be reduced, unaltered or
enhanced in different studies (Hart 1994). Some studies report reduced
peak I Ca,L density in heart failure patients (Ouadid et al. 1995) as well as
in animal models of heart failure (Santos et al. 1995). On the other hand,
a number of other studies have reported no significant change (Beuckel-
mann et al. 1992; Gomez et al. 1997). The discrepancy may be due to
differences in animal species, mode of heart failure induction, and dura-
tion and severity of disease. In any case, since numerous models of heart
failure show clearly reduced Ca2+ transients without reduced I Ca,L, it
appears that other EC coupling defects are important. It has been pro-
posed that disruptions in the spatial relationships between the L-type
Ca2+ channels and RyRs might impair CICR (Gomez et al. 1997) as the
activation of an RyR is sensitive to its geometric relation to the L-type
Ca2+ channel (Stern 1992; Stern & Lakatta 1992).
• SR Ca2+ regulation: The regulation of SR Ca2+ is a function of Ca2+
availability to SERCA, activity of SERCA, Ca2+ storage in the SR, and
Ca2+ leak from the SR (Barry & Bridge 1993; Eisner et al. 2000). SERCA
is regulated by phospholamban and dephosphorylated phospholamban is
an inhibitor of SERCA activity (Kranias et al. 1985; Kim et al. 1990).
SR Ca2+ uptake depends on cytoplasmic [Ca2+] and secondary mecha-
nisms to remove Ca2+ from the cytosol.
The major secondary mechanism to SERCA for cytoplasmic Ca2+ re-
moval is the sarcolemmal NCX (Bers 2001, 2002). Both NCX and SERCA
remove Ca2+ from the cytosol but in the ‘forward mode’, NCX competes
with SERCA for Ca2+ removal and may therefore reduce SR Ca2+ con-
tent. In this regard, both work in concert to facilitate diastolic relaxation
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of the myofilaments (Bers 2001, 2002).
The mRNA and protein abundance of SERCA2a (isoform expressed in
the heart, (Hasenfuss 1998b)) is known to decrease in animal (Hasenfuss
1998a; Zarain-Herzberg et al. 1996; Feldman et al. 1993; Kiss et al. 1995)
and human (Hasenfuss 1998b; Dash et al. 2001; Di Paola et al. 2001)
heart failure. A significant positive correlation between SERCA protein
levels and myocardial function of failing human hearts, assessed by the
force-frequency relation, has been found (Hasenfuss et al. 1994, 1996).
Also, Di Paola et al. (2001) have shown that SERCA protein levels were
significantly reduced in failing but not in compensated hypertrophied hu-
man myocardium indicating that a decrease in SERCA protein abundance
coincides with the development of heart failure.
Phospholamban expression in animal models of heart failure may be re-
duced (Kiss et al. 1995), unchanged (Williams et al. 1994) or increased
(Sun et al. 2005). In human heart failure, protein expression of SERCA
relative to phospholamban is diminished, whether or not protein levels of
SERCA and phospholamban are reduced (Meyer et al. 1995; Dash et al.
2001). Because the stoichiometry of SERCA to phospholamban (relative
SERCA:phospholamban ratio) determines the level of pump inhibition,
this finding may indicate that in the basal low phosphorylated state, PLB-
dependent inhibition of SERCA is more pronounced in failing compared
to non-failing human myocardium (Frank & Kranias 2000; Koss et al.
1997). It is currently accepted that SR Ca2+ uptake is less efficient as a
consequence of reduced SERCA abundance/activity (Pieske et al. 1995;
Schwinger et al. 1995; Dash et al. 2001; Di Paola et al. 2001) and/or its
relationship with the regulatory protein phospholamban (Hasenfuss et al.
1996; Hasenfuss & Pieske 2002). This causes slower removal of Ca2+ from
the cytoplasm resulting in slower relaxation and diastolic dysfunction.
• Na+-Ca2+ exchange: NCX is a passive exchanger present on the sar-
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colemma that, at the steady state, removes Ca2+ from the cytoplasm
to counteract Ca2+ entry via L-type Ca2+ current. NCX extrudes 1
Ca2+ ion for 3 Na+ ions using the electrochemical Na+ gradient and the
net movement of charge results in a net inward current (in the ‘forward
mode’) (Philipson & Nicoll 1992; Bers 2001, 2002). The relative contri-
bution of NCX to cytoplasmic [Ca2+] homeostasis is mainly determined
by the abundance and activity of SERCA, [Na+]i and cytoplasmic [Ca
2+]
(Blaustein & Lederer 1999; Bers 2001). NCX is also voltage-dependent
and can reverse its mode (Na+ out, Ca2+ in) during the action potential,
based on the membrane voltage (Bers 2001). [Na+]i appears to be a ma-
jor factor for species differences in frequency and rest-dependent behavior
of myocardial function (Pogwizd et al. 2001).
NCX actvity is known to be increased in human heart failure (Reinecke
et al. 1996) but it is still unclear if this is compensatory or contributes to
contractile and cytoplasmic [Ca2+] homeostasis dysfunction. There is a
larger contribution of NCX to diastolic relaxation in failing as compared
to non-failing human myocardium (Pieske et al. 1999).
There are three genes that control the expression of NCX in mammals,
with at least 16 alternatively spliced isoforms of NCX1, the dominant
cardiac isoform (Ruknudin et al. 2007; Bers 2001). Whether or not an
isoform shift occurs in hypertrophied or failing myocardium is currently
unknown. The NCX protein is overexpressed in human (Hasenfuss et al.
1999; Flesch et al. 1996; Studer et al. 1994) and animal (Pogwizd et al.
2001; Sipido et al. 2000; Ahmmed et al. 2000; Litwin & Bridge 1997) heart
failure but whether this effect plays a compensatory role or contributes
to dysfunction is still controversial. Sipido et al. (2002) summarized the
published studies of NCX in heart failure and found that, out of 29 animal
studies of heart failure, 14 reported an increase in NCX expression and/or
function, 10 a decrease, and 5 no change. The heterogeneity of results
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appears to be due to a variety of factors such as mode, severity, duration
of pressure overload to the heart, as well as animal species.
Because of the interaction between SERCA and NCX, Ca2+ accumula-
tion into the SR should be inversely related to Ca2+ elimination by NCX.
Assuming that the forward mode of NCX predominates and that pro-
tein levels correlate with activity, Hasenfuss et al. (1999) have shown
that ratio of NCX to SERCA protein levels in myocardium from end-
stage failing human hearts was increased by a factor of 3, compared to
non-failing human hearts. They also found that diastolic performance
of failing human myocardium correlates inversely with protein levels of
NCX and also identified two different phenotypes of SERCA and NCX
protein levels in failing human hearts (Hasenfuss et al. 1999).
1. Increased protein levels of NCX and unchanged SERCA levels with
preserved diastolic function due to effective Ca2+ removal, and im-
paired systolic function due to depressed SR Ca2+ accumulation.
2. Markedly decreased SERCA protein levels and unchanged NCX lev-
els with reduction in both SR Ca2+ uptake and global cytosolic Ca2+
elimination, resulting in impaired systolic as well as diastolic func-
tion.
Other studies confirm that in failing human myocardium there is en-
hanced trans-sarcolemmal, but reduced intracellular Ca2+ cycling, and
this becomes even more pronounced at higher heart rates (Pieske et al.
1999; Schlotthauer et al. 1998). Using ryanodine to block SR function
on ventricular muscle strips of end-stage failing human hearts, Schlot-
thauer et al. (1998) suggest that Ca2+ responsible for approximately 50%
of twitch force is derived from the SR and approximately 50% from sar-
colemmal Ca2+ influx, with increased sarcolemmal component at higher
stimulation frequencies. These findings indicate an increased contribu-
tion of NCX to Ca2+ influx compared to non-failing hearts (Pieske et al.
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Fig. 1.6: Phases of an action potential in normal (solid line) and failing (dotted line)
mammalian ventricle with time course of responsible depolarizing & repolarizing cur-
rents and their respective genes. Figure reproduced from Tomaselli & Marban (1999).
1999). The higher [Na+]i in failing, compared to non-failing, human my-
ocardium may favour reverse-mode NCX function promoting Ca2+ influx
(Pieske & Houser 2003). Increased NCX expression in failing human
(Schillinger et al. 2002) and animal (Pogwizd et al. 2001) myocardium
may be also be associated with increased arrhythmias due to increased
arrhythmogenic inward current.
Action potential (AP) morphology : Prolongation of the AP duration
(APD) is a uniform finding in heart failure (Beuckelmann et al. 1993; Kaab
et al. 1996). This prolongation is particularly prominent at slower (compared
to higher) heart rates (Pieske et al. 1995; Vermeulen et al. 1994). Functional
and structural alterations of various ion channels are thought to underly mod-
ifications of the morphology of the action potential and ion currents, which
may also lead to an increased incidence of arrhythmias (Tomaselli & Marban
1999).
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Reduction in transient outward current (Ito) (Nabauer et al. 1993) and the
inward rectifier K+ current (Beuckelmann et al. 1993) (IK1) are consistently
seen in heart failure. The delayed rectifier K+ current (IK) (consists of three
components: ultra-rapid component, IKur; rapid component, IKr; slow com-
ponent, IKs) is known to be a major determinant of APD (Sanguinetti &
Jurkiewicz 1990). However, very little is known about the role of the IK
in failing human hearts. There is indirect evidence (using computer simula-
tion) that in mild-to-moderate heart failure patients, the relative abundance
of KCNE1 compared to KCNQ1 genes (IKr and IKs channel genes), at least
in part, might contribute to the preferential prolongation of APD by reducing
IKs (Watanabe et al. 2007).
The Na+/K+ ATPase transports K+ into the cell and Na+ out with a sto-
ichiometry of 2:3, thus generating an outward repolarizing current (I Na,K).
Majority of human and experimental data suggest that the expression and
function of the Na+/K+ ATPase pump is reduced in failing hearts (Dhalla
et al. 1991; Houser et al. 1981; Zahler et al. 1996; Spinale et al. 1992).
Reduced I Na,K can contribute to APD prolongation and increased [Na
+]i seen
in failing hearts (Tomaselli & Marban 1999; Pieske & Houser 2003). It is
currently thought that the increased [Na+]i seen in failing hearts is mainly due
to enhanced Na+ influx (Bers et al. 2006). This may contribute to enhanced
reverse-mode NCX leading to increasing depolarizing current.
Other contributing factors include, increase in inward currents such as the
I Ca,L or I NCX and in particular, greater inward I NCX may result from upreg-
ulation of the NCX (increased expression) and the slower decline of the calcium
transient in heart failure (Tomaselli & Marban 1999). Thus prolongation of
APD may be beneficial in heart failure as it may increase Ca2+ influx, thus
having inotropic effects. On the other hand it may reflect a major alteration
with respect to arrhythmogenesis in heart failure (Tomaselli & Marban 1999).
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A. B.
Fig. 1.7: Calcium-myofilament interaction: Schematic showing free-Ca2+ interaction
with Tn-C leading to destabilization of Tn-I–Actin interaction and axial positioning of
troponin-tropomyosin, during low-Ca2+ (A) and high-Ca2+ (B) states. Figure repro-
duced from Day et al. (2007).
Myofilament sensitivity to Ca2+: Cardiac myofilaments are activated by Ca2+
in a graded manner, culminating in force generating cross-bridge attachments.
The relationship between cytoplasmic free-Ca2+ and force development is there-
fore of fundamental importance. Following CICR from the SR, there is an in-
crease in cytoplasmic free-[Ca2+], from the diastolic low-Ca2+ state (Fig 1.7 A)
to the systolic high-Ca2+ state (Fig 1.7 B). The free-Ca2+ binds to troponin-C
(Tn-C) causing destabilization of troponin-I (Tn-I)-actin interaction, leading
to increased myosin interaction with actin, resulting in force production and/or
shortening (Bers 2001, 2002).
Abnormal myofilament function contributes significantly to contractile dys-
function in chronic heart failure although its relative importance compared to
altered Ca2+ homeostasis is currently debated (Day et al. 2007).
Excitation-contraction uncoupling is a key feature of acute myocardial is-
chæmia, which results in intracellular acidification and altered myofilament
sensitivity to Ca2+ (Fig 1.8 A, B). The uncoupling of excitation and con-
traction observed in post-ischæmic myocardium (Fig 1.8 C, D) and chronic
heart failure is however characterized by a dysregulation of excitation and
contraction due to altered Ca2+ cycling and myofilament sensitivity to Ca2+
(Fig 1.8 E, F).
In the failing human myocardium, the amplitude of the Ca2+ transient is re-
46
A. B.
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E. F.
Fig. 1.8: Force-cytoplasmic [Ca2+] relationship: Representative traces of force
(black) and Ca2+ transients (red) (A,C,E) with corresponding force-[Ca2+] relation-
ships (B,D,F). There is reduced force production due to reduced myofilament sensitiv-
ity to Ca2+ during acidosis (A,B) and post-ischæmic reperfusion (C,D). However, in
failing hearts the reduced force production is due to reduced Ca2+ transisent amplitude
despite increased myofilament sensitivity to Ca2+ (E,F). Figure reproduced from Day
et al. (2007).
duced with slower decay (Gwathmey et al. 1987; Morgan et al. 1990), resulting
in a proportionally reduced absolute myocardial force generation (Fig 1.8 E, F)
(Hajjar et al. 1992). However, the force production per unit cross-sectional
area of myofilaments may be unchanged even in severe heart failure (Hajjar
et al. 1992; Denvir et al. 1995). Most studies report an unaltered (Gwathmey
& Hajjar 1990; Perreault et al. 1990; D’Agnolo et al. 1992; Wolff et al. 1995;
Hajjar et al. 2000) myofilament sensitivity to Ca2+ in heart failure but some
studies report an increase (Wolff et al. 1995; Messer et al. 2007). Studies in
failing rat hearts (Lamberts et al. 2007), but not in guinea pigs (Siri et al.
1991), show a frequency-dependent decrease in maximal force due to reduced
myofilament sensitivity to Ca2+ suggesting variability between mammalian
species.
Heart failure is associated with changes in the distribution and content of
myocardial contractile proteins both in human (Schwartz et al. 1992; Nadal-
47
Ginard & Mahdavi 1989; Solaro 1992; Anderson et al. 1995; Margossian et al.
1992; Sutsch et al. 1992) and animal (Li et al. 1997) failing hearts. One
cause of altered myofilament sensitivity to Ca2+ in human cardiomyopathy is
depressed myofibrillar ATPase activity (Alpert & Gordon 1962). It is possible
that differences in distribution and isoform shifts in myofilament proteins may
be responsible for differences between species. Rats and mice shift from fast
to slow myosin heavy chain (α to β-MHC) in heart failure, whereas larger
mammals (rabbit, dog and human) are predominantly β-MHC to begin with
and do not change to a large extent (de Tombe 1998). Varying levels of
contractile protein phosphorylation (Li et al. 1997; Liu et al. 1995) may also
account for differences in myofilament sensitivity to Ca2+ as protein kinase A-
induced hyperphosphorylation of Tn-I (eg. following β-adrenergic stimulation)
can reduce the association between Tn-I and Tn-C, resulting in reduced Ca2+
binding affinity of Tn-C (Ward et al. 2002; Noland et al. 1995; Gaponenko
et al. 1999).
Inducing positive inotropy by altering the myofilament force-Ca2+ relation-
ship is an attractive proposal. Drugs like levosimendan (a Ca2+-sensitizing
agent with phosphodiesterase III inhibiting activity) and milrinone (phospho-
diesterase III inhibitor) can improve myofilament sensitivity to Ca2+ (Mac-
Gowan 2005) and relaxation (Chen et al. 2003b; Hasenfuss et al. 1998).
Other strategies of altering myofilament function may also hold potential ther-
apeutic value for the failing heart. Day et al. (2006) have demonstrated that by
genetic alteration of a single histidine residue (pH-sensitive ‘histidine button’)
of Tn-I (adult cardiac Tn-I isoform at codon 164), mice had preserved systolic
function, attenuated ventricular remodelling up to 6 months after permanent
left coronary artery (LCA) ligation. They also extended the study to failing
human cardiac myocytes, using adenoviral gene transfer of cardiac Tn-I (cTn-
I)–A164H into myocytes. Incorporation of cTn-I–A164H conferred improve-
ments in contractile and relaxation parameters and markedly enhanced the
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force-frequency response in failing human cardiac myocytes. Taken together,
these results suggest that cTnI–A164H acts as a novel molecular inotrope in
the failing heart to improve contractile function and limit left ventricular re-
modelling.
Other important and controversial aspects of cardiomyocyte remodelling are
survival and renewal. These aspects have been reviewed in details by Fedak
et al. (2005).
1.2.2 Changes involving extra-cellular matrix
The extracellular matrix (ECM) of the heart dynamically interacts with various cel-
lular components of the myocardium, including the myocytes and connective tissue
cells. The ECM (2-4% of normal myocardium) is composed of a number of proteins
which include fibronectins, elastins and laminins. The most numerous proteins are
collagens, of which types I and III represent more than 90% of the total content in
the heart (Spinale 2007). Collagen maintains the structural composition, transmits
forces and with elastin, contributes to the elastic properties of the myocardium. In
addition, it acts as a ligand binding protein which affects the function of other com-
ponents of the myocardium (Di Lullo et al. 2002). The myocardial ECM is also a
large reservoir of bioactive signaling molecules (Spinale 2007).
Progression of LV remodelling is accompanied by alterations in the structure and
function of the ECM. Heart failure for instance, leads to an increased collagen type
I, type I/III ratio and cross-linking associated with fibrosis (Spinale 2007). These
alterations in ECM structure and function can occur after injury resulting from
neurohormonal stimuli, changes in LV loading conditions, alterations in myocar-
dial blood supply and metabolism. These changes may be secondary to signaling
pathways that affect repair and remodelling of the myocardium (Spinale 2007).
Patterns of ECM remodelling depend on ætiology of heart failure. In non-
ischæmic DCM, there is an increase in left ventricular chamber radius to wall
thickness ratio, which results in increased myocardial wall stress (see Page 28).
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In idiopathic DCM, the alterations in normal ECM architecture are associated with
reduced collagen cross-linking, which may result in the ECM being more susceptible
to degradation (Gunja-Smith et al. 1996; Klotz et al. 2005b).
The matrix metalloproteinases (MMPs) are a family of more than 25 species of
zinc-dependent proteases that are essential for normal tissue remodelling in processes
such as bone growth and wound healing. MMPs cleave matrix components and are
responsible for collagen denaturation and degradation. Therefore, MMPs and the
tissue inhibitor of metalloproteinases (TIMPs) play an important role in regulating
ECM turnover and involved in the remodelling process. It is currently thought
that an imbalance between MMPs and TIMPs drives adverse ECM changes and LV
remodelling. In end-stage heart failure, increased MMP-1, -2 and -9 and decreased
TIMP-1, -3 and -4 have been implicated in adverse ECM and LV remodelling, and
the abnormal MMP-1/TIMP-1 and MMP-9/TIMP-3 ratios modulate ECM turnover
(Spinale et al. 2000; Spinale 2007; Klotz et al. 2008).
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1.3 Treatment of severe heart failure
Although heart failure is a major public health problem, there are no national screen-
ing efforts to detect the disease at its earlier stages, as there are for breast and
prostate cancer. Heart failure is largely preventable, primarily through the control
of blood pressure and other vascular risk factors. However, the factors that render
a patient at high risk for heart failure have not been clearly defined. In order to
determine the best course of of management, based on symptoms and quality of life,
patients can be classified into different stages of heart failure according to the New
York Heart Association (NYHA) functional classification system (Table 1.5). Also,
the guidelines published recently by the American College of Cardiology (ACC) and
the American Heart Association (AHA) further clarify evaluation and management
of chronic heart failure (Hunt et al. 2001). The present staging system emphasizes
both the evolution and progression of the disease, and defines four stages of heart
failure (Table 1.6).
Table 1.5: NYHA Classification of heart failure: A functional and therapeutic classification
for prescription of physical activity for cardiac patients. Table modified from Braunwald
(2004).
NYHA Class Clinical manifestation
Class I no limitation of activities or no symptoms from ordinary activities.
Class II mild limitation of activity; comfortable with rest or with mild exertion.
Class III marked limitation of activity; comfortable only at rest.
Class IV confined to bed or chair; any physical activity brings on discomfort and
symptoms occur at rest.
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Table 1.6: ACC/AHA staging of heart failure based on evolution and progression of the
disease. Table modified from Hunt et al. (2001). (Abbreviations: HTN - hypertension; CAD -
coronary artery disease; DM - diabetes mellitus; LV - left ventricular; LVH - LV hypertrophy;
MI - myocardial infarction; HF - heart failure)
Stage Description Examples
A Patients at high risk of developing HF
but has no structural disorder of the
heart
HTN, CAD, DM, cardiotoxic drug
therapy, alcohol abuse, history of
rheumatic fever, family history of
cardiomyopathy.
B Patients with a structural disorder of
the heart but who have never developed
symptoms of HF
LVH or fibrosis; LV dilatation
or hypocontractility; asymptomatic
valvular heart disease; previous MI.
C Patients with past or current symptoms
of HF associated with underlying struc-
tural heart disease
Dyspnœa or fatigue due to LV sys-
tolic dysfunction; asymptomatic pa-
tients who are undergoing treatment
for prior symptoms of HF.
D Patients with advanced structural heart
disease and marked symptoms of HF
at rest despite maximal medical ther-
apy and who require specialized inter-
ventions.
End-stage disease who requires spe-
cialized treatment strategies such
as mechanical circulatory support,
continuous inotropic infusions, car-
diac transplantation, or hospice
care.
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The goals of therapy for patients with heart failure and a low ejection fraction
are to improve survival, limit the progression of disease, alleviate symptoms, and
minimize risk factors. The various strategies currently practiced are summarized in
Fig 1.9.
Fig. 1.9: Stages of heart failure and treatment options for systolic heart failure. Figure
reproduced from Jessup & Brozena (2003). (ACE–angiotensin-converting enzyme, ARB–
angiotensin-receptor blocker, VAD–ventricular assist device.)
Patients with stage A heart failure are at high risk for heart failure but do not
have structural heart disease or symptoms of heart failure. This group includes
patients with hypertension, diabetes, coronary artery disease, previous exposure to
cardiotoxic drugs, or a family history of cardiomyopathy. Patients with stage B
heart failure have structural heart disease but have no symptoms of heart failure.
This group includes patients with left ventricular hypertrophy, previous myocardial
infarction, left ventricular systolic dysfunction, or valvular heart disease, all of whom
would be considered to have NYHA class I symptoms. Patients with stage C heart
failure have known structural heart disease and current or previous symptoms of
heart failure. Their symptoms may be classified as NYHA class I, II, III, or IV.
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Patients with stage D heart failure have refractory symptoms of heart failure at rest
despite maximal medical therapy, are hospitalized, and require specialized interven-
tions or hospice care. All such patients would be considered to have NYHA class
IV symptoms. For the purpose of this thesis, definitive treatment of only stage D
heart failure with NYHA class IV symptoms will be considered.
Clinical management and treatment strategies for Stage D/End-stage heart fail-
ure can be broadly classified as the following (Jessup & Brozena 2003) (see Fig 1.9).
• Lifestyle modification: reduction in salt and alcohol intake (Djousse &
Gaziano 2008), smoking cessation, avoidance of nonsteroidal anti-inflammatory
drugs (Page & Henry 2000) and exercise training (Hambrecht et al. 2000; Coats
1999).
• Risk factor control: of the modifiable risk factors such as hypertension
(Mosterd et al. 1999; The Joint National Committee report 1997), diabetes
(Deedwania 2000; UK Prospective Diabetes Study Group 1998; The HOPE
Study Investigators 2000; Brenner et al. 2001) and obesity (Bozkurt & Deswal
2005; Horwich & Fonarow 2002; Sagar et al. 2008).
• Pharmacological therapy:
1. Angiotensin converting enzyme (ACE) inhibitors: act by inhibiting the
renin-angiotensin system, at the level of conversion of angiotensin-I to
angiotensin-II, minimizing the multiple pathophysiological effects of an-
giotensin II and decrease degradation of bradykinin (promotes vasodilata-
tion and natriuresis in the kidney). They reduce afterload, reverse LV
remodelling, improve cardiac performance and improve survival in heart
failure (Pfeffer & Pfeffer 1987; Garg & Yusuf 1995; Levine et al. 1984;
Munzel & J. F. Keaney 2001; Khalil et al. 2001).
Angiotensin receptor blockers (ARB) block renin-angiotensin system at
the level of angiotensin-II binding to its receptor. They are a valuable
54
alternative in patients who cannot tolerate ACE inhibitors because of
severe cough or angio-œdema (Hunt et al. 2005). ARBs have a similar
(Pitt 1995) or improved (Pitt et al. 2000, 1997; The ELITE Study inves-
tigators) beneficial effects as ACE inhibitors and their efficacy may be
improved when combined with ACE inhibitors (Cohn & Tognoni 2001)
in treating heart failure patients.
2. β-blockers: counteract the harmful effects of the sympathetic nervous
system that are activated during heart failure. The beneficial effects of β-
blockers, demonstrated in patients with heart failure from various causes
and of all stages, include improvements in survival, morbidity, ejection
fraction, remodelling, quality of life, the rate of hospitalization, and the
incidence of sudden death (Foody et al. 2002; Farrell et al. 2002). De-
spite temporary exacerbation of symptoms in the short term, β-blockers
improve LV systolic function and reverse LV remodelling in the long term
(Bristow 2000; Groenning et al. 2000).
3. Diuretics: reduce intravascular volume overload, control circulatory con-
gestion and peripheral œdema in symptomatic heart failure patients (Brater
1998). In particular the aldosterone antagonist class of diuretics reduce
retention of salt, myocardial hypertrophy and potassium excretion (We-
ber 2001). They also decrease collagen synthesis and myocardial fibrosis,
reduce morbidity and mortality in heart failure patients (Pitt et al. 1999;
The RALES Study Investigators).
4. Digoxin: inhibits the Na+/K+ ATPase and increases cardiomyocyte con-
tractility. Its therapeutic efficacy in heart failure patients with normal
sinus rhythm has been disputed for many years. Recent evidence shows
that digoxin treatment has no improvement in mortality, but reduces
rates of worsening heart failure and hospitalization (The Digitalis Inves-
tigation Group 1997), and is equally effective at lower doses (Adams et al.
2002).
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5. Inotropic therapy : is mainly reserved for the subset of acute heart fail-
ure patients, such as those with acute heart failure decompensation in
the setting of clinically evident hypoperfusion or shock, or as a bridge
to more definitive treatment, such as revascularization or cardiac trans-
plantation. Chronic oral inotropic therapy has been convincingly shown
to increase mortality in chronic heart failure (Massie et al. 1993; Packer
et al. 1984, 1991). Although positive inotropes improve cardiac contrac-
tility and output, their use in heart failure has consistently been asso-
ciated with increased myocardial oxygen demand, cardiac arrhythmias,
and mortality in a variety of clinical settings (Petersen & Felker 2008).
Recent evidence suggests that levosimendan (see Page 48) appears to be
a useful addition to the treatment options for acute decompensated heart
failure in patients with low cardiac output (Innes & Wagstaff 2003). Fur-
ther evidence investigating hæmodynamic efficacy and mortality versus
other positive inotropes is still required (Landmesser & Drexler 2007).
• Cardiac resynchronization therapy:About 45% of heart failure patients
show widening QRS complexes (>120 ms) on 12-lead electrocardiography
(ECG) and this prolonged QRS duration is an independent predictor of mor-
bidity and mortality in these patients (Wang et al. 2008; Wilensky et al. 1988).
Cardiac resynchronization therapy improves ventricular contraction synchrony
by providing electromechanical coordination. Symptomatic patients with se-
vere systolic dysfunction and intraventricular conduction defects, especially
left bundle-branch block (El Menyar & Abdou 2008), benefit from this ther-
apy.
Cardiac resynchronization can improve global LV function and cardiac output
without increasing myocardial oxygen consumption (Kass et al. 1999). These
acute mechanical effects of cardiac resynchronization therapy result in imme-
diate symptomatic improvements and can be accompanied by more chronic
adaptations that lead to long-term benefit. NYHA class, exercise capacity,
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and quality of life of patients have been demonstrated to improve (Linde et al.
2002; Young et al. 2003). There is measurable reverse-remodelling of the LV
with re-synchronization therapy (Stellbrink et al. 2001), ultimately leading to
improved LV function (Zanon et al. 2008) and patient survival (Turley et al.
2008; Cleland et al. 2005; Bristow et al. 2004).
• Non-transplant, heart failure surgery:
Myocardial revascularization, through either a catheter-based or a surgical
approach, often improves ischæmic symptoms, improves cardiac performance,
and reduces the risk of sudden death (Pusca & Puskas 2007; Bitran et al.
2001; Baumgartner 2001; Hausmann et al. 1997). Surgical techniques designed
to reduce myocardial wall stress include ventricular restoration procedures2
(Starling et al. 2000; Wilhelm et al. 2005; Suma et al. 2007), repair of mitral
regurgitation (Bitran et al. 2001; Bishay et al. 2000; Rothenburger et al. 2002;
Gatti et al. 2003) and external support devices3 (Raman et al. 2001; Bredin &
Franco-Cereceda 2006; Livi et al. 2005). They improve symptoms and survival
in patients with severe LV dysfunction. The short-term results from some of
the above studies are comparable to that after heart transplantation. However,
long-term results and multicenter evaluation will be needed to clearly define
the role non-transplant surgical treatment of advanced heart failure. The
increasing role of left ventricular assist devices (LVADs) in treatment of heart
failure are discussed on Page 60.
2e.g. Batista (Partial Left Ventriculectomy) and Dor (Endoventricular Circular Patch Plasty)
procedures
3e.g. CorCap™ Cardiac Support Device
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• Cardiac transplantation: remains the ‘gold standard’ of surgical therapies
for stage D/end-stage heart failure, refractory to pharmacological therapy .
More than 76,000 heart transplants have been performed worldwide (Taylor
et al. 2007). The one-year survival following heart transplantation is approxi-
mately 85% and at five years 68.5%, with a good quality of life (Zeltsman &
Acker 2002; Grady et al. 2005; Taylor et al. 2007) (Fig 1.10). After the steep
fall in survival during the first 6 months, survival decreases at a very linear
rate (approximately 3.4% per year, with half-life of almost 10 years), even well
beyond 15 years post-transplant (Taylor et al. 2005, 2007) (Fig 1.10).
Fig. 1.10: Kaplan-Meier survival by era for heart transplants performed between
January 1982 and June 2005 worldwide. Figure reproduced from Taylor et al. (2007).
Although transplantation is a very successful definitive treatment option, there
is a severe and worsening shortage of organ donors worldwide (Zeltsman &
Acker 2002; Taylor et al. 2007). There has been a gradual decline in the number
of heart transplants (Fig 1.11), and compared to the number of patients who
are suffering from severe heart failure, transplantation is offered to only a small
proportion of individuals.
Data from the UK Transplant Activity Report 2006-2007 4 shows that of the
819 patients on the transplant list for a cardiothoracic organ in 2006-2007,
4Source: http://www.uktransplant.org.uk/ukt/statistics/statistics.jsp
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Fig. 1.11: Number of heart transplant procedures reported to the Registry of the
International Society for Heart and Lung Transplantation by year. Figure reproduced
from Taylor et al. (2007).
394 (48%) were still waiting at the end of the year, 284 (35%) had received a
transplant and 141 (17%) had either died or been removed from the transplant
list. There is, therefore, a pressing need for the development of alternative
therapies for these patients, especially those aiming to correct the underlying
defect.
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1.4 Ventricular assist device therapy for se-
vere heart failure
Among alternative treatments for end-stage/severe heart failure, mechanical
devices that unload the heart called left ventricular assist devices (LVADs),
have been shown to be suitable and effective in a large number of patients
(Rose et al. 2001; Clegg et al. 2006; Birks et al. 2006; Dandel et al. 2005;
Maybaum et al. 2007). The REMATCH (Randomized Evaluation of Mechan-
ical Assistance for the Treatment of Congestive Heart Failure) clinical trial
demonstrated an 81% improvement in two-year survival among patients re-
ceiving LVAD versus optimal medical management for NYHA IV heart failure
(Rose et al. 2001). There has been an unprecedented expansion in the use
of LVADs for the treatment of severe heart failure. It is estimated that the
total number of LVADs implanted in the last decade is greater than 11,000.5
This trend is likely to continue and is the result of a massive clinical need,
coupled with continued refinements in the design and engineering aspects of
the devices, and more importantly the timing and clinical indications of usage
(Yacoub & Miller 2008). VADs unload the failing heart mechanically by draw-
ing blood from the right or left ventricle and delivering it into the pulmonary
artery or aorta, respectively (Fig 1.12).
Currently, there are three main indications for the use of LVADs in the treat-
ment of severe heart failure, which include ‘bridge to transplantation’, long
term use (destination therapy) and ‘bridge to recovery’. LVAD support is
primarily used as a ‘bridge to transplantation’ where the failing heart can be
supported by mechanical circulatory assistance until a suitable organ becomes
available (Clegg et al. 2006). LVADs allow patients in cardiogenic shock not
only to live but to be mobile and rehabilitated prior to their transplant. Of
patients surviving the first 30 days of support, 84% survive to either trans-
5Source: http://www.thoratec.com/
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Fig. 1.12: The LVAD unloads the left ventricle (LV) by pumping blood from the
LV into the aorta, thus minimizing the mechanical work and load of the LV. Figure
reproduced from http://www.revolutionhealth.com.
plantation or explantation of the device (Mancini & Burkhoff 2005).
The success of VADs as a bridge to transplantation has also led to its consid-
eration as a permanent device, particularly in patients ineligible for transplan-
tation. Such chronic support is termed ‘destination therapy’. Following the
results of the REMATCH trial, use of LVADs as destination therapy is now
approved for some patients ineligible for transplantation (Rose et al. 2001).
However, it is important to keep in mind that problems such as infection,
stroke, bleeding, and device failure remain areas requiring further progress.
It has been observed that in a few patients with complications such as infec-
tions, the LVAD could be removed without requiring transplantation because
left ventricular function had improved significantly (Frazier et al. 1996; Fra-
zier & Myers 1999) and this phenomenon of myocardial functional recovery is
termed as ‘bridge to recovery’. However, the molecular and cellular mecha-
nisms of the clinical ‘recovery’ observed remain unknown. Although the inci-
dence of ‘bridge to recovery’ is hotly debated, it is an exciting indication, both
for the patient (avoids need for transplantation with all of its associated risks
(Birks et al. 2004b)) as well as clinicians and scientists, as it provides a unique
opportunity to study and understand the fundamental myocardial processes
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involved in the progression and regression of heart failure, collectively termed
‘remodelling’ and ‘reverse remodelling’.
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1.5 Reverse Remodelling
Until recently, remodelling was thought to be unidirectional and progressive. How-
ever, the concept of irreversibility has been shown to be incorrect as complete or
partial reversal of remodelling has been documented.
Reverse remodelling occurs in response to pharmacological agents such as ACE
inhibitors and ARBs. These agents reduce afterload leading to reversal of remod-
elling process, improved cardiac performance and improved survival in heart fail-
ure (Pfeffer & Pfeffer 1987; Garg & Yusuf 1995; Levine et al. 1984; Munzel &
J. F. Keaney 2001; Khalil et al. 2001; Pitt et al. 2000, 1997). Despite tempo-
rary exacerbation of symptoms in the short term, β-blockers improve LV systolic
function and also reverse LV remodelling in the long term (Bristow 2000; Groenning
et al. 2000). In failing rat hearts, treatment with selective If current (specific to
pacemaker cells in the sinoatrial node) inhibitor ivabradine, reduces heart rate, im-
proves LV function and reverses remodelling (Mulder et al. 2004; Milliez et al. 2007;
Ceconi et al. 2007). There is measurable reversal of LV remodelling with cardiac
resynchronization therapy (Stellbrink et al. 2001), ultimately leading to improved
patient survival (Cleland et al. 2005; Bristow et al. 2004).
The most profound form of reverse remodelling however, is seen after mechani-
cal unloading by LVADs (Fig 1.13) (Birks et al. 2006; Frazier et al. 1996; Mancini
et al. 1998; Maybaum et al. 2007; Dandel et al. 2005; Hetzer et al. 2001), particularly
when combined with pharmacological therapy (Yacoub 2001; Birks et al. 2006). The
molecular changes and possible mechanisms involved in remodelling and reverse re-
modelling in response to mechanical unloading induced by LVAD treatment, studied
in experimental as well as in clinical samples, are as follows.
1.5.1 Experimental models
Mechanical unloading is one of the important effects of LVAD therapy. This compo-
nent of LVAD therapy can be reproduced in animal models by heterotopic abdominal
63
A. B.
Fig. 1.13: Unloading-induced normalization of heart size. Chest X-ray taken before im-
plantation (A) and after explantation (B) after 505 days of support with a HeartMate vented
electric-LVAD showing profound reduction in heart size. Figure reproduced from Frazier et al.
(1996)).
heart transplantation (Ono & Lindsey 1969).
Beneficial effects of unloading
Several studies have investigated chronic mechanical unloading of normal rodent
hearts using the heterotopic abdominal transplantation technique. Only few studies
involved the transplantation of failing hearts (Ono & Lindsey 1969; Oriyanhan et al.
2007; Tsuneyoshi et al. 2005a; Soppa et al. 2008b). Most studies using experimental
models of heart failure, show beneficial effects of unloading on contractile function.
Takaseya et al. (2004) have shown that the normalized contractile function observed
after 2 weeks of unloading doxorubicin-induced cardiomyopathic hearts, was associ-
ated with increased mRNA and protein expression of SERCA2a. Tsuneyoshi et al.
(2005a) have shown improved SERCA2a, brain natriuretic peptide (BNP) and β2-
AR mRNA expression after 2 weeks of unloading failing rat hearts. Oriyanhan et al.
(2007) have shown that BNP mRNA normalized at 2 weeks and increased after 4
weeks, SERCA2a mRNA were normalized at 2 and 4 weeks but deteriorated after
4 weeks of unloading failing rat hearts. Wang et al. (2007) have shown that 2 weeks
LV unloading of failing rat hearts normalized mRNA expressions of BNP, SERCA2a,
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β1- and β2-AR. Heart failure and mechanical unloading are known to induce a shift
in the expression of myosin heavy chain (MHC) isoforms (Gupta 2007; Oriyanhan
et al. 2007). In human heart failure, α-MHC protein abundance is reduced from 5-
10% to 0-2%, and replaced by β-MHC isoform (with slower contractile properties).
This shift may be responsible for the reduced myocardial contractile and relaxation
function in human heart failure (Palmer 2005).
Harmful effects of unloading
Several studies suggest possible deleterious effects following mechanical unloading.
Ito et al. (2003) have reported depression of contractile reserve and Ca2+ regulation
in myocytes from chronically unloaded normal rat hearts. Oriyanhan et al. (2007)
have recently shown a time-dependent reduction of hypertrophied cardiomyocyte
size and papillary muscle contractile function with increased fibrosis, following het-
erotopic abdominal transplantation of failing rat hearts, suggesting prolonged un-
loading may have detrimental functional consequences. This increase in collagen
content, also seen in some human studies, may also be detrimental to functional
recovery (Klotz et al. 2005b; Bruggink et al. 2006; Li et al. 2001; Madigan et al.
2001; Matsumiya et al. 2005). Myocardial atrophy (as discussed on Page 82) is an
important consequence of mechanical unloading and has been demonstrated in both
human (Soloff 1999; Maybaum et al. 2007) and animal (Rakusan et al. 1997) studies.
This is likely to be an important limiting factor for improving myocardial recovery
in treatment regimes using LVADs.
1.5.2 Clinical studies
Extensive and varied changes in gene and protein expression have been reported dur-
ing and after LVAD treatment. Their exact relationship to clinical and myocardial
function improvements is being studied. The molecular changes observed involve
different components of the myocardium.
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I. Cardiomyocyte biology
LVAD treatment produces significant changes in genes and proteins which control
essential functions of the myocardial cells, which include:
Cell survival and apoptotis: Progressive decline of LV function in cardiomyopa-
thy has been linked to loss of nearly one-third of all cardiomyocytes,as a result
of apoptosis (Narula et al. 2006, 1999, 1996) in human and animal heart failure
(Garg et al. 2005). Pharmacological inhibition of caspases (key enzymes in-
volved in apoptosis) has been shown to attenuate myocardial dysfunction and
ventricular remodelling in animal models of heart failure (Chandrashekhar
et al. 2004; Hayakawa et al. 2003; Wencker et al. 2003). Several changes in
both pro- and anti-apoptotic factors, as well as markers of apoptosis in re-
sponse to LVAD treatment have been reported (Fig 1.14).
An increase in mRNA levels for apoptosis-inhibiting proteins FasEx06del (the
most abundant soluble antagonistic isoform of the apoptosis triggering surface
receptor Fas (Cascino et al. 1996; Schumann et al. 1997)) and Bcl-XL (mem-
ber of Bcl-2 family) with reduced DNA fragmentation have been reported
after LVAD treatment (Bartling et al. 1999; Milting et al. 1999). Upregu-
lation of genes associated with cell growth, DNA repair and apoptosis has
been shown in failing hearts after LVAD support (Chen et al. 2003c). Cyto-
plasmic levels of cytochrome c, a key mediator of the intrinsic mitochondrial
apoptotic pathways were substantially reduced after LVAD support (Arbustini
et al. 2001). Other studies have shown a very low level of apoptosis in failing
hearts, with normalization of overexpressed Bcl-2 (an antiapoptotic protein)
and PCNA6 (repair and/or proliferation marker) after LVAD treatment (Fran-
cis et al. 1999). More recently, de Jonge et al. (2003) have shown a low level
of apoptosis in LVAD-unloaded failing hearts, despite the abundant presence
of mediators and receptors of apoptosis. The abundant expression of FLICE7
6proliferating cell nuclear antigen
7FADD-like IL-1β-converting enzyme
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inhibitory protein (FLIP) after LVAD-unloading, reported in this study, may
have an important role in the inhibition of cardiomyocyte death (de Jonge
et al. 2003). Quantification of apoptosis by TUNEL method (which detects
DNA damage) may underestimate early stages of apoptosis with cytoplasmic
damage (associated with contractile dysfunction) and intact nuclei (termed
apoptosis interruptus, Narula et al. (2006)).
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Fig. 1.14: Summary of main findings reported for changes in apoptotic pathways of
cardiac tissue from heart failure patients taken at LVAD explantation. (1) Bartling
et al. (1999), (2) Milting et al. (1999), (3) Arbustini et al. (2001), (4) de Jonge et al.
(2003), (5) Francis et al. (1999). (PARP - Poly (ADP-ribose) polymerase, PAR - poly
(ADP-ribose), FLIP - FLICE inhibitory protein, PCNA - proliferating cell nuclear anti-
gen, TUNEL - terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling)
(Figure and legend reproduced from Soppa et al. (2008a))
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Mitogen-activated protein (MAP) kinases are serine/threonine-specific protein
kinases that respond to extracellular stimuli (mitogens) and regulate various
cellular activities, such as gene expression, mitosis, differentiation, and cell
survival/apoptosis (Pearson et al. 2001). In mammalian cells, four parallel
kinase cascades that lead to the activation of members of the MAPK family,
such as ERKs (p42 and p44), JNK and p38 protein kinase, have been de-
scribed. Apoptosis signal-regulating kinase 1 (ASK1), an upstream activator
of JNK and p38, has been shown to promote heart dysfunction and dilation
as well as cardiac fibrosis (Yamaguchi et al. 2003). Baba et al. (2003) have
shown decreased activity of ERKs and Akt (an anti-apoptotic kinase) and in-
creased glycogen synthase kinase-3β (downstream target of Akt), along with
reduced apoptosis, in failing human hearts after LVAD support. Studies in
vitro confirm a mechanosensitive regulation (stretch/relaxation leading to ac-
tivation/inactivation) of these kinases (Baba et al. 2003; Ruwhof & van der
Laarse 2000; Sugden 2001). It is possible that these changes may lead to an
altered cardiomyocyte homeostasis and size regulation, due to the opposite
effects of these mechanosensitive pathways.
NF-κB is a crucial transcription factor regulating genes associated with anti-
apoptosis (Baichwal & Baeuerle 1997) and can be activated in failing hearts
(Wong et al. 1998b). It also regulates factors involved in cell survival / apop-
tosis like IL-1, TNF-α, Bcl-xL and HO-1. There is evidence of normaliza-
tion of elevated NF-κB activity after LVAD support with reduced apoptosis
(Wohlschlaeger et al. 2005; Baba et al. 2003).
In summary, the LVAD treatment appears to have a beneficial effect by acting
on the apoptosis phenomenon but the pathways involved are complex. Inter-
rupted apoptosis is possibly a more common stage of apoptosis in the failing
heart and may be a reversible disease state that could be an attractive tar-
get. Further studies to identify the complex temporal and spatial relationships
between these processes are required.
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Modulation of the immune system: The innate immune system plays a major
role in the progression and regression of heart failure (Frantz et al. 2007).
Expression of Toll-like receptors (known to modulate immune and inflamma-
tory responses) leads to the activation of signaling pathways that induce the
expression of cytokines, chemokines, and co-stimulatory molecules. Increased
expression of Toll-like receptors and pro-inflammatory cytokines (IL-1, IL-1β,
IL-6, and TNF-α) has been demonstrated in severe heart failure (Birks et al.
2004a, 2001). The causes of immune system activation by the cardiomyocyte is
thought to be in response to different forms of injury (Yacoub 2001). Another
proposed mechanism is the activation of bacterial endotoxin-mediated path-
ways due to altered gut permeability in heart failure (Niebauer et al. 1999).
Tumor necrosis factor-α (TNF- α) is a frequently studied pro-inflammatory
cytokine that is associated with dilated cardiomyopathy in animals (Mann &
Young 1994) and humans (Habib et al. 1996; Torre-Amione et al. 1996; Levine
et al. 1990). Increased levels of TNF-α protein in the myocardium are nor-
malized after LVAD support (Torre-Amione et al. 1999). Torre-Amione et al.
(1999) have demonstrated a reduction of TNF-α content in failing myocardium
and have suggested that the magnitude of the change can be a useful marker
for recovery in cardiac function. In contrast, Razeghi et al. (2001) have shown
that there was no correlation between the clinical indices of cardiac improve-
ment and the decreased levels of myocardial TNF-α expression after LVAD
support.
Trophic factors: Long term mechanical unloading may induce myocyte atrophy
(Soloff 1999; Kinoshita et al. 1988). Several strategies have been used to
ameliorate or prevent atrophy during LVAD treatment. These include exercise
programs and the use of the β2-AR agonist clenbuterol (Yacoub 2001; Birks
et al. 2006). However the exact mechanisms involved in prevention of atrophy
remain unknown.
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IGF-1 is known to exert beneficial effects on the heart and can improve car-
diac function in the failing heart in-vivo (Duerr et al. 1995) by attenuating the
progression of heart failure and improving regenerative capacity (Welch et al.
2002). IGF-1 is known to induce hypertrophy (Musaro et al. 1999) and regen-
eration in senescent skeletal muscle (Musaro et al. 2001). The role of IGF-1 in
the regulation of myocardial structure in heart failure is unclear. Barton et al.
(2005) have shown elevated myocardial IGF-1 mRNA after LVAD explantation
following ‘combination therapy’ (Yacoub 2001; Birks et al. 2006).
Although mechanical unloading can induce IGF-1 in the heart in experimental
models (Sharma et al. 2006), it is unlikely that this elevation of IGF-1 is
directly related to mechanical unloading alone. Previous studies using real-
time PCR (Razeghi et al. 2003a) and microarray analysis (Hall et al. 2004) have
failed to detect elevated IGF-1 in HF patients treated with LVAD treatment
alone, without pharmacological therapy. Whatever the mechanism resulting
in increased expression, IGF-1 is known to have a number of salutary effects
on heart function (Torella et al. 2004) and can increase regenerative capacity
following injury (Santini et al. 2007). It is also likely to contribute to the
process of recovery through its ability to limit cardiac atrophy induced by
mechanical unloading.
Another group of mediators which have been recently implicated in remod-
elling and reverse remodelling are follistatins (FST) and the related pro-
teins, FSTL1 (also known as TSC-36/FRP/Flik) and FSTL3 (also known as
FRP/FLRG). They act by neutralizing activins, members of the TGF-β super-
family, that are implicated in diverse biological processes including cell prolif-
eration and differentiation, wound healing, inflammation and fibrosis (Harrison
et al. 2005). Lara-Pezzi et al. (2007) have recently shown elevated myocardial
expression of FSTL1 and FSTL3 in heart failure patients at the time of LVAD
implantation. These elevated expression levels returned to normal following re-
covery and LVAD explantation following ‘combination therapy’ (Yacoub 2001;
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Birks et al. 2006). Microarray analysis showed that FST and FSTL1 expres-
sion correlate with extracellular matrix-related and calcium binding proteins,
whereas FSTL3 is associated with cell signalling and transcription. FSTL1
also showed positive correlation with the endothelial cell marker CD31, sug-
gesting a potential link with possibly improved vascularization, a feature of
recovery noted in previous studies (Tansley et al. 2004). Follistatin-like genes
may therefore be linked both to disease severity and to mechanisms underlying
recovery thereby revealing new insight into the pathogenesis of heart failure
and offering novel therapeutic targets.
Cardiac transcription factors that play a critical role in heart development
are promising candidates as regulators of the remodelling process, since the
hypertrophic response appears to involve the reactivation of a fœtal gene pro-
gram (Oka et al. 2007; Olson & Schneider 2003; Izumo et al. 1988). Altered
expression of basic helix-loop-helix (bHLH) transcription factors, HAND1 and
HAND2, has a profound effects on cardiac development (Srivastava et al. 1997;
Bhattacharya et al. 2006) but their role in the adult heart remains unclear.
HAND1 (expressed in ventricles) has been shown to be downregulated in is-
chæmic and non-ischæmic heart failure with unaltered HAND2 (expressed in
atria and ventricles) expression (Natarajan et al. 2001). In contrast, Barton
et al. (2007) have shown in a recent study normalization of elevated HAND1
expression with unaltered HAND2 expression in LVAD explanted patients.
HAND1 expression strongly correlated with expression profile of genes relating
to the mitochondrial compartment, energy pathways and metabolism. These
results suggest altered transcriptional regulation in heart failure is further al-
tered by combination therapy and may contribute to improved LV function
and offer new therapeutic targets.
Calcium handling proteins: Alterations in Ca2+ cycling has been linked closely
to myocardial contractile dysfunction in heart failure (Gwathmey et al. 1987;
Morgan et al. 1990). Reversal of contractile dysfunction of failing hearts fol-
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lowing LVAD-induced unloading is known to be associated with altered gene
expression of key Ca2+ cycling proteins like NCX, SERCA2a and the RyR
(Heerdt et al. 2000; Rodrigue-Way et al. 2005). Upregulation of SERCA2a
mRNA has been demonstrated after LVAD support which was related to æti-
ology of HF (DCM>ICM) and papillary muscle force-frequency relationship
(Heerdt et al. 2006). Some of the key changes in excitation-contraction (EC)
coupling and Ca2+ cycling mechanisms are summarized in Fig 1.15. Ter-
racciano et al. (2004, 2003) have shown that specific changes in EC coupling
(action potential duration shortening, more rapid L-type Ca2+ current (I Ca,L)
fast inactivation, and increased sarcoplasmic reticulum Ca2+ content), and
not regression of cellular hypertrophy, may be the link between structural and
functional reverse remodelling.
Adrenergic receptors and pathways: Normalization of reduced β-AR density
and enhanced inotropic responsiveness has been demonstrated in LVAD sup-
ported failing hearts (Ogletree-Hughes et al. 2001). There was no correla-
tion between duration of unloading and β-AR density, suggesting that other
signaling mechanisms may play an important role in improved inotropic re-
sponsiveness following LVAD support. Improved β-AR agonist-mediated force
generation is associated with normalization of PKA-induced-ryanodine recep-
tor (RyR) hyperphosphorylation, following LVAD treatment of failing human
hearts (Marx et al. 2000; Klotz et al. 2005a). It is possible that the reversal
of PKA-induced RyR hyperphosphorylation is a key underlying mechanism in
restoring β-AR agonist-induced increase in contractility.
Cardiac α-adrenergic receptor (α-AR) stimulation is also known to modulate
various steps of Ca2+ homeostasis and myocardial contractility (Woodcock
2007; Smiley et al. 1998) by mediating positive inotropic effects via inositol
triphosphate and protein kinase-A pathways (Schwinn 1993). Although they
are present in a lower density in the human heart, compared to β-AR, their
role may be more important in severe heart failure with β-AR downregulation
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Fig. 1.15: Summary of the main findings reported for EC coupling of cardiac tissue
from heart failure patients taken at LVAD explantation. (1) Harding et al. (2001),
(2) Terracciano et al. (2004), (3) Chen et al. (2002), (4) Marx et al. (2000), (5) Ter-
racciano et al. (2003), (6) Dipla et al. (1998), (7) Chaudhary et al. (2004), (8) Frazier
et al. (1996), (9) Heerdt et al. (2000). (Figure and legend reproduced from Terracciano
et al. (2007)).
(Bohm et al. 1988). However, their role in the pathophysiology of heart failure
is still unclear. Grigore et al. (2005) have shown an increased α1-AR density
and alteration in receptor distribution, following LVAD unloading.
Sarcomeric and non-sarcomeric cytoskeletal proteins: The major classes of
proteins of the cardiac myocyte include sarcomeric, cytoskeletal and mem-
brane bound proteins. Sarcomeric genes were shown to be up-regulated by
LVAD support, consistent with a possible restoration of sarcomere structure
in reverse ventricular remodelling (Rodrigue-Way et al. 2005). Dystrophin (a
protein associated with cardiomyopathy) links the actin cytoskeletal networks
and the sarcolemmal dystrophin-associated protein complex (DAPC), which
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is in turn associated with the extracellular matrix of the cardiomyocyte. Dis-
ruption of N-terminus of dystrophin in heart failure was shown to be reversed
after LVAD treatment (Vatta et al. 2002, 2004). A specific pattern of changes
in cytoskeletal and non-cytoskeletal gene (Birks et al. 2005) and protein (Latif
et al. 2007) expression have been shown to be associated with significant my-
ocardial functional recovery following LVAD support. Association of integrin
pathway signalling (which have a well known role in mechanotransduction) and
downregulation of EPAC2 (well-described cAMP pathway) can be associated
with significant myocardial functional recovery (Hall et al. 2007).
Using immunocytochemistry, de Jonge et al. (2002) have reported incomplete
normalisation of structural changes in cytoskeletal proteins following LVAD
treatment. These results indicate that despite functional recovery leading to
LVAD explantation, there is incomplete reversal of cytoskeletal gene and pro-
tein modulation. Although persistent structural defects after LVAD treatment
alone have been reported (de Jonge et al. 2002), it would be interesting to know
if there is a normalisation or improvement at a structural level after complete
functional recovery.
Metabolic enzymes: A wide range of metabolic derangements are known to oc-
cur in heart failure which may be self perpetuating and progressive (Ashrafian
et al. 2007). Most of these perturbations result in depletion of myocardial
ATP, phosphocreatine, and creatine kinase with decreased efficiency of me-
chanical work (Ashrafian et al. 2007). Myocardial metabolism is altered fol-
lowing LVAD support but the mechanisms involved are still unclear. Lee et al.
(1998) have shown improvement of cardiomyocyte metabolic dysfunction in
heart failure following LVAD treatment. Cardiolipin is a specific lipid com-
ponent of the mitochondrial inner membrane (made up of L4, L3O, and L2O2
molecular species) whose presence is essential for maintaining mitochondrial
ultrastructure, oxidative ATP formation and substrate transport (Jiang et al.
2000; Ohtsuka et al. 1993; Paradies et al. 1999). Heerdt et al. (2002) have
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shown a reversal of myocyte cardiolipin composition with LVADs in ischæmic
heart failure but not DCM hearts, indicating that specific changes in myocytes
that occur after LVAD treatment are also dependent on ætiology of heart fail-
ure. Mital et al. (2000) have demonstrated that LVAD support of failing hearts
potentiates endogenous NO-mediated regulation of mitochondrial respiration.
Razeghi et al. (2002) have reported reversal of depressed UCP3 expression
which may be an important mechanism for reducing the formation of oxygen-
derived free radicals. These findings suggest that LVAD treatment can reverse
depressed metabolic gene expression in the failing human heart (Razeghi et al.
2002).
In the failing heart, despite increases in some ATP synthesizing pathways (such
as glycolysis), other pathways, such as the creatine kinase-phosphocreatine sys-
tem, decrease (Ingwall & Weiss 2004; Nascimben et al. 1996). However, ATP
levels have been shown to be 30% lower in the failing human myocardium
(Nascimben et al. 1996; Starling et al. 1998; Beer et al. 2002). The crea-
tine pool has been shown to be reduced in heart failure and its reduction
is related to heart failure severity (Nakae et al. 2003). Cullen et al. (2006)
have reported normalization of elevated myocardial arginine:glycine amidino-
transferase (AGAT) levels in failing hearts treated with ‘combination therapy’.
AGAT is a rate-limiting enzyme in the creatine synthesis pathway. These
changes suggest a response to heart failure that involves elevated local cre-
atine synthesis. The mechanisms leading to induced AGAT expression are
unknown but may be a response to the depletion of the local creatine pool in
heart failure (Nascimben et al. 1996).
II. Extracellular matrix
Changes in extracelluar matrix (ECM) and collagen metabolism following mechan-
ical unloading have been studied by various groups. Varying changes in collagen
content following LVAD support have been reported. Some groups report a de-
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crease (Akgul et al. 2004; Bruckner et al. 2001, 2000; Thompson et al. 2005) and
others, an increase (Klotz et al. 2005b; Bruggink et al. 2006; Li et al. 2001; Madi-
gan et al. 2001; Matsumiya et al. 2005) in collagen content. The reasons for these
differing responses remain unclear but may relate to differences in heart failure æti-
ology (Li et al. 2001), duration of unloading (Madigan et al. 2001; Bruggink et al.
2006), differences between patients with and without evidence of improved func-
tion (Maybaum et al. 2007), and the use of pharmacological therapy (Yacoub 2001;
Milting et al. 2006; Klotz et al. 2007). The influence of collagen cross linking on
ventricular stiffness and/or dilatation was first reported by Norton et al. (1997).
Subsequently, Klotz et al. (2005b) reported an increase in collagen cross linking
after LVAD treatment. The use of ACE inhibition and aldosterone antagonists in
the ‘Harefield Protocol’ was designed to reduce both the amount and possibly cross
linking of collagen (Yacoub 2001). Subsequently, it has been demonstrated that
ACE inhibition in LVAD supported failing hearts reduces LV collagen content and
stiffness (Klotz et al. 2007).
The matrix metalloproteinases (MMPs) and their inhibitors, the tissue inhibitors
of MMPs (TIMPs), play a key role in ECM maintenance and are responsible for
collagen denaturation and degradation. They are altered in chronic HF in humans
(Li et al. 1998; Spinale et al. 2000). It is now accepted that an imbalance between
MMPs and TIMPs leads to adverse ECM and LV remodelling (Wilson & Spinale
2001). Li et al. (1998) have shown increased MMP-9 (content and activity) and
reduced TIMP expression (-1, -3 and -4) in heart failure but, an increase in TIMP
expression (-1 and -3) and a decrease in MMPs (-1 and -9, content and activity),
following LVAD treatment of failing hearts (Li et al. 2001). Felkin et al. (2006) have
reported high myocardial MMP-1 and MMP-8 expression in patients requiring LVAD
support, without compensatory changes in collagen or TIMP expression, which may
be linked to elevated cytokine expression.
Klotz et al. (2005b) have reported that following LVAD support, MMP-1 and
MMP-9 tended to decrease with a normalization of the MMP-1/TIMP-1 ratio. In a
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subsequent study, Klotz et al. (2007) have reported reversal of TIMP-1 levels with
normalization of MMP-1/TIMP-1 ratio following LVAD support, especially in pa-
tients receiving concomitant ACE-inhibitor therapy. In addition, the ACE-inhibitor
therapy also prevented the increase in collagen and cross-linked collagen deposi-
tion (Klotz et al. 2007). Bruckner et al. (2004) have shown that patients bridged
to transplantation who gain the maximum improvements in LVEF during LVAD
support, had less fibrosis at the time of device implantation. This suggests that a
pre-implant assessment of degree of fibrosis may predict myocardial improvement
during LVAD support. In a recent study, Felkin et al. (2007) have reported higher
levels of pro-fibrotic markers collagen type I, III and Thy1 (fibroblast marker) in
patients who failed to recover having received ‘combination therapy’ compared to
those who recovered. Moreover, in patients who recovered, higher expression levels
of collagen I, III and Thy1 at explant correlated with poorer subsequent function as
determined by ejection fraction measured at 1, 2 and 5 years post-explant.
III. Endothelial and microvascular function
Abnormalities in structure and function of coronary microcirculation has been shown
in various cardiovascular diseases (Camici & Crea 2007), with severe reduction in
coronary flow reserve in patients with DCM (Weiss et al. 1976; Neglia et al. 1995).
Tansley et al. (2004) have shown increased myocardial flow with significantly im-
paired coronary flow reserve in patients treated with LVAD support. Although
direct evidence of alterations in myocardial vasculature is lacking, there is indi-
rect evidence that some mechanisms involved in vascular regulation are affected by
LVAD treatment. Hall et al. (2004) have shown altered regulation of genes involved
in the regulation of vascular organization and migration in the heart (neuropilin-1,
FGF9, Sprouty1, stromal-derived factor 1, and endomucin) after LVAD treatment.
Huebert et al. (2004) have shown upregulation of Sprouty1 (intrinsic inhibitor of the
Ras/MEK/ERK pathway) in endothelial cells, associated with a significant decrease
in VEGF-induced endothelial cell proliferation. This suggests that Sprouty1 may
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modulate myocyte and vascular alterations in response to mechanical load. Recent
studies have demonstrated the utility of using analysis of the transcriptome, glycome
and proteome in understanding endothelial cell apoptosis (Affara et al. 2007).
Endothelins (ET) may also play a role in cardiac muscle contraction and induce
either an increase or a decrease in contractility (Penna et al. 2006). Thompson et al.
(2005) have shown that ET-1 and plasma BNP levels correlate with LV function im-
provement and myocardial morphological changes during LVAD support. Morawietz
et al. (2000) have demonstrated normalization of myocardial ETA receptor expres-
sion with unchanged endothelin-converting enzyme-1 following LVAD treatment.
The natriuretic hormones ANP and BNP are known to have compensatory diuretic
activity during heart failure and are induced by mechanical stretch of chamber walls.
Milting et al. (2001) have shown variable time courses of ANP and BNP changes,
based on VAD types with no clear correlation to mechanical unloading alone.
IV. Role of neurohormonal activation
Alterations in neuroendocrine regulation, including the renin-angiotensin-aldosterone-
system (RAAS) and plasma catecholamines, are common features in heart failure
(Jessup & Brozena 2003). James et al. (1995) have shown a decrease in neuroen-
docrine activation during LVAD support, including a decrease in angiotensin II,
plasma epinephrine, norepinephrine, and arginine vasopressin levels, and plasma
renin activity. Myocardial tissue levels of angiotensin I and II, known regulators of
myocardial collagen synthesis, have been shown to be further increased after LVAD
support (Klotz et al. 2005b). This may contribute to increased collagen cross-linking,
decreased degradation of immature collagen, and increased production of new col-
lagen leading to increased LV stiffness reported by Klotz et al. (2005b).
Apelin, the ligand of the angiotensin receptor-like 1 (APJ), has been shown to
have strong inotropic effects (Szokodi et al. 2002; Berry et al. 2004). Plasma APJ
levels are decreased (Chong et al. 2006) with upregulated myocardial expression
(Atluri et al. 2007) in heart failure. Chen et al. (2003a) have shown that APJ
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was the most significantly upregulated gene after LVAD support of failing hearts.
They have also shown that apelin is localized primarily in the endothelium of the
coronary arteries and is found at a higher concentration in cardiac tissue (by en-
zyme immunoassay) after LVAD unloading. These findings may imply an important
paracrine signaling pathway in the heart contributing to alterations in myocardial
inotropic response. Farkasfalvi et al. (2006) have shown an elevation of APJ ex-
pression, with a strong positive correlation to LVEF improvement. This trend was
seen in hearts of patients that underwent explantation of LVAD following myocardial
functional recovery. Monitoring APJ expression may provide a target for monitoring
myocardial recovery.
V. Microarray studies
With the emergence of microarray technology, it is now possible to simultaneously
assess the expression of tens of thousands of gene transcripts, providing a resolution
and precision of characterization not previously possible. Using this technique sev-
eral groups have elucidated gene expression alterations in failing hearts after LVAD
unloading (Table 1.7). Changes described in these studies are not however uniform
and the relationship of the genomic changes to myocardial structural and functional
recovery are still unclear. The reasons for these differing responses remain unclear
but may relate to differences in ætiology of heart failure, duration of unloading,
differences between patients with and without evidence of improved function, and
the use of pharmacologic therapy such as ‘combination therapy’ (Yacoub 2001; Birks
et al. 2006). However this technique offers exciting prospects for understanding the
interplay of various mechanisms simultaneously to further our understanding of pro-
gression and reversal of heart failure.
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Table 1.7: Gene expression alteration in failing hearts after LVAD treatment
Study
Number of patients Paired / Unpaired data Key gene alterations described
Pre-LVAD Post-LVAD
Rodrigue-Way et al. (2005) 12 12 paired ↑Ca2+ handling, ↑sarcomeric, →fibroblast markers
Blaxall et al. (2003) 6 6 paired ↑295, ↓235 genes
Margulies et al. (2005) 157 28 unpaired ↑75%, 11%-recovery, 5%-normalized, 2%-overcorrection
Hall et al. (2004) 19 19 paired ↑85, ↓22 genes (vascular signaling network related)
Chen et al. (2003c) 7 7 paired ↑∼1400, ↓∼1700 genes
Chen et al. (2003a) 11 11 paired ↑APJ, ↓natriuretic peptides
Hall et al. (2007) 6 6 paired ↑integrin pathway signaling, ↓c-AMP pathway signaling
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1.6 Unloading-induced myocardial atrophy
The heart is capable of considerable growth and shrinkage, with a dynamic range of
at least 100% (Hill & Olson 2008). Decrease in cardiac mass to levels that are well
below normal is termed cardiac ‘atrophy’. It occurs in conditions of weightlessness
(Goldstein et al. 1992; Summers et al. 2007), bed rest (Perhonen et al. 2001), extreme
inactivity in patients with spinal cord injury (de Groot et al. 2006), and profoundly
during mechanical unloading by LVAD (Kinoshita et al. 1988; Nakatani et al. 1996).
Normalization of after-load following stenotic aortic valve replacement leads to re-
gression of left ventricular hypertrophy with no evidence of atrophy (Krayenbuehl
et al. 1989; Villari et al. 1995; Perez de Arenaza et al. 2005), suggesting trophism
of the heart is dependent on load.
A 26% decrease in LV mass due to unloading-induced atrophy (induced by con-
striction of the inferior vena cava in dogs) has been shown to occur within 10 days
(Lisy et al. 2005). Ventricular unloading by heterotopic transplantation in rodents
can lead to atrophy in under 1 week (Ito et al. 2003; Ritter et al. 2000), and becomes
more pronounced with time (Kolar et al. 1995; Rakusan et al. 1997; Welsh et al.
2001; Minatoya et al. 2007; Oriyanhan et al. 2007). These studies indicate that
unloading induced-atrophy can ensue rapidly when myocardial loading conditions
are altered.
The decrease in heart size is mainly caused by a decrease in cell size rather than
a loss of cells through apoptosis (Schena et al. 2004). Hypertrophy is considered
to result from an increase in the ratio of protein synthesis to protein degradation,
whereas in atrophic remodelling of the unloaded heart, activation of both protein
synthesis and degradation occurs and the relative balance of these two processes
determines the trophic response (Razeghi & Taegtmeyer 2005, 2006). It is cur-
rently thought that to maintain homeostasis, a fine balance between atrophy and
hypertrophy occurs, and is regulated by a complex molecular signalling pathways in
which Akt (serine/threonine-specific protein kinase) plays a central role (Hoffman &
Nader 2004; Sacheck et al. 2004; Sandri et al. 2004; Stitt et al. 2004). Deactivation
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of overexpressed Akt1 in mice leads to a 40% decrease in cardiac mass in just 1 week
(Shiojima et al. 2005).
Muscle atrophy is an energy-requiring process involving the ubiquitin–proteasome
system which catalyzes the degradation of the bulk of muscle proteins, especially
myofibrillar components (Lecker et al. 2006; Glass 2003). The regulation of muscle
atrophy in the heart may occur by suppression of pro-growth pathways or direct
stimulation of protein degradation by negative regulators of growth (Ni et al. 2006;
Rothermel et al. 2001; Hardt & Sadoshima 2004), whereas in skeletal muscle, acti-
vation of ubiquitin ligases (also called ‘atrogenes’) leads to atrophy (Sandri et al.
2004; Bodine et al. 2001; Glass 2003; Lecker et al. 2004). Recent evidence suggests
activation of key regulators of cardiac atrophy (Muscle and atrophy F-box protein
(Mafbx), Atrogin-1 and Muscle and Ring Finger protein-1 (MuRF-1)), involved in
pro-atrophic signaling pathways, reverses cardiac hypertrophy (Razeghi & Taegt-
meyer 2006).
Following LVAD-induced mechanical unloading, there is normalization of dilated
LV dimensions and cardiomyocyte size (Dandel et al. 2005; Maybaum et al. 2007;
Wohlschlaeger et al. 2005; Margulies 2002; Terracciano et al. 2004). While shorter
periods of mechanical unloading do not substantially affect contractile function,
despite reduction in cell size, prolonged mechanical unloading induces dysfunction
(Ritter et al. 2000; Welsh et al. 2001; Ito et al. 2003; Oriyanhan et al. 2007). Sev-
eral studies show time-dependent changes in cardiomyocyte and papillary muscle
contractile function and EC coupling that can impair cardiac performance after
prolonged unloading (Ito et al. 2003; Minatoya et al. 2007; Oriyanhan et al. 2007;
Kolar et al. 1995). Unloading induced-atrophy could therefore be an important im-
pediment to cardiac muscle functional recovery and removal of the LVAD, limiting
the efficacy of combination therapy (Yacoub 2001). Minimizing unloading-induced
atrophy may be an important strategy to maximize the beneficial effects of mechan-
ical unloading.
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1.7 LVAD as a ‘Bridge to Recovery’
The incidence of bridge to recovery varies from centre to centre around the world
and, except for one study (Dandel et al. 2005), is about 4-9% (Frazier & Myers 1999;
Mancini et al. 1998; Maybaum et al. 2007). At the Harefield Hospital, UK, a prospec-
tive trial using a combination of mechanical unloading by LVAD (HeartMater I, Tho-
ratec Corporation, USA) and pharmacological therapy (termed combination ther-
apy) has led to a substantially improved recovery rate of greater than 70% (Birks
et al. 2006).
The rationale of the combination therapy is to achieve maximal unloading of
the myocardium combined with a two-staged, pharmacological therapy, aimed at
remodelling reversal. This is followed by stimulation with β2-adrenoceptor (AR) ag-
onist clenbuterol, to prevent ‘unloading-induced atrophy’ (see Page 82) and induce
development of ‘physiological’ hypertrophy (Yacoub 2001; Hon & Yacoub 2003).
As published in Birks et al. (2006), the two-staged pharmacological therapy is as
follows.
Stage I: Treatment with four drugs in this stage is intended to enhance reverse
remodelling. Therapy is initiated immediately after the patient had been
weaned from inotropic therapy with adequate end-organ recovery, following
LVAD implantation. The four drugs and the maximum titrated doses are as
follows:
• ACE inhibitor – Lisinopril, 40 mg daily
• Non-selective β-blocker – Carvedilol, 50 mg twice daily
• Diuretic/Aldosterone antagonist – Spironolactone, 25 mg daily
• Angiotensin receptor blocker – Losartan, 100 mg daily
Stage II: The second stage of pharmacological therapy aims to minimize ‘unloading-
induced atrophy’. After maximal regression in the left ventricular end-diastolic
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and end-systolic diameters (LVEDD and LVESD respectively) are achieved,
with the LVAD in place and a constant left ventricular size maintained for
at least 2 weeks according to echocardiographic assessment, clenbuterol is ad-
ministered. Clenbuterol treatment is titrated to maintain resting heart rate
<100 bpm and achieving a maximum dose of 2,100 µg/day (commenced at an
initial dose of 40 µg twice daily, then at a dose of 40 µg three times daily, and
finally at a dose of 700 µg three times daily). Before clenbuterol is started,
carvedilol is replaced by the selective β1-AR blocker, bisoprolol, to reduce the
detrimental effects of chronic β1-AR stimulation (Xiao 2001).
In this study (Birks et al. 2006), echocardiography was performed before LVAD im-
plantation and then weekly after implantation for the first month, every 2 weeks for
6 months, and monthly thereafter. After week 4, measurements were obtained both
when the LVAD was on and when it was off. In the patients who showed a sustained
improvement in left ventricular function and exercise capacity with the LVAD turned
off and met the following criteria (Table 1.8), the LVAD was explanted.
Table 1.8: LVAD explantation criteria for Harefield Hospital ‘Bridge to Recovery’ study with
LVAD off for 15 minutes. Table compiled from Birks et al. (2006).
LVEDD < 60 mm
LVESD < 50 mm
left ventricular ejection fraction (LVEF) > 45%
left ventricular end-diastolic pressure (LVEDP) < 12 mm Hg
resting cardiac index > 2.8 L/m2
maximal oxygen consumption (VO2 max) with exercise > 16 ml/kg/min
increase in minute ventilation (VE) relative to the production of carbon dioxide
(VCO2) (VE/VCO2 slope) < 34
Of the 24 patients with non-ischæmic dilated cardiomyopathy who underwent
LVAD implantation as a part of the study, 9 were excluded due to poor clinical status,
inability to complete Stage II drugs or death. Of the remaining 15 patients who
were enrolled in the study and received the complete course of combination therapy,
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11 (73%) had sufficient recovery to meet the explantation criteria (Table 1.8),
and were explanted. This number represents 46% of all 24 patients who received
the LVAD. Freedom from recurrent heart failure in surviving patients was 100% and
89% at one and four years after explantation, respectively. Average ejection fraction
was 64% at 59 months after explantation and all patients were NYHA Class I.
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1.8 β2-adrenergic stimulation & clenbuterol
1.8.1 β-adrenergic system
Catecholaminergic cardiac β-AR stimulation serves as the most powerful means to
increase cardiac output in response to stress or exercise, commonly known as ‘fight-
or-flight’ response. β-ARs are G-protein (guanosine triphosphate binding proteins)-
coupled receptors (GPCRs) and intracellular propagation of GPCR signaling is an
intricate process orchestrated by a wide array of G-proteins (Fig 1.16). Most
G-proteins can commonly couple with a number of ligands including histamine,
serotonin, and glucagon receptors which stimulate both Gs and Gi protein subtypes
in human heart (Kilts et al. 2000). The consequences of coupling a single receptor to
multiple G-proteins in physiological and pathophysiological states remains unclear
and currently an area of active research.
Prolonged stimulation of β-AR by an agonist leads to a reduction in receptor
responsiveness, termed as ‘desensitization’. This process is thought to be mediated
either by a negative feedback regulation by PKA or by the G-protein-coupled re-
ceptor kinase (GRK) family (GRK1–6), in particular GRK2, which is also known
as β-adrenoceptor kinase 1 (βARK1) (Xiao et al. 2004; Xiao 2001).
Differences between β1- and β2-AR signalling
Cardiac tissue expresses three β-AR subtypes: β1, β2 and β3 (Xiao 2001; Xiao et al.
2004; Gauthier et al. 1998, 2000). The β1-AR is considered the more abundant
receptor in most species with expression levels of 75-85%, compared with ∼25%
β2-AR (Bristow et al. 1986; Xiao 2001). These β-AR subtypes are currently be-
lieved to have distinct, or sometimes even opposite, physiological and pathological
roles (Xiao et al. 2004; Xiao 2001) (Fig 1.16). The β1-AR subtype appears to
stimulate solely the stimulatory G-protein (Gs) pathway and couple to the classic
Gs–adenylyl cyclase (AC)–cAMP–protein kinase A (PKA) signaling pathway, re-
sulting in the phosphorylation of numerous proteins involved in metabolism, growth
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Fig. 1.16: Schematic showing the dual coupling of β2-AR to Gs and Gi proteins, and compart-
mentalization of G-protein specific downstream signalling. Stimulation of Gs activates Gs-AC–
cAMP–PKA signaling. However, Gi stimulation activates Gi–Giβγ–phosphatidylinositol 3-
kinase (PI3K)-protein kinase B (PKB) pathway which both compartmentalizes and negates
the concurrent Gs–AC–cAMP–PKA signaling, and also exerts an anti-apoptotic effect in car-
diomyocytes. Figure reproduced from Xiao et al. (2004). (Abbreviations: βARK-ct, a pep-
tide β-AR kinase inhibitor of Gβγ signaling; CaMKII, Ca2+-calmodulin-dependent protein
kinase II; LY294002, a PI3K inhibitor; PLB, phospholamban; PTX, pertussis toxin)
and cell survival (Xiao et al. 2004; Xiao 2001). PKA-dependent phosphorylation of
regulatory proteins involved in cardiac EC coupling (L-type Ca2+ channels, phos-
pholamban, Tn-I and -C, glycogen phosphorylase kinase) leads to increased cardiac
contractility (positive inotropic effect), acceleration of cardiac relaxation (positive
lusitropic effect) and increased heart rate (positive chronotropic effect).
Increasing evidence indicates that β2-AR stimulates both Gs and pertussis toxin
(PTX)-sensitive, inhibitory G-protein (Gi), leading to activation of a separate Gi–
Gβγ–phosphatidylinositol 3-kinase (PI3K)-protein kinase B (PKB) cascade (Fig 1.16).
This additional Gi pathway compartmentalizes and negates the concurrent Gs-
independent signals. β1-AR stimulation alone dœs not increase Gi activity (Xiao
et al. 1999; Kilts et al. 2000). Given the signalling to Gs and/or Gi, the effects of
β2-AR stimulation on cardiac function and regulation are unclear.
For instance β2-AR stimulation alone fails to accelerate the decay of the intra-
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cellular Ca2+ transient and the contractile relaxation in various mammalian species
(Xiao & Lakatta 1993; Kuznetsov et al. 1995; Lemoine & Kaumann 1991; Borea
et al. 1992), except in humans and dogs (Kaumann et al. 1996, 1999; Altschuld
et al. 1995; Kuschel et al. 1999b). These findings suggest differences in intracellular
signal transduction pathways initiated by β2-AR, compared to those activated by
β1-AR and may be species-dependent.
β-AR stimulation and cell survival
Studies in-vivo and in-vitro suggest that prolonged β-AR signaling causes cardiac
myocyte apoptosis (Geng et al. 1999; Communal et al. 1998; Shizukuda et al. 1998).
In addition, pharmacological evidence suggests β1-AR and β2-AR stimulation may
exert different effects on cardiac cell survival (Communal et al. 1999; Zaugg et al.
2000). Studies in-vitro and in-vivo using cardiomyocytes expressing only β1-AR or
β2-AR show that stimulation of β1-AR alone leads to cardiac apoptosis; however
stimulation of only β2-AR activates pro-apoptotic and anti-apoptotic signals with
the net effect being improved cell survival (Zhu et al. 2001; Schena et al. 2004).
β2-AR stimulation has been shown to reduce apoptosis in a rat model of chronic
heart failure (Ahmet et al. 2004, 2005; Xydas et al. 2006a). The increased β1-AR
induced apoptosis is mediated by activation of Ca2+/calmodulin kinase II (CaMKII),
independent of cAMP–PKA signaling whereas the anti-apoptotic effect of β2-AR
stimulation is mediated through Gi–Gβγ–PI3K signaling pathway, which activates
the survival factor Akt (Zhu et al. 2003) (Fig 1.16).
Cardiac hypertrophy induced by β-AR stimulation
β1- and β2-ARs display different and opposing effects on gene expression, cell sur-
vival and apoptosis. Stimulation of β1-ARs in cultured neonatal rat cardiac my-
ocytes produces hypertrophy through activation of a PI3K–Akt–GSK-3β–GATA4
signaling pathway (Morisco et al. 2000, 2001a). However, this appears to be inde-
pendent of PTX-sensitive Gi signaling (Morisco et al. 2001b) or MAPK/ERK signal
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transduction pathway activation (Morisco et al. 2000).
In contrast, β2-AR stimulation protects myocytes against apoptosis induced by
enhanced β1-AR signaling, hypoxia, and reactive oxygen species (Chesley et al.
2000; Zhu et al. 2001; Communal et al. 1999). Overexpression of cardiac β1-AR (5-
40 fold) leads to cardiac hypertrophy, myocyte apoptosis, and fibrosis within a few
weeks after birth, and heart failure within several months (Engelhardt et al. 1999;
Bisognano et al. 2000). Overexpression of cardiac β2-AR (100-200 fold) dœs not
produce hypertrophy or heart failure, up to the age of 1 year but increases in-vivo
left ventricular function (Milano et al. 1994; Dorn et al. 1999; Liggett et al. 2000).
However, higher levels of expression of β2-AR (350-1000 fold) results in pathological
phenotypes (Dorn et al. 1999; Liggett et al. 2000), possibly due to spontaneous
‘agonist independent β2-AR activation’ (Milano et al. 1994; Chidiac et al. 1994;
Bond et al. 1995).
β-AR modulation in heart failure
The opposing effects of β-AR subtypes on cardiac myocyte growth and cell death
may partly explain the inverse relationship between plasma norepinephrine levels
(with higher affinity for β1-AR than for β2-AR) and survival in patients with chronic
heart failure (Cohn et al. 1984). It is possible that the selective down-regulation of
only β1-ARs (Bristow et al. 1982, 1986; Brodde et al. 2006; Kiuchi et al. 1993) in
the presence of unchanged β2-ARs (Bristow et al. 1986) in the failing hearts may
represent a protective mechanism to slow the progression of cardiomyopathy and
myocyte apoptosis. Indeed, β1-AR selective blockers (eg. metoprolol and bisopro-
lol) effectively reduce mortality and morbidity of heart failure patients (Bristow
2000), whereas non-selective β-AR blockers (eg. propranolol) induce myocardial
depression and worsening of cardiac contractile dysfunction (Talwar et al. 1996).
Ahmet et al. (2004) have also shown that administration of β2-AR agonists after
myocardial infarction in rats reduced the extent of left ventricular dilation, infarct
expansion and ejection fraction decline. Treatment with metoprolol (β1 blocker) was
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less effective than the β2-AR agonists in improving ejection fraction. These stud-
ies intuitively suggest that selective stimulation of β2-AR and blockade of β1-AR
subtypes simultaneously may be beneficial but further studies would be required to
clarify this point. However, there is some evidence to suggest that the combination
of β2-AR stimulation and β1-AR blockade may not be synergistic and no additional
benefit possible (Xydas et al. 2006a).
Heart failure results in increased amounts or activity of Gi proteins (Kiuchi
et al. 1993; Gu et al. 1998; Eschenhagen et al. 1992; Bohm et al. 1994) and a
selective down-regulation of β1-AR, leading to a higher β2-AR/β1-AR ratio (Bristow
et al. 1982, 1986; Brodde et al. 2006; Kiuchi et al. 1993). Therefore, up-regulation
of Gi proteins may result in the reduced β-AR mediated inotropic effect in the
decompensated failing heart. This hypothesis is supported by the finding that PTX
treatment (Gi inhibition) restores the diminished β-AR mediated, inotropic response
in cardiomyocytes from failing rat (Kompa et al. 1999) and human hearts (Brown
& Harding 1992). Also selective blockade of β2-AR in failing human cardiomyocytes
with ICI 118,551 reduces contractility by stimulating the Gi pathway (Gong et al.
2002).
Agonist-independent activation of β2-AR
Cardiac- specific overexpression of β2-AR (by∼200 fold) leads to an agonist-independent
enhancement in both the baseline adenylate cyclase activity and myocardial contrac-
tility (Xiao et al. 1999; Milano et al. 1994; Bond et al. 1995). Tevaearai et al. (2002)
have shown that adenoviral-delivered β2-AR overexpression in failing rabbit hearts,
enhances functional improvement during chronic mechanical unloading. This sup-
ports the use of β2-AR stimulation in preventing the negative effects of chronic
unloading.
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1.8.2 Effects of clenbuterol
The long-acting (half life: 36-39 hrs), β2-AR agonist, clenbuterol (4-amino-α-(t-
butylaminomethyl)-3,5-dichlorobenzyl alcohol hydrochloride, Fig 1.17) has been
originally used as a bronchodilator in the treatment of asthma (Salorinne et al.
1975; Gobel 1975; Anderson & Wilkins 1977).
Fig. 1.17: Molecular structure of Clenbuterol hydrochloride. (Figure reproduced from
www.sigmaaldrich.com)
One of the important side effects of this drug was skeletal (Rehfeldt et al. 1994;
Bardocz et al. 1992; Maltin et al. 1992; Agbenyega & Wareham 1990) and cardiac
(Wong et al. 1998a, 1997; Petrou et al. 1995) muscle hypertrophy. In heart failure
patients, clenbuterol can increase skeletal muscle mass and strength (George et al.
2006; Kamalakkannan et al. 2008).
Clenbuterol acts through both β1 and β2 adrenergic receptors, but with different
potency (Mazzanti et al. 2007). Although classed as a β2-AR agonist, there is evi-
dence for the existence of specific additional binding sites (exosites) for clenbuterol,
and that exosites exist on non-ligand recognition regions of the β2-AR protein, which
may explain the long duration of action on airway smooth muscle (Coleman et al.
1996; Anderson et al. 1994). Recent evidence from this laboratory shows that, unlike
other β2-AR agonists, clenbuterol predominantly activates the Gi protein (Siedlecka
et al. 2008). There is evidence that the β2-AR–Gi subtype specific stimulation has
cardioprotective effects and beneficial functional consequences in rodent ischæmic
cardiomyopathy and may also be enhanced when combined with β1-AR blockade
(Ahmet et al. 2004, 2005; Xydas et al. 2006a).
The ability of clenbuterol to induce structural changes in the myocardium is con-
troversial. Studies have shown that clenbuterol administration has a beneficial effect
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on fibrosis and apoptosis. Wong et al. (1997) have shown that clenbuterol adminis-
tration in conjunction with pressure overload by aortic banding in rats increases LV
mass with less fibrosis and collagen content than banding alone (Wong et al. 1998a).
George et al. (2006) report no change in collagen content in heart failure patients
treated with clenbuterol during mechanical unloading by LVAD. Petrou et al. (1995)
used clenbuterol for improving the performance of the latissimus dorsi muscle in rats
as a treatment strategy for end-stage heart failure by dynamic cardiomyoplasty, and
also found that clenbuterol-treated rat hearts expressed elevated levels of mRNA
to ANP without a concomitant increase in skeletal α-actin and β-MHC, consistent
with a ‘physiological’ form of cardiac hypertrophy (Ghorayeb et al. 2005; Kong et al.
2005; Wakatsuki et al. 2004) (see Page 32). As β2-AR stimulation alone dœs not
produce cardiac hypertrophy (Milano et al. 1994; Dorn et al. 1999; Liggett et al.
2000), it is possible that the the modest cardiac hypertrophy (∼20%) seen is this
study may be due to concomitant β1-AR stimulation (Burniston et al. 2005). Hon
et al. (2001) found that clenbuterol treatment during pulmonary artery banding of
sheep improved systolic function of the chronically pressure-overloaded right ven-
tricle. These findings led to the hypothesis that unloading-induced atrophy after
LVAD treatment (Kinoshita et al. 1988; Nakatani et al. 1996) may be countered by
the treatment with clenbuterol and also stimulate a physiological form of cardiac
hypertrophy in failing hearts (Yacoub 2001; Hon & Yacoub 2003; Birks et al. 2006).
Burniston et al. (2005) have shown a dose-dependent, β1-AR mediated, clenbuterol-
induced myocardial apoptosis, necrosis and collagen content in the heart and skeletal
muscle of the rat after clenbuterol administration. Although the β1-AR was not se-
lectively blocked in this study, it is possible to predict that this strategy would
further improve the beneficial effects of clenbuterol during mechanical unloading
in heart failure. Based on the above rationale to maximize the β2-AR mediated
beneficial effects of clenbuterol during mechanical unloading, bisoprolol a selective
β1-AR blocker, is used in combination with clenbuterol in the patients treated with
LVADs (Yacoub 2001; Hon & Yacoub 2003; Birks et al. 2006) (see Page 82).
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Abuse of clenbuterol
Clenbuterol is one of the most commonly abused drugs for gaining muscle mass in
bodybuilding and other sports (Delbeke et al. 1995; Clarkson & Thompson 1997;
Spann & Winter 1995; Prezelj et al. 2003). Clenbuterol is widely abused as a “di-
etary supplement”, commonly used as a slimming aid despite lack of sufficient clin-
ical data supporting such use (Parr et al. 2008; Casali et al. 2007). Clenbuterol and
other β-AR agonists are commonly misused as repartitioning agents8 in meat pro-
duction and as a doping substance to improve athletic performance (Prezelj et al.
2003; Mazzanti et al. 2003). Meat contaminated with high levels of clenbuterol
(0.8-7.4 mg/kg) causes adverse health effects in human, reduces the performance
in exercise and disturbs reproductive system and hormone response (Sporano et al.
1998; Brambilla et al. 1997). Clinical presentation of clenbuterol intoxication include
gross tremors of the extremities, tachycardia, nausea, headaches, dizziness, hyper-
tension, hypokalæmia, hypophosphatæmia and hypomagnesæmia (Barbosa et al.
2005; Hoffman et al. 2001).
Other effects of clenbuterol
Clenbuterol is also known to enhance regeneration of peripheral nerves in rodents
(Frerichs et al. 2001; Zeman et al. 2004), inducing redistribution of white blood cells
in the circulation (Shirato et al. 2007), stimulating egress of hematopoietic stem
cell from bone marrow (Katayama et al. 2006) and decreasing body fat (Zhou et al.
2007). There is weak evidence to suggest that use of clenbuterol was better than
placebo in the treatment of stress urinary incontinence in adults (Alhasso et al. 2005;
Tsakiris et al. 2008). Due to effects on skeletal muscle, clenbuterol has also been used
for treating cancer-related anorexia/cachexia (Mantovani et al. 2001; Bruera 1998).
Clenbuterol induces the synthesis of endogenous nerve growth factor (NGF) and
may itself be a myotrophic factor released by neuron endings and therefore has been
8β-AR agonists that alter carcass composition by partitioning energy away from fat deposition
and towards protein accretion (Moser et al. 1986).
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used for the treatment of the neurodegerative disease, amyotrophic lateral sclerosis
for its neuroprotective effects (Puls et al. 1999; Semkova & Krieglstein 1999).
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1.9 Hypotheses
The evidence detailed in this Chapter suggests LVAD treatment of failing hearts,
with or without combined pharmacological treatment, affects the ventricular remod-
elling process with reversal of LV dilatation. This is associated with a large number
of molecular changes affecting key pathways in the myocardium.
Compared to only mechanical unloading of failing hearts (Frazier & Myers 1999;
Mancini et al. 1998; Dandel et al. 2005; Maybaum et al. 2007), mechanical unloading
combined with pharmacological therapy used in the Harefield Hospital ‘bridge-to-
recovery’ strategy (Yacoub 2001; Hon & Yacoub 2003; Birks et al. 2006) has an
improved incidence myocardial functional improvement. Although there are several
drugs in the pharmacological component (see Page 84), the use of clenbuterol is
unique to the Harefield Hospital ‘bridge-to-recovery’ strategy when compared to
other ‘bridge-to-recovery’ studies (Frazier & Myers 1999; Mancini et al. 1998; Dandel
et al. 2005; Maybaum et al. 2007), and this may underly the improved myocardial
functional recovery rate (4-9% vs 73%). Based on the above evidence, it would be
interesting to know the answers to the following questions regarding the two key
factors (chronic clenbuterol administration and mechanical unloading) involved in
the Harefield Hospital ‘bridge-to-recovery’ strategy.
• What are the effects of clenbuterol on a normal heart, compared to a failing
heart?
• What are the effects of mechanical unloading on a normal heart, compared to
a failing heart?
• Does clenbuterol have any additional effects on the changes induced during
mechanical unloading of a normal heart, compared to a failing heart?
This thesis tests the hypothesis that two key factors (chronic clenbuterol adminis-
tration and mechanical unloading in heart failure) involved in the Harefield Hospital
‘bridge-to-recovery’ strategy using ‘combination therapy’ play a role in myocardial
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recovery by inducing a partial or complete normalization or compensatory modifi-
cations in EC coupling mechanisms. In an attempt to answer the above questions,
the following hypotheses were tested in this thesis.
1. Chronic administration of clenbuterol alters myocardial structure and function
and affects calcium handling in normal rat hearts.
2. Mechanical left ventricular unloading and the consequent left ventricular atro-
phy results in altered whole-heart and cellular function in non-failing/normal
rat hearts.
3. Clenbuterol treatment during mechanical unloading of a normal rat heart nor-
malises whole-heart and cellular function.
4. Clenbuterol has an additional benefit when combined with mechanical unload-
ing in the treatment of failing rat hearts.
The basic mechanisms of clenbuterol treatment in heart failure and during me-
chanical unloading were studied in a rat model to eliminate some of the confounding
factors associated with the clinical situation. In particular, the effects of chronic
administration of clenbuterol on whole heart and cellular function in normal my-
ocardium were first studied, followed by the investigation of the effects of mechani-
cal unloading induced by heterotopic abdominal heart transplantation. The role of
clenbuterol and mechanical unloading in heart failure were studied using a chronic
post-ischæmic cardiomyopathy model. Each one of the above hypotheses have been
tested in the results chapters.
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Chapter 2
Materials & Methods
2.1 Choice of experimental models
2.1.1 Model of mechanical unloading
The principle of mechanical unloading is to reduce the mechanical load of the LV
and minimize wall stress and ventricular work. An LVAD, therefore empties the
LV cavity and pumps the blood into the ascending aorta, as shown in Fig 2.2 A,
Page 104. Heterotopic abdominal heart transplantation, first described by Ono
& Lindsey (1969), also achieves a similar objective wherein the heart is perfused
normally but no blood enters the LV cavity (due to a competent aortic valve), thus
minimizing mechanical load and wall stress. Mechanical unloading can be achieved
reliably by heterotopic abdominal heart transplantation, as shown by many studies
(Rakusan et al. 1997; Razeghi et al. 2003b, 2006; Ito et al. 2003; Tsuneyoshi et al.
2005a). Availability of an inbred strain (Lewis rats) avoids the compounding effects
of immunological rejection following heterotopic abdominal heart transplantation of
isografts1 (Forbes & Guttmann 1984; Luketich et al. 1989; Huber et al. 1985).
1a graft of tissue/organ between two individuals who are genetically identical (eg. monozygotic
twins). Transplant rejection between two such individuals virtually never occurs.
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2.1.2 Model of heart failure
Patients involved in the Harefield Hospital ‘bridge to recovery’ study (Yacoub 2001;
Birks et al. 2006) suffered from idiopathic dilated cardiomyopathy. It would therefore
have been ideal to have a similar animal model of heart failure. Previous studies
of animal models of heart failure have employed various methods to apply chronic
wall stress to the ventricle, genetic manipulation and cardiotoxic drug therapy in
several species (Elsner & Riegger 1995). Alternative methods employed by others
include rapid electrical pacing (Shinbane et al. 1997), or constrictive banding of the
ascending aorta (Prasad et al. 1979; Siri et al. 1989).
However, various practical and theoretical considerations preclude the use of
some of these methods (Elsner & Riegger 1995). Animal models of heart failure
resulting from genetic manipulation (eg. spontaneously hypertensive rats) were not
considered appropriate due to the prolonged and varying time period required for
development of heart failure (18-24 months) (Boluyt et al. 1995; Bing et al. 1995).
These factors lead to difficulty in reproducing a predictable and definitive degree of
heart failure. Chronic cardiotoxic drug (eg. Doxorubicin) administration was not
considered appropriate as the effects are dose dependent and cumulative (Hayward
& Hydock 2007), multiple injections required, causes extensive cell damage with ul-
trastructural changes (Weinberg & Singal 1987) and can affect EC coupling directly
(Timolati et al. 2006; Keung et al. 1991). Myocardial dysfunction secondary to rapid
electrical pacing is difficult to achieve in rats due to practical considerations. Aortic
banding is technically feasible procedure mainly for developing LV hypertrophy but
development of heart failure is variable and is dependent on the degree of aortic
constriction achieved (Feldman et al. 1993).
Myocardial infarction caused by permanent left coronary artery (LCA) ligation
was chosen as the preferred mode of heart failure induction in this thesis as it is
a well established, reproducible model of LV dysfunction (Loennechen et al. 2002;
Ahmet et al. 2004, 2005; Xydas et al. 2006a). Coronary artery ligation mimics
the commonest clinical scenario of patients developing chronic heart failure due
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to progression of ventricular remodelling following a myocardial infarction. Other
advantages of coronary artery ligation included the high rate of development of heart
failure as well as technical simplicity and low cost.
2.1.3 Choice of animal species
The choice of rat as the animal model was based on the following considerations.
Rat is known to possess both β1- and β2-AR (Xiao & Lakatta 1993; Xiao 2001) and
previous studies have shown a hypertrophic response of LV to clenbuterol treatment
(Petrou et al. 1995; Wong et al. 1997, 1998a).
The evidence from the above studies suggested that measurable physiological
effects would be induced following heterotopic abdominal heart transplantation of
non-failing and failing hearts, allowing the hypotheses of this study to be tested.
From a technical viewpoint, rat LV cardiomyocyte isolation is a robust and reli-
able technique with extensive experience in our laboratory (Terracciano & MacLeod
1997; Stagg et al. 2006; Fukushima et al. 2007). The rat heart is of a reasonable
size to allow accurate assessment of in-vivo LV function and size, by trans-thoracic
echocardiography, and ex-vivo function by an intraventricular balloon in both re-
cipient and transplanted hearts. The rat is also a good candidate from practical
points such as cost and the need for a significant number of housed animals over
many weeks. Taken together, these factors led to the decision to use adult rats for
all experiments.
The features of cardiac EC coupling in normal hearts of many different animal
species has been described previously (for detailed reviews, see Hasenfuss (1998a),
Hasenfuss & Pieske (2002), Bers (2001) and Bers (2002)). A wide variation of pa-
rameters of cardiomyocyte function and electrophysiological properties are known
to occur depending on the animal species. This is perhaps unsurprising consider-
ing differences in functional demand, whole organ size, and normal beating rate.
The action potential profile and gain of CICR, for example, differ significantly be-
tween mouse, rat, guinea-pig, and human (Trautwein & McDonald 1978; Varro
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et al. 1993a). In rat hearts the force of contraction shows a negative correlation
with increasing frequency, which is opposite to that seen in guinea-pigs, rabbits and
humans. Ideally this study should be performed in an animal with cardiac EC cou-
pling similar to that of human to ultimately increase our understanding of the role
of mechanical unloading and β2-AR agonist therapy in patients with heart failure.
However, the various considerations laid out above led to the decision to use adult
rats. The relevance and interpretation of the experimental data, obtained in this
thesis, for humans is discussed in subsequent chapters.
2.2 Surgical procedures
All animal procedures were in accordance to the United Kingdom Animals (Scientific
Procedures) Act 1986, under Project Licence: PPL-70/5698 and Personal Licence:
PIL-70/17636. Only male Lewis rats weighing 200-300g (purchased from Harlan,
UK and Charles River, UK) were used for all experiments.
2.2.1 Induction of heart failure
Heart failure was achieved by ligation of left coronary artery or one of its branches,
as described by Pfeffer et al. (1979). Rats were anæsthetised with 1-2% Isoflurane
via Bain nose cone and weighed. Fur on the neck and chest was removed with hair
clipppers. Amoxycillin and buprenorphine were injected subcutaneously. The ani-
mal was placed in the supine position and a 2 cm midline skin incision was made on
the neck and neck muscles separated and retracted to expose the trachea. An 18 G
vascular cannula mounted on a blunt-tipped, metal guide was used as an uncuffed
endotracheal tube. The tip of the tongue was retracted by forceps to straighten
the epiglottis and the vascular cannula with the metal guide, inserted through the
larynx blindly. Entry into the trachea was visually confirmed by seeing the cannula
in the translucent trachea. The metal guide was then removed, airway secured and
connected to a volume controlled ventilator (Model 683 Rodent Ventilator, Harvard
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Apparatus Ltd, UK) via a Y-cannula, delivering inspiratory, and removing expi-
ratory gases. Correct endotracheal intubation was confirmed by chest movements,
synchronized with the ventilator. The tidal volume was adjusted to ∼8 ml/kg and
ventilatory rate to ∼60 breaths/min.
The animal was then turned into a right-lateral position and left forelimb re-
tracted away to expose the left chest. Skin was incised obliquely from xyphisternum
to left axilla. The pectoralis major muscle was separated from the latissimus dorsi
muscle by blunt dissection, exposing the chest wall. A left anterior thoracotomy was
performed through the 4th intercostal space and the left lung pushed away with a
gauze swab, clearly exposing the pericardium. After dividing the pericardium verti-
cally, the left coronary artery’s major branches were identified visually as thin, white
streaks. The distribution of the branches was variable between animals. The curved
needle of a 6.0 Prolener suture was passed under one of the major left coronary
artery branch (left anterior descending, diagonal or intermediate), just at the level
of the left atrial appendage and the vessel ligated tightly for permanent occlusion
(Fig. 2.1 A). Blanching of the anterior left ventricular free wall was observed when
a major branch was ligated resulting in a 30-40% infarction of the left ventricu-
lar circumference (Fig. 2.1 B). If a smaller area of blanching was seen, then an
additional left coronary branch was ligated to achieve a larger infarct.
After visually confirming development of the acute myocardial infarction (purple
discolouration of ischæmic area), the left lung was reinflated by sequential occlusion
of the expiratory outlet tubing during inspiratory phase, to increase positive end-
exipiratory pressure. Following complete reinflation of the left lung, the chest wall
was closed with 4.0 Prolener, and care taken to avoid puncturing the lung. The
pectoralis major and latissimus dorsi muscles were approximated and skin closed
with 2.0 Mersilkr. Isoflurane was discontinued and the animal ventilated with only
100% oxygen until full recovery of spontaneous ventilation. The endotracheal tube
was then removed and animal transferred to the cage with access to food and water.
The duration of the procedure was 15-20 mins and overall mortality, 31/146 (∼ 21%).
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A B
Fig. 2.1: Induction of myocardial infarction by ligation of left coronary artery was achieved
by passing a 6.0 Prolener suture and ligating tightly (A) and observing for blanching of the
anterior LV wall (B). (Pictures taken by Dr Joon Lee)
Majority of the deaths occurred within the first 24 hours. Reduction in LV function
was monitored by weekly echocardiography (procedure described on Page 113). Rats
were considered to be in heart failure when left ventricular ejection fraction (LVEF)
was below 40%.
2.2.2 Heterotopic abdominal heart transplantation.
The circuit of blood flow and anatomical relations are shown in Fig 2.2 B. The
donor heart is perfused by oxygenated blood from the recipient abdominal aorta.
Due to a competent aortic valve, only the coronary arteries are perfused, with only
minimal blood entering the LV cavity via Thebesian veins (Ansari 2001). The
coronary blood drains into the right atrium via the coronary sinus, right ventricle,
pulmonary artery and emptied into recipient inferior vana cava (IVC).
Procedure of heterotopic abdominal heart transplantation.
For both experiments involving mechanically unloading a normal or failing rat heart,
the surgical techniques were similar. The procedure involved simultaneous anæsthe-
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Fig. 2.2: Mechanical unloading by LVAD vs heterotopic abdominal heart transplantation.
The flow of blood (arrows) through the left heart and LVAD (A) show the principle of me-
chanical unloading wherein the LV is emptied to minimize mechanical load and wall stress.
The anatomical relations of a heterotopically transplanted heart and blood flow (arrows) are
shown in B. In this setting, no blood enters the LV due to a competent aortic valve. Blood
perfusing the coronary arteries collects in the coronary sinus which drains into the RA, RV,
PA and then into recipient IVC. Therefore the LV is mechanically unloaded, similar to the
role of an LVAD shown in A. (RA-Right atrium,RV-Right ventricle, LA-Left atrium, LV-Left
ventricle, IVC Inferior vena cava, PA Pulmonary artery).
sia of randomly selected, donor (for HF experiments, only after confirming LVEF
<40%) and recipient rats using 5% isoflurane (IsoFlor, Abbot Laboratoriesr) for
induction. Surgical plane of anæsthesia was maintained using 1-2% isoflurane via
two separate Bain face masks. The fur on the scruff of the neck and abdomen of the
recipient, and the chest of abdomen of the donor, were removed by hair clippers.
Both animals were placed in the supine position. Only the recipient was placed on
a heating mat (to prevent cooling of body temperature) and received 10-15 mg/kg
amoxycillin trihydrate (Clamoxyl LAr, Pfizer, USA) as antibiotic prophylaxis and
10-20 µg/kg buprenorphine hydrochloride (Vetergesicr, Reckitt & Colman, UK) for
analgesia, subcutaneously. The same dose of amoxycillin and buprenorphine have
been used for all animal procedures.
Preparation of the recipient: Following midline laparotomy, the retroperitoneum
overlying the infra-renal, abdominal aorta and IVC was opened and 1.5 cm of
both the vessels cleared of fat. If any lumbar arteries or veins were present
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within this 1.5 cm segment, they were ligated or diathermied to prevent back-
bleeding after aortotomy and venotomy. Subsequently the abdominal aorta
and IVC were clamped proximally and distally, using two vascular occlusion
clamps. The heating mat was then switched off to prevent heating of the
ischæmic lower limbs. A 3 mm aortotomy and venotomy was made in the
occluded portion of the aorta and IVC respectively. One to two drops of 1000
IU/ml heparin (Monaparin™, CD Pharmaceuticals Ltd, UK) were applied on
vessels and covered with a warm saline soaked swab to keep the tissues moist
while the donor heart was harvested. The duration of this procedure was
5-8 mins.
Harvesting the donor heart: The donor’s abdomen was first opened via midline
laparotomy and infra-renal portion of abdominal aorta and IVC clamped just
about their respective bifurcations. Heparin (1000 IU) was injected into the
IVC above the clamp to prevent microvascular thrombosis of donor heart dur-
ing cardioplegic arrest. After 1-2 min, the abdominal aorta was cannulated
by a 20 gauge arterial line (Leadercathr, Vygon, UK) with the tip in the aor-
tic arch and guide-wire removed. The cannula-mouth was inspected for free
arterial bleeding to confirm correct placement. The chest was then rapidly
opened by a midline sternotomy and the intra-thoracic IVC partially divided
to empty the heart. Approximately 50 ml of cardioplegia solution (refer to So-
lutions) at ∼ 4℃, was rapidly infused via the long arterial cannula to arrest
the heart. Retrograde coronary perfusion was visually confirmed by blanching
of the heart, clearing of the coronary arteries and egress of clear cardioplegia
solution from the intra-thoracic IVC venotomy. LV distension was carefully
avoided by controlling rate of cardioplegia infusion to prevent excessive ven-
tricular distension which may lead to acute LV failure on reperfusion. After
complete cessation of all ventricular and atrial activity, crushed ice was placed
in the thoracic cavity for further myocardial protection. At this pont, a timer
was started to measure myocardial ischæmic time. Both lung hila were ligated
105
with 4.0 Mersilkr (Ethicon, USA) and the lungs excised. Subsequently the
IVC, SVC and left azygos vein were individually ligated and divided. The
brachiocepalic branch was ligated flush with the aortic arch and the aorta di-
vided just distally. The main pulmonary artery was divided just before its
bifurcation. The heart was then carefully retracted and dissected away from
the trachea and oesophagus and placed in ice-cold cardioplegia. The duration
of this procedure was 10-12 mins.
Anastomosis of donor heart into recipient: The donor heart was placed on
cold saline-soaked swabs in the abdomen of the recipient. End-to-side anas-
tomoses of the donor aorta to recipient abdominal aorta, pulmonary artery
to recipient IVC (Fig. 2.2) were performed using continuous 8.0 Prolener
(Ethicon, USA; Product code: W2775) suture as decribed previously (Ono
& Lindsey 1969). After completion of the anastomosis, the heating mat was
switched on, the vascular clamps released and end of ischæmic time noted.
The duration of this procedure was 20-25 mins. Spontaneous recovery of
donor heart beat was observed in most cases and in some cases gentle tap-
ping on the LV resumed sinus rhythm. Hæmostasis was secured by additional
sutures or biocompatible tissue-glue, Vetbond™(3M Healthcare, USA), if nec-
essary. The donor heart was then observed till complete recovery of spon-
taneous rhythm and abdominal wall closed with 5.0 Vicrylr (Ethicon, USA;
Product code: W9106) and and skin with 2.0 Mersilk (Ethicon, USA; Prod-
uct code: W775). Skin wound was cleaned with Povidone-Iodine (Videner,
Adams Healthcare, UK) for infection prophylaxis, and recipient then placed in
a prone position. When required, an osmotic minipump containing clenbuterol
(Clenbuterol Hydrochloride, Sigmar, Sigma-Aldrich Company Ltd, UK; Prod-
uct Code: C5423) or saline (Sodium Chloride 0.9% w/v, Baxter Healthcare
Ltd, UK; Product Code: B1324) was inserted subcutaneously into the scruff
of the neck as described on Page 108.
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2.2.3 Explantation of a transplanted heart
The transplanted hearts were explanted either at 1 week or 5 weeks post-surgery
depending on the experimental protocol. The recipient was anæsthetised with 1-2%
isoflurane via Bain nose cone and weighed. Fur on the abdomen and groin areas
were removed with hair clipppers. Midline laparotomy was performed and bowel-
loops adherent to the transplanted heart were carefully dissected and separated. All
adhesions were also separated from the abdominal aorta and IVC, 1-2 cm proximal
and distal to the anastomoses. Lumbar arteries and veins were ligated and divided
to competely free the abdominal aorta and IVC from the posterior abdominal wall.
Ligatures were passed around the vessels, above and below the anastomoses but not
tied.
The right groin was dissected to expose the femoral vein and heparin (500 IU)
was infused to prevent microvascular thrombosis. After 1-2 mins, the proximal and
distal ligatures were tied to isolate the transplanted heart from the recipient’s circu-
lation. An aortotomy was performed on the recipient abdominal aorta, distal to the
anastomosis and a 19 gauge cannula inserted and secured in-situ. The donor pul-
monary artery was partially divided to allow the right ventricle to empty its blood
volume. Ice-cold normal Tyrode solution (∼ 50 ml, refer to Solutions on Page
165) was infused through the cannula to induce hypothermic arrest and myocardial
preservation during transportation for cardiomyocyte isolation. Retrograde coro-
nary perfusion was confirmed by blanching of the heart and egress of clear solution
through the pulmonary arteriotomy. The rate of infusion was altered to prevent
right ventricular dilation and ventricular failure. After complete cessation of atrial
and ventricular activity, the recipient abdominal aorta and IVC were clamped above
the proximal ligature and below the distal ligature and the two vessels divided be-
tween the ligatures and clamps. The duration of this procedure was 20-30 mins.
The transplanted heart along with a portion of the recipient vessels, incorporating
the perfusion cannula, were transferred into ice-cold normal Tyrode solution and
rapidly transported to a Langendorff apparatus and perfused with normal Tyrode
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solution at 37℃ through the 19 gauge cannula. When required, after establishment
of spontaneous heartbeat, the left atrium was incised for placing an intraventricular
balloon for assessing the LV pressure-volume relationship (described in detail on
Page 118), after which only LV cardiomyocytes were isolated (described in detail on
Page 123).
2.2.4 Insertion of osmotic minipumps
Osmotic minipumps (ALZETr, USA) were used for all experiments requiring clen-
buterol or saline administration. The following models of osmotic minipumps were
used to ensure accurate and complete delivery of clenbuterol or saline within the
treatment period (Table 2.1).
Table 2.1: Models of osmotic minipumps used for chronic clenbuterol administration.
* Model 2001 has sustained delivery up to 1 week and model 2002 up to 2 weeks. (adapted
from www.alzet.com/products/specifications.php)
Model No. Time (days) Volume (µl) Infusion rate (µl/hr)
2001D 1 200 8
2001* 3 200 1
2002* 9 200 0.5
2ML4 28 2000 2.5
Principle of osmotic minipumps: Osmotic minipumps work on the principle of
osmotic displacement. The impermeable reservoir (Fig. 2.3 B), is filled with
the drug or control solution of known concentration. A required amount of
drug can be delivered by altering the concentration of the test solution based
on the formula
K = C×Q (2.1)
where K = compound delivered per hour (µg), C = concentration of solu-
tion (µg/µl), and Q = release rate of pump (µl/hr). When the minipump is
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Fig. 2.3: Schematic picture of an osmotic minipump (Model no. 2ML4, ALZETr). A.
Osmotic minipump, external appearance. B. Cross sectional view showing the various layers
(modified from www.alzet.com).
placed subcutaneously, due to the high osmolality of salt in the osmotic layer
(salt sleeve) surrounding the impermeable reservoir, water enters the pump
through its outer semipermeable layer (Fig. 2.3 B). Entry of water increases
the pressure in the salt sleeve, causing compression of the flexible reservoir and
delivery of the drug solution into the animal via the exit port of the minipump.
Drug dosage: The dose of clenbuterol used in all studies was 2 mg/kg-bodyweight/day
and was dissolved in saline. The concentration of the solution injected in the
reservoir was altered appropriately to deliver a dose of 2 mg/kg-bodyweight/day,
depending on the weight of the animal and the model of the minipump used.
Minipumps filled with only saline were used as control.
Surgical procedure: Osmotic minipumps were implanted under general anæsthe-
sia using 1-2% isoflurane via a Bain nose cone. Skin on the scruff of the neck
was incised, separated from the subcutaneous tissues by blunt dissection and
minipump inserted with the minipump exit port caudally, and skin closed with
clips. The duration of this procedure was ∼ 5 mins. Amoxycillin for antibi-
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otic prophylaxis and buprenorphine for analgesia, were given subcutaneously.
At the end of the experiments minipumps were removed after the animal was
sacrificed and the residual volume noted to confirm delivery of the solution.
2.2.5 Implantation of telemetry transmitters
Implantable miniature PhysioTel™ transmitters from Data Sciences International
(DSI™, USA) were used to monitor real time blood pressure (BP) and ECG changes
from conscious animals. Different surgical techniques (described below) were used for
implanting transmitters which recorded BP and/or ECG data from transplanted and
non-transplanted hearts. Following surgical implantation of the transmitter, the ani-
mals were recovered and housed in individual cages and monitored for the duration of
the experiment. The experimental animals were placed on designated receivers (DSI
PhysioTel™ Receivers Model RPC-1) and the transmitter radio-frequency signals
processed by the acquisition software (Dataquest A.R.T.™ 2.3-Acquistion, DSI™)
and stored on the computer hard drive for off-line analysis. Data was collected
either continuously or at set intervals depending on the experimental protocol.
Abdominal implantation for BP and ECG acquisition
Telemetry transmitters (Model C50-PXT, PhysioTel™), capable of simultaneously
monitoring blood pressure and ECG, were used for monitoring the physiological
effects of clenbuterol in normal rats over a 28 day period.2 Rats weighing 200-300g
were assigned randomly to be treated with clenbuterol or saline.
Following general anæsthesia using 1-2% isoflurane via Bain nose cone, the fur
on the scruff of the neck and abdomen were removed by hair clippers. The animal
was placed in the supine position over a heating mat under which the telemetry
receiver was placed for testing the function of the transmitter during implantation.
Amoxycillin for antibiotic prophylaxis and buprenorphine for analgesia were given
subcutaneously.
2Results described in Chapter 3
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The abdomen was opened by a midline laparotomy. The retroperitoneum over-
lying the infra-renal, abdominal aorta and IVC was opened and 1.5 cm of both
the vessels occluded, using two vascular occlusion clamps. An aortotomy was made
in the occluded portion of the aorta using an angled bevel of a 21 G needle and
the blood pressure recording catheter of the telemetry device inserted up to 1 cm
and fixed in-situ using biocompatible tissue-glue (Vetbond™). The distal clamp was
then partially released and hæmostasis ensured by more glue if necessary and then
both clamps were removed slowly. The transmitter was activated using a magnetic
switch and the blood pressure trace checked to ensure appropriate placement of the
catheter. The transmitter was fixed to the abdominal wall with sutures, intraperi-
toneally.
The ECG leads were then passed through a separate small incision in the ab-
dominal wall and exteriorirized. Both leads were tunneled subcutaneously and the
metallic tip of the white lead (−ve) fixed by a 4.0 Prolener suture to the right
pectoralis major muscle, just below the right shoulder. The metallic tip of the red
lead (+ve) was fixed to the lower end of the left ribcage muscles thus forming the
Einthoven Lead II configuration, parallel to the conduction axis of the heart. The
abdomen was closed with 5.0 Vicrylr and skin with 3.0 Mersilkr. The animal was
then placed in a prone position and an osmotic minipump containing clenbuterol or
saline was implanted subcutaneously as described above. Amoxycillin for antibiotic
prophylaxis and buprenorphine for analgesia were given subcutaneously. The du-
ration of this procedure was 15-20 mins. The animal was recovered and placed in
individual cage on a PhysioTel™ receiver. Data were collected either continuously
or at set intervals depending on the experiment, after a short period of rest to allow
for the animals to recover from surgery.
Abdominal implantation for ECG acquisition from transplanted heart
Telemetry transmitters (Model TA10EA-F20, PhysioTel™), which only detect ECG
signals, were used for recording the ECG changes from heterotopically transplanted
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hearts in the abdomen. After completion of the vascular anastomoses of the donor
heart and before reperfusion (as described on Page 103), the ECG leads were fixed as
follows. The transmitter’s white lead (−ve) was fixed to the SVC stump of the donor
heart, just above the sinoatrial node with 8.0 Prolener. The red lead (+ve) was fixed
to the apex, forming the Einthoven Lead II configuration, parallel to the conduction
axis of the heart. The vascular clamps were then released and hæmostasis ensured.
After complete recovery of sinus rhythm, the telemetry transmitter was switched
on with a magnet and ECG signal confirmed on the recording computer. The
transmitter was then fixed to the anterior abdominal wall with 5.0 Vicrylr sutures
and abodomen closed. Amoxycillin for antibiotic prophylaxis and buprenorphine for
analgesia, were given subcutaneously. The animal was recovered and placed in an
individual cage on a PhysioTel™ receiver, with free access to food and water. Data
were collected either continuously or at set intervals depending on the experiment,
after a short period of rest to allow for the animals to recover from surgery.
Subcutaneous implantation for ECG acquisition only
Telemetry transmitters (Model TA10EA-F20, PhysioTel™) were used for recording
the ECG changes from rats with heart failure, treated with clenbuterol or saline over
a 1 week period.3 Rats (4∼6 weeks after LCA ligation) were anæsthetised using 1-2%
isoflurane via Bain nose cone. Fur on the chest and scruff of the neck were removed
and animal weighed. Echocardiography was performed to confirm heart failure (see
Page 113 for details) and animal placed in the supine position. A 2-3 cm, oblique
skin incision was made over the left chest and skin separated from the muscles. A
subcutaneous tunnel, extending from left anterior chest wall to right infraclavicular
region, was fashioned and a 1 cm skin incision was made. The leads were fixed as
described above for the abdominal implantation for BP and ECG acquisition. The
telemetry transmitter was fixed to the left, lateral chest wall with 4.0 Prolener and
skin closed with clips. Average procedure duration was 10-15 mins.
3Results shown in Chapter 5
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2.3 Assessment of in-vivo cardiac function
2.3.1 Echocardiography
Echocardiography was performed to assess development of cardiac hypertrophy or
heart failure as described previously (Yang et al. 1999; Gardin et al. 1995; Hoit
et al. 1995; Pollick et al. 1995; Tanaka et al. 1996). Examinations were carried un-
der isoflurane anæsthesia at a maintenance concentration of 1.5% and oxygen flow
rate of 400 ml/min for all examinations to maintain a comparable depth of anæsthe-
sia. The chest hair was removed by clippers and warmed ultrasound transmission
gel (Sonogelr, AnaWiz Ltd, UK) was applied on the chest to improve the acoustic
signal. An ACUSON Sequoia™ C256 (Siemens Medical Solutions, USA) echocardio-
graphy machine with a 14 MHz phased-array, transducer (15L8-S, Siemens Medical
Solutions, USA) was used. The probe’s lateral and axial resolution were 0.35 mm
and 0.25 mm, respectively.
A 2D short axis view was acquired at the mid-papillary level to assess LV function
and confirm presence of scar in the anterior wall for experiments involving heart
failure. Images were acquired at end-diastole and end-systole from a cine-loop and
LVEF calculated as shown in Fig. 2.4 and Table 2.2. The M-mode image in 2D
short axis view was acquired for measuring LV wall thickness, LV diameter, LV
function (LVEF and Fractional Shortening) and estimating LV mass as shown in
Fig. 2.5 and Table 2.2.
For experiments in which the effects of clenbuterol on a normal heart were stud-
ied,4 echocardiography was performed at the end of 28 days of treatment in a blinded
fashion.5 For experiments in which the effects of clenbuterol in heart failure were
studied,6 weekly echocardiography was performed from 2 weeks post-LCA ligation.
Only animals with a LVEF <40% on 2D echocardiography at 4-6 weeks were classed
as failing and included in the heart failure group. These animals were randomised
4Results shown in Chapter 3.
5Echocardiography for this set of experiments were performed by Dr Tom Smolenski, PhD.
6Results shown in Chapter 5.
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for treatment with saline, clenbuterol or as donors for heterotopic abdominal heart
transplantation.
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Fig. 2.4: Representative 2D echocardiography images at midpapillary level of a normal and
a failing LV. Normal LV in diastole (A) and systole (B). The endocardial edge is marked in
diastole (C) and systole (D) and area calculated. The change in area is used to calculate the
LVEF (Table 2.2). A failing heart in diastole (E) and systole (F) showing thinning of the
anterior wall due to scar formation (white arrows) from myocardial infarction. Area change
from diastole (G) to (H) is lesser than normal heart.
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Fig. 2.5: Representative M-mode echocardiography images at midpapillary level of a normal
(A, B) and a failing LV (C) by placing the M-mode line of interest, passing through the
middle of the anterior and posterior LV wall (inset in B). Normal LV trace (A) showing
papillary muscle artifacts (white arrows, B) and lines in diastole and systole, with markings
delineating epicardial and endocardial borders to measure wall thickness changes. Subsequent
calculation formulæ are shown in Table 2.2. A failing LV (C) showing an akinetic anterior
wall, thinning of the posterior wall with reduced systolic thickening.
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Table 2.2: Echocardiography calculation formulæ from M-mode and 2D measurements from
short axis view, at mid-papillary level. (LV -Left Ventricular, LVd -LV diastolic diameter, LVs-
LV systolic diameter, LVPWd -LV Posterior Wall diastolic thickness, LVPWs-Posterior Wall
systolic thickness, LVAWd -Anterior Wall diastolic thickness, LVAWs-Anterior Wall systolic
thickness, LVEDV -LV End Diastolic Volume, LVESV -LV End Systolic Volume, LVdArea-LV
diastolic Area, LVsArea-LV systolic Area), 1.04-Specific gravity of myocardium. Formulæ re-
produced from Administrator Manual, 2003 (ACUSON Sequoia™ 512 Ultrasound System).
Measurements from M-mode
LV End Diastolic Volume = 7.0(2.4+LV d) × LV d3
LV End Systolic Volume = 7.0(2.4+LV s) × LV s3
LV Posterior Wall % Thickening = LV PWs−LV PWdLV PWd × 100
LV Anterior Wall % Thickening = LV AWs−LV AWdLV AWd × 100
LV Ejection Fraction % = LV EDV−LV ESVLV EDV × 100
LV Stroke Volume = LV EDV − LV ESV
LV % Fractional Shortening = LV d−LV sLV d × 100
LV Mass = 1.04× [(LV AWd + LV d + LV PWd)3 − LV d3]
LV Mass, corrected = (0.8× LV Mass) + 0.6
Measurements from 2D
LV Ejection Fraction % = LV dArea−LV sAreaLV dArea × 100
2.3.2 Conscious blood pressure and ECG monitoring by
telemetry
The details of PhysioTel™ telemetry transmitter implantation has been described
above. Data were recorded on a dedicated desktop computer, either continuously
or in a scheduled fashion using Dataquestr A.R.T., Acquisition 2.3 software (DSI™,
USA), depending on the experiment.
For experiments in which effects of clenbuterol on a normal heart were studied,7
BP and ECG data were recorded continuously for 3-4 hours, between 08:00 and
13:00 hours for the 1st week. This was to reduce the variability between groups due
7Results shown in Chapter 3.
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to effects of circadian rhythm on blood pressure (Hall et al. 1977; Su et al. 1987;
Smith et al. 1987) and ECG changes (Benessiano et al. 1983; Otsuka et al. 1985;
Stohr 1988; Hashimoto et al. 1999). Thereafter, only 3-4 hours of continuous data
(between 08:00 and 13:00 hours) was recorded at the end of 2nd, 3rd and 4th weeks.
Blood pressure data was analysed with Dataquestr A.R.T., Analysis 3.1 software
(DSI™, USA) and ECG data by using Physiostatr ECG Analysis 4.0, (DSI™, USA).
For experiments in which effects of clenbuterol on a normal heart during me-
chanical unloading were studied,8 data was collected for 5 minutes, every hour for
7 days. For experiments in which effects of clenbuterol on a failing heart were stud-
ied,9 data was recorded continuously following recovery from surgical implantation
of telemetry transmitter for 7 days. Data was analysed for RR-interval changes and
incidence of arrhythmias using ECG-Auto© 2.5.0.3 (EMKA Technologies, France).
2.4 Assessment of ex-vivo cardiac function
2.4.1 Intraventricular balloon for pressure-volume relation-
ship assessment
This technique is based upon the the principle that in an isovolumetrically beat-
ing heart, the end-diastolic pressure-volume relationship is equivalent to the end-
diastolic pressure-volume relationship of a beating heart performing work. Suga
et al. (1973) have shown that in a normally ejecting denervated canine left ventricle
in-vivo, the time-varying ratio (Et) of instantaneous pressure (Pt), to instantaneous
volume (Vt), is minimally affected by end-diastolic volume (preload), aortic pressure
(afterload), contractile state or heart rate. In a subsequent study, Suga & Sagawa
(1974) have shown that the same relationship (Et∼Pt/Vt), was also valid in ex-vivo
canine left ventricles.
In most ex-vivo studies, the heart is usually perfused by aortic root cannula-
8Results shown in Chapter 4.
9Results shown in Chapter 5.
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tion at constant pressure but frequently at constant flow (as in this thesis), with
warmed oxygenated solutions. The left ventricle does not fill with the perfusate
as the aortic valve is competent, and therefore does not perform pressure-volume
work. If, however, an intraventricular balloon is inserted, the ventricle can contract
isovolumetrically. Due to the technical ease with which a variety of parameters can
be measured, a single heart can provide maximum information about the condition
of the myocardium. Subsequent LV cardiomyocyte isolation allows whole-heart and
cell level functional assessment in the same heart. Mechanical parameters such as
left ventricular end-diastolic pressure (LVEDP), left ventricular end-systolic pressure
(LVESP), developed pressure (LVESP-LVEDP), load-independent systolic contrac-
tility (+dP/dT) and load-independent diastolic relaxation(−dP/dT) can be reliably
assessed as shown in previous studies (Weber et al. 1986; Smolenski et al. 2001;
Jayakumar et al. 2001; Ogino et al. 1996; Van-Kerckhoven et al. 2000).
The balloon was made in the laboratory from polyvinylidene chloride ‘cling’ film
(Clingorapr, Terinex Ltd, UK) wrapped around the tip of a 18 gauge plastic can-
nula and tied in place with a 4.0 Mersilkr suture (Fig 2.6). The volume of the
balloon was adjusted to have a fully distended volume of ∼400 µl, without any rise
in pressure. The balloon and cannula were connected to a closed, water filled system
incorporating a pressure transducer (ISOTEC™, Harvard Apparatus, UK; Product
code: BS4 73-0090) and a 2 ml microsyringe (Gilmontr, UK) to change the balloon
volume. Hearts were removed and cannulated on a constant flow Langendorff ap-
paratus (achieved by a peristaltic pump) and perfused with normal Tyrode solution
at 37℃. The intraventricular balloon was inserted into the LV cavity through the
mitral valve, after partially excising the left atrium. After regaining spontaneous
contraction, hearts were paced to enable uniform comparison as heart rate can affect
diastolic filling time and relaxation. Hearts were paced at ∼300 bpm by a tempo-
rary cardiac pacemaker (Mini-Pacer™, PACE Medical Inc, USA; Model EV4543)
with copper electrodes on the RV and LV (Fig 2.7). Pressure and pacing signals
were relayed by a transducer amplifier (Harvard Apparatus, UK) to a computer and
119
A. B. C.
2 ml microsyringe
intraventricular balloon
pressure transducer
outlet to equilibrate to 
atmospheric pressure
5 ml syringe to 
prime the balloon
connected to 
Langendorff
aortic cannula
Fig. 2.6: Setup of intraventricular balloon for pressure-volume relationship assessment (A).
Balloon on the tip of 18 gauge plastic cannula, connected to a 2 ml microsyringe, 5 ml syringe
and pressure transducer via two 3-way taps. Another 3-way tap on the pressure transducer can
be opened to air to equilibrate to atmospheric pressure for zeroing or measure the perfusion
pressure at the aortic cannula of Langendorff perfusion apparatus. Inset showing close-up of
balloon in filled (B) and empty states (C).
data recorded simultaneously on 2-channels using Axoscope 8.2© (Axon Instruments
Inc., USA).
A series of pressure traces were recorded by increasing the balloon volume by
25 µl increments, between a range of 0 to 300 µl, as shown in Fig 2.8 A. When
a balloon volume of 100 µl was reached, the closed pressure transducer system was
opened to air to equilibrate with atmospheric pressure, allowing water in the bal-
loon to be ejected. This point at which LVEDP was zero was taken as zero volume.
This manœuvre also enabled the balloon to mould itself to the endocardial surface
and completely unfold, thus reducing dead-space, i.e. space between balloon and
endocardium (Suga & Sagawa 1979) (Fig 2.6). Another series of recording was
performed, as described above, and recording stopped when the LVEDP reached
>20 mm Hg. The recording with minimal noise and arrhythmias was analysed.
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temporary pacing  box
heart pacing electrodes
heart
pacing electrodes
Fig. 2.7: Setup for ventricular pacing
The duration for each recording was approximately 4-5 mins. After obtaining a
satisfactory recording, the intraventricular balloon was removed, bi-ventricular pac-
ing stopped and the heart allowed to beat spontaneously for ∼1 min perfused by
normal Tyrode solution. Subsequently, the heart was arrested by low calcium so-
lution and LV cardiomyocyte isolation by enzymatic dissociation was continued as
described on Page 123. Data were analysed using Clampfit 8.2© (Axon Instruments
Inc., USA). A minimum of 10 traces were averaged from a steady-state region after
balloon volume increment (Fig 2.8 B, C). Diastolic, systolic and developed pres-
sures were calculated as shown. Rate of contractility and relaxation were assessed
by measuring +dP/dT and −dP/dT, respectively.
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Fig. 2.8: Ex-vivo left ventricular pressure traces recorded at 25 µl increments of balloon
volume (A). Diastolic pressure re-zeroed at the end of series by equilibrating the closed pres-
sure system to atmospheric pressure and allowing the balloon to empty. A minimum of 10
traces, from the stable region of each LV filling volume (B), were averaged (C) and systolic,
diastolic and developed calculated as shown using Clampfit© 8.2 software (pClamp™ 8, Axon
Instruments Inc., USA). The calculated +dP/dT and −dP/dT are highlighted by crosses.
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2.5 Assesment of cardiac hypertrophy
Animals were weighed at the start and end of all experiments. Hearts were weighed
only for experiments in which the effects of clenbuterol on a normal heart were stud-
ied, as described below (results described in Chapter 3). Failing and transplanted
hearts could not be weighed due to presence of variable degree of adhesions and
sometimes thrombi in the LV, reducing the accuracy of true heart weight. Cell
surface area (method described on Page 126) was used to assess development of
hypertrophy or atrophy in these groups.
For results described in Chapter 3, heart weight was assessed after dissecting
away adherent tissue. The aorta was cut below the brachiocephalic branch and the
heart blotted on filter paper and weighed. Heart weight was normalized to body
weight and tibial length. As clenbuterol can affect skeletal muscle mass (Babij &
Booth 1988; Claeys et al. 1989; Maltin et al. 1987), tibial length was considered most
appropriate. A caliper was used to measure the distance from the tibial crest to the
heel and was taken as tibial length for that animal. To account for the different
body weights and tibial lengths, the ratios of heart weight-to-body weight and heart
weight-to-tibial length were used as indices of cardiac hypertrophy.
2.6 Assessment of myocyte function
2.6.1 Cardiomyocyte isolation by enzymatic digestion
Transplanted and non-transplanted hearts were collected under general anæsthesia.
Transplanted hearts were collected and cannulated in-situ as described on Page 107.
Non-transplanted hearts were collected after injecting heparin (500 IU) into the
IVC. The chest was opened and heart excised rapidly and placed in normal Tyrode
solution (refer to Solutions, Page 165) at 37℃ with heparin (20 IU/ml). The
heart was allowed to beat for 5-10 seconds to empty blood from the ventricles, then
transferred to normal Tyrode solution at ∼ 4℃ and transferred to a cell isolation
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apparatus (Fig 2.9), ensuring minimal myocardial ischæmic time.
heart
heating jacket
water baths for solutions
16 gauge cannula
recirculating heaters
normal Tyrode solution
low calcium solution
enzyme solution
bubble traps
peristaltic pump
Fig. 2.9: Cardiomyocyte isolation apparatus. Solutions warmed in the water bath are circu-
lated by a peristaltic pump to perfuse the heart connected to the 16 gauge perfusion cannula.
Cardiomyocyte isolation was carried out using a modification of standard enzy-
matic digestion protocols described previously (Hering et al. 1983; Tytgat 1994).
Aorta was cannulated using a 16 gauge cannula and fixed securely with 1 or 2 lig-
atures and perfused with normal Tyrode solution (refer to Solutions, Page 165)
at 37℃, in the presence of 100% oxygen. The heart was perfused slowly by a peri-
staltic pump (MasterFlexr L/S™ Economy Drive, Cole-Parmerr Instrument Com-
pany Ltd., UK) and flow rate gradually increased to 10-12 ml/minute until regular
heartbeat was established.
Low calcium solution (refer to Solutions, Page 165) was perfused for 5 min-
utes to arrest the hearts and improve cell separation. The hearts were then per-
fused with enzyme solution (refer to Solutions, Page 165) containing Type-2 col-
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lagenase (1 mg/ml, Worthington Biochemical Corporation, USA; Product code:
CLS2, 292 units/mg) and hyaluronidase (0.6 mg/ml, Sigmar, Sigma-Aldrich Com-
pany Ltd, UK; Product code: H-3506, 451 units/mg) for 8-10 minutes. Atria and
right ventricle were then excised and discarded.
The whole of the left ventricle was used for non-infarcted hearts. For failing
hearts, the infarcted scar tissue was visually assessed and removed from the LV.
Only viable left ventricle was minced and resuspended in fresh collagenase and
hyaluronidase enzyme solution, agitated for 5 min in the presence of 100% oxygen.
The digested tissue was gently triturated to yield a single-cell suspension and fil-
tered through a nylon mesh with an average pore size of 300 µm. The residue was
then resuspended in enzyme solution with fresh collagenase and hyaluronidase for
another 1 to 2 digestions. The cell suspension was centrifuged at 500 rpm for 1 min
(SORVALLr Legend RT, Kendro Laboratory Products, Germany), supernatant dis-
carded and cell pellet resuspended in enzyme solution (refer to Solutions, Page 165)
and re-centrifuged at 500 rpm for 1 minute. The supernatant was discarded again
and cell pellet resuspended in enzyme solution free from hyaluronidase and colla-
genase, stored at room temperature and all cellular experiments were performed
within 7-8 hours of cell isolation. Using this method, approximately 70% of the
resulting cardiomyocytes were rod-shaped and Ca2+-tolerant.
2.6.2 Cell size assessment
Cardiomyocytes were examined using an Olympus IX-71™ inverted microscope with
a ×60 oil-immersion objective. Digital images of rod-shaped cardiomyocytes were
acquired using an IonOptix Myocam™ camera (IonOptix Corp, Milton, MA, USA)
attached to the microscope light path, and a standard personal computer (PC) using
screen-capture software (HandySnap© 0.5 beta, WisePixel Multimedia). All analysis
were performed oﬄine using ImageJ 1.37v software (Rasband 2007; Abramoff et al.
2004). Digital images of rod-shaped cardiomyocytes were aligned horizontally and
their outline was marked manually. The projected 2D cell area was calculated from
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0.1 = 
0.1 mm = 351 pixels
1µm = 3.51 pixels
Fig. 2.10: Assessment of cell size by planimetry. Digital image of a cardiomyocyte aligned
horizontally (A). The cell outline was traced manually and cell area was taken as the area
within this outline (B). Only length and width were calculated by ‘bounding rectangle’ method
as shown (C). Graticule photographed at ×60 magnification for pixel–µm conversion (D).
the number of pixels within the traced outline. Maximum cardiomyocyte length and
width were calculated by the ‘bounding rectangle’ method, which is the smallest
rectangle enclosing the cell tracing (Fig 2.10). Data output in pixels was coverted
to µm using a graticule (Fig 2.10 D) photographed at ×60 magnification (1 µm =
3.51 pixels). Although the true cell area is a 3-dimensional parameter, the projected
2D cell area (calculated as elaborated above) was used as the cell area for this thesis.
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2.6.3 Sarcomere shortening
Myocardial contractility may be defined as the ability of the myocardium to do
work that does not depend on preload or afterload. During cell contraction, the
optically measured distance between the wide A-bands (optically dense) and narrow
I -bands (transparent) shortens (Fig 2.11). This sarcomere shortening has been
shown to be comparable to whole cell shortening assessment techniques, as a method
of accurately quantifying cardiomyocyte contractility, and is independent of cell
size (Delbridge & Roos 1997; Brady 1991; de Tombe & ter Keurs 1990; Krueger
et al. 1980; Rieser et al. 1979). Sarcomere shortening was measured for assessing
cardiomyocyte contractility in all experiments described in this thesis.
Freshly isolated cardiomyocytes were studied for their contractile characteristics.
All parameters were measured in field-stimulated cardiomyocytes which were not in-
dividually mechanically stretched, and therefore represent the baseline contractility
at minimum load. It is possible that the myocytes may be adherent to the bath to
variable extents and thus may not be at ‘zero’ load. Cardiomyocytes were placed
onto a bath held within the stage of an Olympus IX-71™ inverted microscope. Ap-
proximately 5 µl of 1 mg/ml laminin solution (Sigma-Aldrich, UK) was applied to
the bath before plating cardiomyocytes to aid their adhesion to the bath floor. After
a period of 5-7 minutes, cells were superfused with normal Tyrode solution at 37℃
(flow rate, 12-15 ml/min) and sarcomere shortening recorded.
Images were acquired at ×60 magnification and 240 frames/second. During field
stimulation (0.5-2 Hz, pulse duration = 5 ms) using platinum electrodes connected
to an IonOptix Myopacer™ bipolar field stimulator (IonOptix Corp), The output
voltage was adjusted to stimulate over 80% of the rod-shaped cardiomyocytes and
was usually in the range of 10-20 V. Images of contracting cardiomyocytes were
acquired using an IonOptix Myocam™ video camera (model CCD100M, IonOptix
Corp.) attached to the microscope light-path. The signal was processed using an
IonOptix Video Power Controller™ and IonOptix Fluorescence System Interface™
connected to a standard computer running IonOptix IonWizard data acquisition
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software (Version 5.0, IonOptix Corporation, USA). To acquire sarcomere shortening
and changes in cytoplasmic [Ca2+] simultaneously, cardiomyocytes were illuminated
with red light (wavelength > 600 nm) to limit photobleaching of Indo-1 (please also
refer to Page 137 and Fig 2.14).
The sarcomere pattern was digitised by the software (IonWizard, IonOptix Cor-
poration, USA), using fast Fourier transformation into a frequency power spectrum,
corresponding to the average sarcomere length within the manually selected region
of the cardiomyocyte (Fig 2.11). This yielded real time changes of sarcomere length
averaged for the cardiomyocyte. Oﬄine analysis of sarcomere shortening was per-
formed using IonWizard 5.0 software (IonOptix Corporation, USA). Between 10
and 20 representative steady-state contractions were averaged with reference to the
field-stimulation signal. The main parameters analyzed for comparison between
groups were magnitude of contraction (amplitude, Amp), speed of contraction (time
to peak-shortening, TTP), and speed of relaxation (time to 50% relaxation, T50 and
time to 90%-relaxation, T90) (please refer to Page 140, Fig 2.15).
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Fig. 2.11: Sarcomere shortening assessment. Low (A) and high magnification (B) images of
cardiomyocyte sarcomere structure. Schematic image (C) of the individual sarcomere bands,
responsible for the striated optical properties. Representative cardiomyocyte’s ‘region of in-
terest’ sarcomeres (within yellow box) analysed and a optical density trace (black) generated
(D). Frequency power spectrum peak (red trace), derived by fast Fourier transformation from
the optical density trace, within the limits set manually (green lines). Figures A, B and C
reproduced from Ford (2000).
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2.6.4 Cytoplasmic calcium measurement
The dynamics of cytoplasmic [Ca2+] is a key determinant of EC coupling. Epiflu-
orescence microscopy using Indo-1 fluorescence ratio was used to monitor changes
in [Ca2+] as previously described (Terracciano & MacLeod 1997). This type of
microscopy uses light of an appropriate wavelength to stimulate fluorescence in a
sample. The emitted fluorescence of a particular wavelength is then measured by a
photomultiplier and recorded as a Ca2+ transient.
Background to epifluorescence microscopy and fluorescent indicators
Fluorescent indicators have been used to measure cytoplasmic [Ca2+] originally by
Ridgway & Ashley (1967) using aequorin (Ca2+-sensitive luminescent protein that
converts ATP into light) to measure calcium transients in single muscle fibers. Sub-
sequently, various fluorescent indicators have been used to measure cytoplasmic
[Ca2+]. These can be broadly divided into three categories (Dustin 2000)
• Single-excitation, fluorescence intensity modulating indicators - increased flu-
orescence intensity in Ca2+-bound form, eg. Quin-2, Fluo-3
• Single-excitation, dual emission indicators - Ca2+-binding causes a blue-shift
in emission wavelength, eg. Indo-1
• Dual-excitation, single emission indicators - change in optimal excitation and
unchanged emission wavelengths, eg. Fura-2a
Non-ratiometric Ca2+-sensitive indicators: Tsien et al. (1982) used Quin-2
(excitation 339 nm, emission 492 nm) in intact lymphocytes to measure cytoplasmic
[Ca2+] at 120 nM range after calibration of fluorescence intensity to cytoplasmic
[Ca2+]. They reported a 5-fold increase in fluorescence intensity upon Ca2+-binding
compared to Ca2+-free state. They also reported toxic effects and blunting of the
Ca2+ transients. Other groups (Sheu et al. 1987; duBell & Houser 1987; Wheeler
et al. 1988) have used Quin-2 to measure cytoplasmic [Ca2+] in cardiomyocytes.
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However, there are several limitations associated with the use of Quin-2. These
include possible cell damage from ultra-violet wavelength exposure and high loading
concentrations required due to low fluorescence quantum yield. As with all Ca2+-
sensitive indicators, which are Ca2+-chelators, buffering of free-cytoplasmic [Ca2+]
can affect the magnitude and kinetics of total-cytoplasmic [Ca2+] fluxes reducing the
measurement accuracy (Tsien et al. 1982). At short excitation wavelengths, there
is considerable cellular autofluorescence that may interfere with cytoplasmic [Ca2+]
estimation. The fluorescence intensity of Quin-2 is also affected by variable and
unaccountable factors such as illumination intensity, emission recording efficiency,
indicator concentration and cell thickness. Photobleaching causes a time-dependent
decay of emission intensity, thus making it unsuitable for experiments requiring
prolonged observation. Also, Quin-2 has high affinity to bind with Ca2+ at 10−7
M cytoplasmic [Ca2+], corresponding to cardiomyocyte diastolic cytoplasmic [Ca2+]
(Fabiato 1983; Bers 2001). The Ca2+-binding is saturated at ∼30 µM cytoplasmic
[Ca2+] (Grynkiewicz et al. 1985) and thereafter emission signal blunted, thus making
it unsuitable for estimating free-∆cytoplasmic [Ca2+] at systolic levels of 10−6 M
cytoplasmic [Ca2+] (Fabiato 1983; Bers 2001). Non-specific, high affinity binding to
other divalent cations such as Mg2+ can also affect the cytoplasmic [Ca2+] estimation
and quenching of Quin-2 fluorescence (Grynkiewicz et al. 1985).
Minta et al. (1989) first used Fluo-3 to measure cytoplasmic [Ca2+] and reported
a 40-fold increase in fluorescence intensity upon Ca2+-binding. Fluo-3, Fluo-4 and
their derivatives all exhibit large fluorescence intensity increases on binding Ca2+.
Unlike the ultra-violet light-excited indicator Indo-1, there is no accompanying spec-
tral shift. Fluo-3 (excitation ∼506 nM, emission 526 nM) has fluorescence intensity
of ∼200 fold in the Ca2+-bound state (FMAX) compared to FMIN , its Ca2+-free state
(Harkins et al. 1993).
Ratiometric Ca2+-sensitive indicators: Ratiometric measurements however elim-
inate distortions of data caused by cell thickness, photobleaching, variations in in-
dicator loading and retention, compartmentalization, incomplete hydrolysis of con-
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jugated cell-permeant ester, indicator leakage and instrumental factors such as il-
lumination stability (Grynkiewicz et al. 1985; Paredes et al. 2008). Indo-1 is a
single excitation (360±10 nm), dual-emission (405 & 485 nm) fluorescent indica-
tor. When bound to Ca2+, Indo-1 fluorescence undergoes a blue-shift in emission
wavelength (485−→405 nM) (Fig 2.12 A). Thus, Ca2+ concentration can be deter-
mined by ratioing the fluorescence intensities at the two wavelengths (Fig 2.12 B).
This ratioing technique avoids problems associated with uneven dye distribution,
cell thickness and photobleaching.
Myocytes were loaded with the Ca2+-sensitive indicator, Indo-1 acetoxymethyl
ester (Indo-1 AM, Molecular Probes Inc., USA; Product code: I1203) (Fig 2.12) for
all experiments presented in this thesis. The AM ester allows the Indo-1 molecule
to permeate10 through the cell membrane and enter the extra-sarcoplasmic retic-
ular cytoplasm where the ester componenent is hydrolysed by cytosolic esterases
into its Ca2+-sensitive, anionic, free form which binds with only free-cytoplasmic
[Ca2+]. The only alternative method of using pure Indo-1 salts necessitates direct
microinjection into cells. Not only is this cumbersome, but the membrane integrity
and cytoplasmic composition are disturbed (Sauvadet et al. 1996). The method us-
ing the Indo-1 AM preparation enables simultaneous loading of many cells without
disrupting their cell membranes.
Indo-1 has a lower Ca2+-binding affinity in-vitro (Kd=230 nM) compared to
Fluo-3 (Kd=390 nM) and an even lower in-vivo Ca
2+-binding affinity (Kd=844 nM).
Despite the advantages of a ratiometric dye, Indo-1 signal-to-noise ratio is lower
compared to Fluo-3, with less intense fluorescence emission (Dustin 2000). The
cleaved ester is also fluorescent and may affect the free-cytoplasmic [Ca2+] estimation
(Haugland 1996).
As with all Ca2+-sensitive indicators, Ca2+-buffering by Indo-1 may affect the
Ca2+-release channel microdomain Ca2+ concentration, restitution to diastolic cyto-
10In this preparation the Indo-1 is made membrane-permeable temporarily by masking its
charged groups with esterifying groups.
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plasmic [Ca2+] and kinetics of myofilament-∆cytoplasmic [Ca2+] interaction. There-
fore, all cardiomyocyte contractile studies presented in this thesis were performed in
the Indo-1 loaded cells for uniform buffering of cytoplasmic [Ca2+]. A uniform free-
cytoplasmic [Ca2+] is assumed in all groups, thus allowing comparison of contractile
function, cytoplasmic Ca2+ cycling and myofilament sensitivity to Ca2+, between
experimental groups.
Calibration of Indo-1 fluorescence was not performed for the following reasons.
It is only effective if performed in each individual cell. Given the nature of the
calibration procedures, this would not be feasible. The accuracy of calibration can
be affected by various cellular, experimental and instrumental factors. The relation-
ship between Indo-1 fluorescence and cytoplasmic [Ca2+] can be calculated by the
following formula (Grynkiewicz et al. 1985),
[Ca2+] = Kd (
R− R
min
Rmax − R
) b (2.2)
where Kd is Ca
2+-binding affinity constant, R is the observed fluorescence ratio
(F405/485), Rmax is the fluorescence ratio at high [Ca
2+], Rmin is the minimum ratio
value in the virtual absence of Ca2+ and b is constant which equals Sfλ/Sbλ (Sfλ
= fluorescence emitted by free dye, Sbλ = fluorescence emitted by Ca
2+-bound dye
measured at wavelength λ).
Accurate in-vivo Kd values must be known to estimate true cytoplasmic [Ca
2+]
as small variations in Kd can produce large differences in estimated [Ca
2+] (Bassani
et al. 1995a). Unless performed at the beginning and end of every experimental
study, in-vivo limits of Ca2+-sensitivity may vary widely. Applying average values
for Rmin and Rmax and b to each single cell calibration can be misleading, as there
are variations of these values in different cells and they can depend on several factors
including the individual myocyte fluorescent indicator binding to myocyte protein
(Hove-Madsen & Bers 1992).
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Indo-1 loading method
LV cardiomyocytes were incubated with 10 µM Indo-1 AM for 20 minutes at room
temperature, the supernatant discarded and replaced with enzyme-free solution.
Cells were left at room temperature for at least 1 hour to allow de-esterification of
Indo-1 by cytosolic esterases. All the experiments were performed at 37℃ within
7-8 hours.
B.A.
Molecular formula: C47H51N3O22
Synonym: 1H-Indole-6-carboxylic acid, 2-[4-
[bis[2-[(acetyloxy)methoxy]-2- oxoethyl]amino]-
3-[2-[2-[bis[2- [(acetyloxy)methoxy]-2-
oxoetyl]amino]-5-
methylphenoxy]ethoxy]phenyl]-, 
(acetyloxy)methyl ester
Indo-1, AM
C.
Fig. 2.12: Indo-1 excitation and emission spectra. Absorption and fluorescence emission
spectra (excited at 338 nm) of Ca2+-saturated (wave A showing blue-shift) and Ca2+-free
(wave B) Indo-1 (A). The Ca2+-saturated and Ca2+-free emission wavelength-cytoplasmic
[Ca2+] relationship from 0 to 43.5 µM free-cytoplasmic [Ca2+] showing a spectral shift at all
cytoplasmic [Ca2+] (B). Molecular structure and chemical formula of Indo-1, AM (C). Figures
reproduced from Invitrogen™, UK
Indo-1 fluorescence acquisition
Only the Indo-1 fluorescence results presented in Chapter 3, were acquired using
Epifluorescence Apparatus-1 (Fig 2.13). All other Indo-1 fluorescence results were
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acquired with Epifluorescence Apparatus-2 (Fig 2.14).
• Epifluorescence Apparatus-1. The details of the experimental setup are shown
in Fig 2.13. Indo-1 loaded, LV cardiomyocytes were field stimulated at
0.5, 1 and 2 Hz by a bipolar stimulator at 10 V with a 5 ms pulse during
normal Tyrode solution perfusion. Cells were illuminated by red light at a
wavelength of > 600 nm and the cell under study, positioned in the centre of
the viewing field and background fluorescence subtraction was performed with
illumination switched off. The fluorescence of an empty field, adjacent to the
cell, was taken as background fluorescence. The individual (405 and 485 nm)
signals were set to zero using an analogue ratio amplifier and cell placed back
in the centre of the visual field (identified by its bluish fluorescence). Data was
collected using Clampex 8.2© (Axon Instruments Inc., USA). Indo-1 was ex-
cited by ultraviolet light at a wavelength of 360±10 nm from a 75 Watt Xenon
short arc lamp (Osram GmbH, Germany; Product code: XBOr 75 W/2 OF2).
Ultraviolet light exposure was limited only to the period of recording steady-
state Ca2+ transients, to limit photobleaching. Emitted fluorescent light was
collected and directed via dichroic mirror filters to photo-multiplier tubes that
measured the light at 405 nm (F405) and 485 nm (F485) wavelengths. These two
emission signals were ratioed (F405/485). Changes in Indo-1 fluorescence ratio
(F405/485) were used as a qualitative indication of changes in free cytoplasmic
[Ca2+].
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Fig. 2.13: Epifluorescence Apparatus-1
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• Epifluorescence Apparatus-2. Both setups (Epifluorescence Apparatus-1 & -2)
and operation were similar, apart from sarcomere length measurement. The
details of the experimental setup are shown in Fig 2.14. Cardiomyocytes
were field stimulated by a bipolar stimulator (MyoPacer, IonOptix Corpo-
ration, USA) at 10-20 V with a 5 ms pulse during normal Tyrode solution
perfusion. Cells were illuminated by red light at a wavelength of > 600 nm,
directed to an intensified CCD-camera (Ionoptix Myocam CCD 100M, IonOp-
tix Corporation, USA), enabling the cell in the field of view to be visualised on
a monitor for simultaneous measurement of sarcomere shortening as described
on Page 127. Indo-1 excitation and fluorescence emission measurements were
performed as described on Page 135.
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Fig. 2.14: Epifluorescence Apparatus-2
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Indo-1 fluorescence analysis
Changes in Indo-1, and thus the dynamics of the Ca2+ transients, were assessed
by analysing of the following parameters (Fig 2.15). Indo-1 fluorescence data ac-
quired from Epifluorescence Apparatus-1 was analyzed using Clampfit© 8.2 (Axon
Instruments Inc., USA) software. Simultaneously acquired Indo-1 fluorescence and
sarcomere length data from Epifluorescence Apparatus-2 was analyzed using Ion-
Wizard 5.0 (IonOptix Corporation, USA) software.
TTP fluorescence was the time taken from baseline fluorescence to peak fluores-
cence. Transient amplitude was the difference between systolic and diastolic ratioed
fluorescence values. T50 was the time taken for the Indo-1 transient to decline by
50% of the transient amplitude from peak systolic fluorescence. T90 was the time
taken for the Indo-1 transient to decline by 90% of the transient amplitude from
peak systolic fluorescence. A monoexponential curve was fit from maximum return
velocity to calculate the time constant (τ) of steady-state Ca2+ transient decay.
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Fig. 2.15: Indo-1 transients and sarcomere shortening analysis-Epifluorescence Apparatus-2.
Indo-1 transients and sarcomere shortening acquired simultaneously at 1 Hz field stimulation
(A) using IonWizard 5.0 acquisition software (IonOptix Corporation, USA). Data was anal-
ysed using IonWizard 5.0 analysis software (IonOptix Corporation, USA). A minimum of 10
consecutive traces were averaged, with reference to the stimulation trigger (T0), and all indices
calculated as shown (B). A monoexponential curve was fitted from maximum return velocity to
calculate the time constant (τ) of Ca2+ transient decay. Amp−Amplitude (difference between
diastolic and systolic values), TTP−Time to peak fluorescence or shortening, T50−Time to
50% decline in amplitude of Indo-1 fluorescence or sarcomere relaxation, T90−Time to 90%
decline in amplitude of Indo-1 fluorescence or sarcomere relaxation.
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Sarcoplasmic reticulum Ca2+ content and Ca2+ extrusion
SR Ca2+ content was assessed by rapid application of 20 mM caffeine in normal
Tyrode solution. This technique was first described by Fabiato & Fabiato (1975),
Chapman & Leoty (1976) and Fabiato (1985). The principle underlying this tech-
nique is the increased probability of RyR channel opening in the presence of caffeine
(1-5 mM) due to a shift in Ca2+-dependence of RyR channel gating, as reported
by Rousseau & Meissner (1989) in lipid bilayer studies. A higher concentration of
caffeine (20 mM) ensures maximal RyR channel opening and release of maximal SR
Ca2+. The Ca2+ released from the SR in the presence of caffeine was first mea-
sured as the SR Ca2+ content by integration of I NCX by Varro et al. (1993b). In
Indo-1 loaded cells, the free-Ca2+ released from the SR binds to Indo-1 and a fluores-
cence signal produced as described earlier. Although Indo-1 fluorescence signal can
be strongly quenched by caffeine, it occurs in a [Ca2+]- and wavelength-independent
manner and does not affect the ratioed transient signal kinetics (O’Neill et al. 1990).
Caffeine can also increase the myofilament sensitivity to Ca2+ (Fabiato 1981; Wendt
& Stephenson 1983; Eisner & Valdeolmillos 1985). Therefore all cardiomyocyte con-
tractile studies, presented in this thesis, were performed before caffeine application.
The amplitude of the caffeine-induced Ca2+ transient was taken as a measure of
the total Ca2+ available in the SR. The decay of the caffeine-induced Ca2+ transient
in the presence of caffeine was attributed to extrusion by NCX only. This is based on
the assumption of negligible relative contribution of plasmalemmal Ca2+ATPase and
mitochondrial-uniporter, to Ca2+ fluxes in rat cardiomyocytes (Varro et al. 1993b;
Bassani et al. 1994; Bers 2001; Maier et al. 2003).
Prior to evaluating SR Ca2+ content, cardiomyocytes were stimulated at 1 Hz
for 20-30 s to achieve steady-state SR Ca2+ content. Stimulation was stopped (for
∼3 s) and caffeine applied. Only for the results presented in Chapter 3, the
caffeine application protocol shown in Fig 2.16 A was used. For all other ex-
periments, the caffeine application protocol shown in Fig 2.16 B was used. A
pre-pulse of 0Na+/0Ca2+ solution was applied (to inactivate NCX-mediated Ca2+
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1 second
20mM Caffeine + Normal Tyrode (8 s)Normal Tyrode
1 second
20mM Caffeine + Normal Tyrode (8 s)Normal Tyrode
0 Na+/0 Ca2+(100 ms)
0 Na+/0 Ca2+  + 20mM Caffeine (1 s)
A.
B.
Fig. 2.16: Caffeine-induced Ca2+ transient protocol. Cardiomyocytes were stimulated at 1
Hz (black arrows) to achieve steady-state SR Ca2+ content. The stimulation was stopped and
20 mM caffeine alone (A) or combined with 0Na+/0Ca2+ solution (B) were applied.
extrusion), followed by 20 mM caffeine in normal Tyrode solution (see Solutions,
Page 165). Time constants for twitch and caffeine-induced Ca2+ transients were
calculated by fitting a monoexponential curve on the decay phase using IonWizard
5.0 or Clampfit© 8.2 (Axon Instruments Inc., USA) software (Fig 2.17).
Fractional SR Ca2+ release was calculated by expressing the single twitch Ca2+
transient amplitude, preceding the caffeine-induced Ca2+ transient, as a percentage
of SR Ca2+ content (Bassani et al. 1993, 1995b; Carvalho et al. 2006).
Fractional SR Ca2+ release =
Amplitude
caffeine
− Amplitude
twitch
Amplitude
caffeine
× 100 (2.3)
Rate constants for Ca2+ decline in caffeine, indicating NCX function (κ
NCX
), and
during the twitch (κ
twitch
) were calculated as descibed by Maier et al. (2003).
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2.6.5 Relative contribution of sodium-calcium exchanger to
calcium extrusion
The SR Ca2+ transport rate can be described by the following equation.
κ
SR
= κ
twitch
− κ
NCX
(2.4)
This is based on the assumption that the plasmalemmal Ca2+ATPase and mitochon-
drial uniporter contribution to Ca2+ removal from the cytosol is negligible (Bers
2001). The relative contribution of SR-mediated reuptake (rate constant, κ
SR
) and
NCX-mediated extrusion to Ca2+ removal from the cytosol, was assessed by using
the rate constants for Ca2+ decline in caffeine (κ
NCX
) and during the twitch (κ
twitch
),
as shown by Maier et al. (2003).
Caffeine-induced Ca2+ transient
Twitch Ca2+ transient
monoexponential curves
A.
B.
Fig. 2.17: Twitch Ca2+ transients (black) followed by 20 mM caffeine induced Ca2+ transient
(grey) (A). Normalized twitch and caffeine-induced Ca2+ transients (B) for comparison of time
constants by fitting monoexponential curve (red)
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2.6.6 Myofilament sensitivity to calcium
Cardiomyocyte myofilament length and tension respond to changes in cytoplasmic
[Ca2+] (∆ [Ca2+]) in a graded manner and their interaction is complex. Myofilament
sensitivity and responsiveness to Ca2+ are known to be depressed in hypertrophy
(Gwathmey et al. 1990), hence this aspect was also assessed in this thesis.
Traditionally, the relationship between myofilament length and tension has been
studied in skinned (permeabilized) cardiac muscle preparations by altering [Ca2+]
of the superfusate and studying the length or tension changes produced (Solaro
et al. 1974; Fabiato & Fabiato 1975; Harrison & Bers 1989a). However, the [Ca2+]-
length/tension relationship is affected by species, sarcomere length (Endo 1972a,b;
Hibberd & Jewell 1982), phosphorylation state (Silver 1986), pH and ionic equilibria
(Miller & Smith 1984), and temperature (Harrison & Bers 1989a,b). The myofil-
aments are sensitive to submicromolar [Ca2+] and therefore errors in estimating
free-[Ca2+] in buffered solutions, which is temperature-dependent, can also affect
the estimation of myofilament sensitivity to ∆[Ca2+].
Hysteresis loops were generated between pCa2+ (−log[Ca2+]) and developed ten-
sion, in rat ventricular trabeculæ, by Harrison et al. (1988). They showed a direct
relationship between sarcomere length and tension and
1. pCa2+-tension relationship demonstrated by hysteresis loops were unaffected
by chemical factors such as caffeine, carnosine and an increased pH
2. myofilament sensitivity to Ca2+ increased as [Ca2+]o and resting sarcomere
length were reduced
Xiao et al. (1994) have shown that the relationship between twitch-shortening
and Indo-1 fluorescence can be used to detect changes in myofilament sensitivity
to Ca2+. Based on this study, Bailey et al. (1997) developed a modified approach
of generating hysteresis loops between ∆ sarcomere length−∆cytoplasmic [Ca2+]
which was used in all experiments described in this thesis.
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The temporal relationship between sarcomere length and Indo-1 fluorescence
(Fig 2.18 A) can be represented as a hysteresis loop (Fig 2.18 B). The relax-
ation phase of this loop shows a linear relationship between sarcomere length and
Indo-1 fluorescence (Fig 2.18 C). Loops were generated for all cells studied using
GraphPad Prismr 4.03 (GraphPad Software Inc., USA). A constant region of the
declining phase of the loop (the region between 20-80% from the peak of the sar-
comere shortening) was selected and the slope value of this line was calculated by
fitting a linear regression line (Fig 2.18 D). Only slope values of the regression lines
with a goodness of fit (r2) greater than 0.8 were used for this analysis and data from
each treatment group were compared to assess changes in myofilament sensitivity
to Ca2+. Although Indo-1 fluorescence was not calibrated to cytoplasmic [Ca2+],
the relationship between Indo-1 fluorescence and cytoplasmic [Ca2+] are sufficiently
linear in the range of measurements reported (20% to 80% of a Ca2+ transient)
(Bassani et al. 1995a; Levi et al. 1996) adding to the validity of the method.
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Fig. 2.18: Representative sarcomere shortening and Ca2+ transient traces acquired simultaneously (A). Hysteresis loop was generated (B) and the
region between 20-80% (arrows) from the peak shortening was selected (C). A linear regression line (red) was fitted and slope calculated (D).
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2.7 Electrophysiological parameters
Whole-cell clamping was employed for direct measurements of membrane potentials
and currents in intact cardiomyocytes for all experiments described in this thesis.
High-resistance microelectrodes were used for action potentials (AP) and L-type
Ca2+ currents (I Ca,L) (these experiments were performed by Dr C. M. N. Ter-
racciano and Dr M. A. Stagg). The NCX current (I NCX) was measured using the
whole-cell patch clamping method, employing low-resistance patch pipettes (these
experiments were performed by Dr J. Lee). The whole-cell membrane capacitance
data were also obtained as part of these experiments, for expressing current density.
Membrane capacitance is a measure of cell surface area and was compared to the
cell surface area estimation, made using planimetry, in some experiments.
2.7.1 Action potential measurement
These experiments were performed by Dr. C. M. N. Terracciano and Dr. M. A.
Stagg. Fast changes in membrane potential can be measured in intact cells with
minimal disruption to the composition of the cytoplasm using switch clamping.
Cardiomyocytes were superfused with normal Tyrode solution at 37℃ and studied.
The bath was attached to a Nikon Diaphot 200™ inverted microscope, supported by
a vibration-isolation table (Technical Manufacturing Corporation. Peabody, USA).
The whole setup was enclosed in a Type-2 Faraday cage (Technical Manufacturing
Corporation) to shield the microscope setup and minimize interference from external
static electrical fields.
High-resistance electrode micropipettes were fabricated from borosilicate glass
tubes of 0.86 mm inner diameter (Harvard Apparatus, UK) using a microprocessor-
controlled Flaming/Brown pipette-pulling machine (Model P97, Sutter Instruments,
CA, USA). Standardized protocols used in the laboratory ensured consistent re-
sistance values of electrode micropipettes. Pipette resistance was 15-30 MΩ, and
pipette-filling solution contained (in mM) KCl, 2000; HEPES, 5; EGTA, 0.1; pH, 7.2.
147
bath
electrode
sensing
electrode
cell
+
_
amplifier
pipette 
solution
superfusate
Fig. 2.19: High-resistance electrode configuration. The micropipette tip impaled the car-
diomyocyte, forming a high-resistance seal. Due to the narrow bore of the micropipette tip,
minimal dialysis occurs between the pipette-filling solution (coloured in grey) and the cyto-
plasm. However voltage and current clamping can be performed reliably in this configuration
using switch clamping. One AgCl electrode wire is placed inside the pipette (sensing elec-
trode). An AgCl pellet electrode is placed in the superfusate bath to complete the circuit
(bath electrode). Figure adapted from The Axon Guide (Sherman-Gold 1993).
The solution-filled micropipette was mounted onto an Axon HS-2A headstage
(Axon Instruments Inc.), manoeuvered by a Burleigh PCS-5000™ piezoelectric micro-
manipulator (EXFO Lifesciences, Ontario, Canada), to place the tip of the mi-
cropipette adjacent to the desired cell. After placing the tip of the micropipette
adjacent to the desired cell in the bath superfusate, a 100 Hz, 10 mV square wave
pulse was applied. The potential difference between the electrodes (pipette offset)
was then calibrated to zero. The pipette resistance and pipette capacitance were
compensated. The pipette tip was then advanced onto the cardiomyocyte by the
micromanipulator. A potential difference of -50 mV or greater was considered to
confirm pipette entry into the cell. All measurements were made in Discontinuous
Current-Clamp (DCC) mode using an Axon 2B amplifier (Axon Instruments, CA,
USA). A schematic representation of the circuit is shown in Fig 2.19.
Action potentials (AP) were measured at stimulation frequencies of 1, 3, and
5 Hz using a 1 ms, 1.2-1.4 nA pulse. The APs measured were analyzed using
Clampfit© 8.2 software (Axon Instruments, CA, USA). Traces were averaged with
reference to the stimulation signal, and the time to 50% repolarization (APD50) and
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time to 90% repolarization (APD90) were taken as a measure of the AP duration
for comparison between groups as shown in Fig 2.20.
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Fig. 2.20: Action potential properties
2.7.2 L-type calcium current measurement
These experiments were performed by Dr. M. A. Stagg. L-type calcium cur-
rent (I Ca,L) was measured using the same hardware configuration as for AP, but
in voltage-clamp mode and the amplifier was set to discontinuous Single Electrode
Voltage-Clamp mode (dSEVC). Current-voltage (I-V) relationships for I Ca,L (Fig
2.21 E) were built using 450 ms depolarization steps from a holding potential of
−40 mV (range −45 mV to +50 mV, in 5 mV increments at 1 Hz) as shown in
Fig 2.21 A. The holding the membrane potential at -40 mV, rather than at the
normal resting membrane potential of -75 mV, enabled activation of I Ca,L without
contamination by the voltage-gated sodium channel current. I Ca,L was taken to
be the peak current elicited (usually at 0 mV) following depolarization, minus the
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maintained current (Fig 2.21 C, D). This current was normalized to the whole-cell
capacitance to calculate current density, for uniform comparison between groups.
The measured current is nifedipine-sensitive (10 mM nifedipine, specific antago-
nist of the L-type Ca2+ channel) and 4-aminopyridine-insensitive (antagonist of the
K+ channel), hence attributable to I Ca,L. Inactivation of L-type Ca
2+ channels is
time-, Em- and cytoplasmic [Ca
2+]-dependent (Lee et al. 1985; Kass & Sanguinetti
1984; Sanguinetti & Kass 1984; Hadley & Hume 1987). The individual components
were assessed as follows. To study time-dependent inactivation, a bi-exponential of
the I Ca,L measured at 0 mV was fitted to the decay, and fast and slow components
of I Ca,L inactivation identified (τfast and τslow).
The voltage-dependency of activation and inactivation of the I Ca,L were studied
using a double-pulse protocol, as described by Keung et al. (1991). The voltage-
dependent steady-state activation profile was derived from a series of depolarizating
steps, similar to the protocol used to assess the I-V relationship of I Ca,L (Fig
2.22 A). The conductance (GMAX) of the maximum I Ca,L was calculated and the
conductance of all the other currents were expressed as a fraction of this maximum
(G/GMAX).
The steady-state inactivation (F/FMAX) profile was derived from the second
pulse of the double-pulse protocol (Fig 2.22 A). The train of pre-pulses were to en-
sure a steady-state loading of the SR (Keung et al. 1991). The conductance (FMAX)
of the maximum I Ca,L was calculated. The conductance of all the other currents
were expressed as a fraction of this maximum (F/FMAX). Boltzmann curves were
fitted to the mean data points for analyses of G/GMAX and F/FMAX (Fig 2.22 D).
All I Ca,L data were analyzed using Clampfit
© 8.2.
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Fig. 2.21: I Ca,L measurement and analysis: Protocol used for measuring I Ca,L using 450
ms depolarization steps from a holding potential of −40 mV (range −45 mV to +50 mV, in 5
mV (A). Representative I Ca,L traces recorded using above protocol (B). The inward current
traces were selected (dotted square in B) and maintained current taken as 0 nA (C and D).
The I Ca,L elicited at 0 mV is shown in red (usually the largest current). The peak current was
recorded and plotted against voltage step as an I-V relationship. The decay phase of the I Ca,L
was assessed using a bi-exponential fit and taken as decay rate constants τfast (Ca
2+-sensitive
component) and τslow (time-sensitive component) (F).
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Fig. 2.22: Voltage-dependent activation and inactivation of I Ca,L were studied using a
double-pulse protocol (A). Following a series of 200 ms inactivating prepulses applied from
a holding potential of −50 mV, the membrane potential was held at −40 mV for 5 ms, and
then a test pulse was applied. Representative I Ca,L traces recorded using the above protocol
are shown (B). When the maximal current was recorded during the pre-pulse, no current was
recorded in the test pulse (C). The conductance of during the pre-pulse and test pulse were
expressed as a fraction of the maximum conductance. Boltzmann curves were fitted to the
mean data points to obtain the profiles of G/GMAX and F/FMAX (D).
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Cell capacitance measurement
A capacitor is an electrical/electronic device that can store energy in the electric
field of a non-conductor (dielectric), between a pair of conductors. The interface
of the lipid bilayer cell membrane (acts like a dielectric) between the cytoplasm
and superfusate (conductors) are a similar arrangement and thus acts as an elec-
trical capacitor (The Axon Guide, Sherman-Gold (1993)). The capacitance of a
parallel-plate capacitor is proportional to the surface area of the conducting plate
and inversely proportional to the distance between the plates. The capacitance
of the membrane (C m) can be approximated by the equation for a parallel-plate
capacitor.
Cm ≈ εA
d
; A ≫ d (2.5)
where A is the membrane surface area, ε is the permittivity of the membrane, d
is the membrane thickness, when A≫d. Under most physiological conditions ε
and d can be assumed to be constant. Therefore C m is directly proportional to
the membrane area. For all experiments in this thesis, C m was measured after
establishing the stable whole-cell configuration by means of a Capacitative Surge
Technique, described by Fenwick et al. (1982) : a 10 mV step was applied at ∼100
Hz and a monoexponential curve fitted to the decay phase of the resulting membrane
current trace. Once the decay time constant (τ) of this curve was determined, C m
was calculated by the following equation.
Cm =
I0 . τ
Vstep
(2.6)
where I0 is the membrane current at time = 0, τ is the monoexponential decay
constant of the capcitative current I0, and Vstep is 10 mV (Fig 2.23)
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Fig. 2.23: Principle of cell membrane capacitance measurement using the Capacitative Surge
Technique. Vm = membrane voltage; Vstep = voltage step, usually 10 mV; Im = membrane
current; I0 = initial membrane current, at t = 0; Qm = charge held by membrane, represented
by the area under the curve; τ = time constant of the monoexponential curve fitted to the
decay phase of the current trace. Figure adapted from The Axon Guide (Sherman-Gold 1993).
2.7.3 Sodium-Calcium exchanger current density measure-
ment
These experiments were performed by Dr. J. Lee. The NCX current(I NCX) was
measured using the whole-cell patch clamping method, using low-resistance patch
pipettes. The advantages of this technique compared to high-resistance micropip-
pette are lower access resistance and less noise from interference, thereby allowing
smaller currents to be recorded reliably. The low-resistance is due to a larger tip di-
ameter (∼1 µm), allowing dialysis of the pipette-filling solution into the cytoplasm.
This allows control of the the intracellular environment.
Cardiomyocytes were placed in a bath on the stage of a Nikon TE2000-U™ in-
verted microscope. Laminin (∼5 µl) was used to improve cell adhesion. Cells were
superfused at 37℃ with K+-free solution containing (in mM) NaCl 140; HEPES
10; glucose 10; MgCl2 1; CaCl2 1; CsCl 6; pH 7.4. In addition, the solution con-
tained 0.01 mM strophanthidin (Sigma-Aldrich Company Ltd, UK) to eliminate the
current attributable to Na+/K+ ATPase, and 0.01 mM nifedipine (Sigma-Aldrich
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Fig. 2.24: Low-resistance electrode configuration showing the principle of whole-cell clamping
configuration. The setup is similar to the high-resistance electrode but after forming a high-
resistance patch on the cell membrane (confirmed by >1 GΩ seal), the patch is ruptured in a
controlled manner using a combination suction and voltage pulses. A few minutes are allowed
for complete dialysis of pipette-filling solution (coloured in grey) into the cytoplasm before
recording the nickel-sensitive I NCX .
Company Ltd, UK) to eliminate that attributable to I Ca,L. Low-resistance electrode
micropipettes were fabricated using standardized protocols ensuring consistent re-
sistance values (2.3-3.5 MΩ). The pipette-filling solution contained (in mM) CsCl
45; HEPES 20; MgCl2 11; Na2ATP 10; CsOH 100; EGTA 50; CaCO3 25; pH 7.2
with CsOH. The high concentration of Ca2+-EGTA were added to buffer cytoplas-
mic [Ca2+], which was esimated to be 250 nM, as previously described by Quinn
et al. (2003). Pipettes were held by an Axon pipette holder (model HL-U) with
a side-vent connected to a 1 ml syringe via a three-way tap for application of air
suction as required during the patching process. The pipette holder was attached
to an Axon CV-7A headstage, which was manœuvered by a Burleigh PCS-5000™
micromanipulator.
The patch pipette tip was inserted into the superfusate, pipette-offset zeroed and
manœuvered onto the cardiomyocyte membrane whilst monitoring visually and via
oscilloscope (changes in 100 Hz, 10 mV square wave). After formation of a high-
resistance (> 1 GΩ) seal, voltage was clamped at -40 mV and membrane ruptured
using a combination of suction and application of a brief voltage transient. After
achieving the whole-cell configuration, a period of ∼4 minutes was allowed for com-
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Fig. 2.25: Descending ramp protocol for recording I NCX
plete dialysis of the pipette-filling solution into the cytoplasm. Following dialysis,
the resting membrane potential was usually in the region of −35 mV, and the access
resistance was 3∼6 MΩ.
Using a continuous single electrode voltage-clamp (cSEVC) mode on a Multi-
clamp 700A™ amplifier (Axon Instruments Inc., USA), from a holding potential of
−40 mV, a 3 s descending ramp was applied from +80 mV to −120 mV at 0.1
Hz (Fig 2.25). Compared to dSEVC, cSEVC of a whole-cell patch gives superior
signal-to-noise ratio, making it ideal for recording small whole cell currents. The
ramp was applied repeatedly until a steady-state was reached, and then acquired
5 times to yield an average current for analysis. Once a steady-state current was
recorded, 5 mM NiCl2 was added to the superfusing solution, and further current
traces acquired at the new steady-state. Ni2+ at this concentration is known to
block all NCX activity (Brommundt & Kavaler 1987; Kimura et al. 1987). The
I NCX was taken as the 5 mM Ni
2+-sensitive component of the active current, which
was normalized to the whole-cell capacitance for cross-group comparisons. I NCX
was calculated for various command voltage points to obtain the current-voltage
(I-V ) relationship, which was subsequently used for cross-group comparisons. Data
were analyzed using Clampfit© 8.2 software.
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2.8 Protein expression analysis by Western Blot-
ting.
Protein expression was quantified by the western blotting technique, supervised by
Dr N. Latif. The principle of this method is the use of a protein-specific anti-
body (primary antibody) directed against a desired protein in a given sample of
tissue homogenate or extract. This protein-primary antibody complex is detected
by a secondary antibody-enzyme conjugate, which is specific for the primary anti-
body. The enzyme conjugated to the secondary antibody, allows visualization of the
primary antibody.
2.8.1 Protein extraction from tissue samples
All western blotting studies were performed on freshly, snap-frozen LV tissue sam-
ples, usually the whole LV. The frozen LV was stored at −80℃ for all experiments
until required. For experiments described in Chapters 4 & 5 the hearts were
perfused in-vivo with ice-cold normal Tyrode solution, containing 1 mM NaF and
1 mM Na3VO4 (to prevent dephosphorylation of proteins), before the LV was snap-
frozen. For experiments described in Chapter 5, tissue samples were collected only
from the basal, anteroseptal region of the LV, as shown in Fig 5.3, Page 237.
For experiments described in Chapter 3, LV samples were homogenized in a
buffer (homogenzing buffer) containing 10 mM Tris HCL (pH 8.0), 0.3% Triton X-
100, 1 mM EDTA and 1 tablet of Protease Inhibitor Cocktail (Sigma-Aldrich, UK;
Product code: P-8340) per 10 ml buffer. For experiments described in Chapters 4
& 5, the homogenzing buffer contained 1% Sodium Dodecyl Sulphate (SDS), 1 mM
NaF, 1 mM Na3VO4 and 1 tablet of Protease Inhibitor Cocktail per 10 ml buffer.
The frozen tissue was crushed to a powder using a mortar and pestle. Care
was taken to ensure the tissue remained frozen during this process by adding liquid
nitrogen to the mortar. The powdered tissue was added to 200 µl of homogenzing
buffer and further broken down using a combination of sonication and crushing.
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The mixture was centrifuged (SORVALLr Legend RT, Kendro Laboratory Prod-
ucts, Germany) at 1500 rpm for 4 minutes at 4℃. The supernatant containing the
extracted protein was collected and stored at 4℃. The pellet was resuspended in
100 µl of homogenzing buffer, further broken down using a combination of sonication
and crushing, and centrifuged as above. The supernatant was collected and pooled
with the supernatant from the first cycle and pellet discarded. This step maximized
the yield of extracted protein. After total protein concentration was estimated as
described below, the protein extracts were aliquoted and stored at −80℃ for future
use. Each aliquot was used only once to avoid degradation and dephosphorylation
of protein after freeze-thaw cycles.
2.8.2 Isolation of mixed-membrane preparation
For experiments where ryanodine receptor 2 (RyR2) and phosphorylated phospho-
lamban (P-16, phosphorylated at Serine 16 site) were studied,11 a mixed-membrane
preparation was isolated as follows. These procedures were supervised by and per-
formed in the laboratory of Prof A. J. Williams, NHLI, Imperial College London.
Frozen LV samples were crushed in a mortar & pestle, in the presence of liquid
nitrogen to prevent protein degradation and dephosphorylation. The crushed tissue
was transferred into 20 ml of Solution-A (see Solutions, Page 166) with 1 µl/ml
of Protease Inhibitor Cocktail at 4℃. The crushed tissue was further broken by
a homogenizer. The solution containing the homogenized sample was centrifuged
at 10,000 g for 20 mins at 4℃. Supernatant was collected and stored in a tube
placed on ice. The pellet was resuspended in 10 ml of Solution-A and all the above
steps were repeated twice, after which the pellet (fraction containing nuclei) was dis-
carded. The collected supernatant was placed in an ultracentrifuge and centrifuged
at 100,000 g for 45 mins at 4℃. The supernatant was discarded and the pellet con-
taining the mixed-membrane fraction was resuspended in 1 ml of Solution-B (see
Solutions, Page 165). Total protein concentration of the supernatant was esti-
11Results shown in Chapter 4.
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mated, as described below, and the sample was aliquoted and stored at −80℃ until
further use.
2.8.3 Total protein concentration estimation
Total protein concentrations were estimated using a Bicinchoninic Acid (BCA) Pro-
tein kit (Pierce, USA; Product code: 23227) using bovine albumin as a standard
sample. The BCA Protein Assay is based on the reduction of Cu2+ to Cu+ by
protein in an alkaline medium with the highly sensitive and selective colourimetric
detection of the cuprous cation (Cu+) by bicinchoninic acid. The purple-colored
reaction product is formed by the chelation of two molecules of BCA with one Cu+
cation. 50 µl of protein standards (bovine albumin), with a concentration of 0, 6.25,
12.5, 25, 50, 100, 200 and 400 µg/ml were added to a 96 well plate in duplicate. 50 µl
of the test samples, at two different concentrations (1:10∼1:100), were also loaded
on the 96 well plate in duplicate. 200 µl of reagent containing bicinchoninic acid was
added to all the samples and the plate incubated at 37℃ for 30 mins, to allow the
reaction to develop. The 96 well plate was placed in a µQuant™ Microplate Spec-
trophotometer (BioTek Instruments, Inc., USA), and colour of the sample detected
at 560 nM wavelength. Total protein concentration was determined by colorimetric
analyis using KCjunior™ 1.41.3 software (BioTek Instruments, Inc., USA).
2.8.4 Casting SDS gels
For majority of the experiments, commercially available 10% NuPager Novex Bis-
Tris Gels (Invitrogen™, UK) were used. For some experiments Tris-Glycine gels
were made in the laboratory and used within 2 days. The separating gel of desired
consistency (6%, 10% and 12%) were made by adding substances 1, 2 and 5 together
(as shown in Table 2.3) and de-gassed under vacuum for 15 mins to remove dissolved
air. This step was to prevent formation of bubbles due to 10% SDS (Substance 3).
Subsequently substances 3, 4 and 6 were added and the solution poured into a cast
of required size. 100 µl of isobutanol was poured on top of the gel to remove bubbles.
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5 ml of the final solution was placed in a test tube to monitor the progress of the
polymerization reaction, which was usually completed by 1 hour.
Table 2.3: Tris-Glycine gel preparation. Details of making ‘separating’ (6%, 10%
and 12%) and ‘stacking’ gels. (SDS- Sodium dodecyl sulphate, TEMED - N,N,N’,N’-
Tetramethylethylenediamine)
Substance 6% 10% 12% Stacking gel
1 Acrylamide/Bis (30%/0.8%) 8 ml 16.6 ml 40 ml 5 ml
2 1.5 M Tris-HCl, pH 8.8 12 ml 12.5 ml 25 ml -
3 10% SDS 400 µl 500 µl 1 ml 300 µl
4 fresh 10% Ammonium persulfate (APS) 135 µl 250 µl 500 µl 300 µl
5 Water 19.46 ml 20.1 ml 33.5 ml 17 ml
6 TEMED 10 µl 10 µl 50 µl 25 µl
7 0.5 M Tris-HCl, pH 6.8 - - - 7.5 ml
After confirming that the separating gel had completely polymerized, isobutanol
was removed by washing with water. Care was ensured to remove all the water
and isobutanol from the gel-air interface. The stacking gel was prepared similarly
by adding substances 1, 5 and 7 together (as shown in Table 2.3) and de-gassed
under vacuum for 15 mins. Subsequently substances 3, 4 and 6 were added and the
solution poured on top of the running gel and a comb was inserted to create the
required number of lanes. 5 ml of the final solution was placed in a test tube to
monitor the progress of the polymerization reaction, which was usually completed
by 4 hours. The gels were wrapped in moist paper towels wrapped in cling film,
stored at 4℃ and used within 2 days.
2.8.5 Loading and running SDS gels
Protein sample loading and running procedures were different based on the type of
gel.
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• Bis-Tris gels: 20-40 µg of protein sample were diluted with ×4 NuPAGEr
LDS Sample Preparation Buffer, pH 8.4 (Invitrogen™, UK; Product code -
NP0007) and 0.5M Dithiothreitol (Invitrogen™, UK; Product code - D1532)
at a proportion of 1 part LDS Buffer : 4 parts protein sample, 1 part Dithio-
threitol. Water was added to make up an equal final volume of all samples.
10µl of Rainbow™ Molecular Weight Marker (GE Healthcare Life Sciences,
UK; Product code - RPN756) was used to monitor progress of protein elec-
trophoresis. The samples were vortexed and incubated for 5 mins at 70℃ to
to denature the proteins (except in experiments where phospholamban was
studied). Samples were allowed to cool and pipetted into the lanes, ensur-
ing no ‘spill-over’ of sample betweeen lanes. The gel-running tank was filled
with NuPAGEr MOPS SDS Running Buffer (Invitrogen™, UK; Product code
- NP0001) and electrophoresis performed at 110 mA/200 V for 60-90 mins or
until lane-front was at the bottom of gel and 220 kDa molecular weight marker
was clearly resolved.
• Tris-Glycine gels: 10-40 µg of protein sample under study was diluted with
×5 Læmmli sample buffer (refer to Solutions on Page 165) at a proportion of 1
part Læmmli sample buffer : 5 parts protein sample. 10µl of Rainbow™Molec-
ular Weight Marker was used to monitor progress of protein electrophoresis.
Water was added to make up an equal final volume of all samples. The sam-
ples were vortexed and incubated for 5 mins at 70℃ to denature the proteins
(except in experiments where phospholamban was studied). Samples were al-
lowed to cool and pipetted into the lanes, ensuring no ‘spill-over’ of sample
betweeen lanes. The gel-running tank was filled with Tris-Glycine running
buffer (please refer to Solutions on Page 165) and electrophoresis performed
at 110 mA/200 V for 60-90 mins or until lane-front was at the bottom of gel
and 220 kDa molecular weight marker was clearly resolved. For experiments
involving RyR,12 gels were run for 3-4 hours until the 220 kDa molecular weight
12Results shown in Chapter 4
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marker progressed into the lower third of the gel. This step was to ensure sep-
aration of high molecular weight proteins (>200 kDa). Heating of the gel was
prevented by continuous circulation of coolant in cooling jacket of the tank.
2.8.6 Protein transfer onto nitrocellulose membrane
While electrophoresis was being performed, blotting pads were soaked in the ap-
propriate transfer buffer. For Bis-Tris gels, NuPAGEr Transfer Buffer (Invitro-
gen™, UK; Product code - NP0006-1) and for Tris-Glycine gels, Tris-Glycine transfer
buffer (please refer to Solutions on Page 165) were prepared with 10% Methanol.
Hybond™-C Extra (Amersham Biosciences, UK ) mixed ester nitrocellulose mem-
branes and Whatmanr 3MM CHR Chromatography Paper (Fischer-Scientific, UK;
Product code - 3030917) were cut to the same size as blotting pads. Gels were care-
fully removed, placed underwater in the transfer buffer, and nitrocellulose membrane
placed on top with no air bubbles at the interface. Soaked Whatmanr paper and
blotting pads were placed on either side to form a sandwich. The transfer apparatus
was assembled so that the proteins were transferred from the gel to nitrocellulose
membrane, towards the positive electrode. The current was adjusted to 100 mA for
60-70 mins. For experiments where RyR and CaV1.2(α1C) were studied, transfer was
performed overnight in a cooled tank at 500 V/100 mA, to ensure complete migra-
tion of high molecular weight proteins into the nitrocellulose membrane. Complete
transfer of proteins was confirmed by Ponceau S staining (please refer to Solutions
on Page 165) of nitrocellulose membrane. Ponceau S stain binds reversibly to all
proteins on the membrane and does not interfere with the subsequent antibody reac-
tion with the specific protein. Destaining was performed by washing the membrnes
in Tris-Buffered Saline with 0.05% Tween-20 (TBS-T, please refer to Solutions on
Page 165).
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2.8.7 Probing for specific proteins
Membranes were blocked overnight at 4℃ in 3% (wt/vol), non-fat, dried milk in
TBS-T. All membranes were washed at least three times with TBS-T between all
subsequent steps. Membranes were then incubated overnight at 4℃ separately in
the corresponding primary antibody at an optimized concentration, derived from
titration experiments (as shown in Table 2.4). This was followed by exposure to
Horse Radish Peroxidase-conjugated, species-specific, secondary antibody (as shown
in Table 2.4) for 60 mins, followed by 4 × 15 mins washes in TBS-T.
Positivity was detected using enhanced chemiluminescence (ECL™Western Blot-
ting Detection Reagents, Amersham Biosciences, UK) or SuperSignalr West Femto
Maximum Sensitivity Substrate (Pierce, USA). Visualization of the protein bands
were captured on Hyperfilm™ MP (Amersham Biosciences, UK). Levels of expression
of each protein were quantified using a laser densitometric analysis using Quantity
One© 1-D Analysis Software (Bio-Rad, USA). For results described in Chapter 3,
densitometry was performed using GeneTools© Analysis Software (Syngene, USA).
The optical density values were standardised to β-tubulin reactivity or total pro-
tein optical density on the same blot. Total protein was detected by incubating the
nitrocellulose membrane in Amido Black stain (please refer to Solutions on Page
165) for 1 min, followed by rocking in Amido Black Destaining Buffer (please refer
to Solutions on Page 165) for 15-20 mins or until all bands were clearly visible.
Amido Black binds irreversibly to all proteins and hence used to detect total protein,
which was taken as the optical density of all bands within each lane.
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Table 2.4: Western blotting antibodies and concentrations
Protein
Primary antibody Secondary antibody (HRP)
Detection
Concentration Species Source Concentration Species Source
CaV1.2(α1C) 1:50 rabbit BD Biosciences 1:5000 anti-rabbit Dako SuperSignal
RyR 1:300 rabbit form Prof J Colyer, Leeds 1:5000 anti-rabbit Dako SuperSignal
SERCA2a 1:500 mouse Affinity Bioreagents 1:1000 anti-mouse Dako ECL
Phospholamban 1:20,000 mouse Affinity Bioreagents 1:1000 anti-mouse Dako ECL
Phosphorylated Phospholamban 16 (P-16) 1:3000 rabbit Cyclacel 1:1000 anti-rabbit Dako SuperSignal
NCX 1:500 rabbit Swant 1:1000 anti-rabbit Dako SuperSignal
Calsequestrin 1:1000 rabbit Affinity Bioreagents 1:1000 anti-rabbit Dako ECL
Troponin I (TnI) 1:1000 rabbit Cell Signaling Technology 1:1000 anti-rabbit Dako SuperSignal
Phosphorylated Troponin I (Phos-TnI) 1:500 rabbit Cell Signaling Technology 1:1000 anti-rabbit Dako SuperSignal
Gαi 1:300 mouse BD Biosciences 1:1000 anti-mouse Dako SuperSignal
β-Tubulin 1:2000 mouse Affinity Bioreagents 1:1000 anti-mouse Dako ECL
GAPDH 1:100,000 mouse Affinity Bioreagents 1:1000 anti-mouse Dako ECL
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2.9 Solutions
All chemicals were sourced from VWR International Ltd, UK or Sigma-Aldrich Com-
pany Ltd, UK. Ultrapure, mineral, bacterial and particle-free water from NANOpure
DIamond™ (Barnstead, USA) laboratory water system was used for making solu-
tions. Only for Low Calcium solution, AnalaRr water (BDH, UK) with a Ca2+
concentration <0.05 ppm, was used.
2.9.1 Solutions used in cardiomyocyte isolation
Normal Tyrode (mM) NaCl, 140; KCl, 6; MgCl2, 1; glucose, 10; N -
2-hydroxyethylpiperazine-N ’-2-ethansulphonic acid (HEPES), 10;
CaCl2, 1; pH 7.4.
Low Calcium (mM): NaCl, 120; KCl, 5.4; MgSO4, 5; CaCl2, 0.04;
sodium pyruvate, 5; glucose, 20; taurine, 20; HEPES, 10; nitriloacetic
acid (NTA), 5; pH 6.96.
Enzyme Solution (mM): NaCl, 120; KCl, 5.4; MgSO4, 5; sodium
pyruvate, 5; glucose, 20; taurine, 20; HEPES, 10; CaCl2, 0.2; pH
7.4.
2.9.2 Solutions used in heterotopic abdominal transplanta-
tion
Cardioplegia Solution (Plegivexr, Ivex Pharmaceuticals, UK) (mM):
Sodium, 147; Potassium, 20; Magnesium, 16; Calcium, 2; Procaine,
1; Chloride, 204.
NaCl Intravenous Infusion 0.9% w/v (Baxter Healthcare Ltd, UK) (mM):
Sodium, 154; Chloride, 154.
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2.9.3 Solutions used in cellular experiments
Rapid changes in solutions were achieved by solenoid valves (The Lee Company,
Electro-Fluidic Systems Group, USA; Product code: LFAA1200210H) and a custom-
built perfusate solenoid driver, which were controlled by a computer generated pro-
tocol on Clampex© 8.2 software. Flow rate of 12-15 ml/min was achieved using this
system, ensuring rapid changes in the cell superfusing bath.
K+-free Tyrode (mM): NaCl, 140; HEPES, 10; glucose, 10; MgCl2,
1; CaCl2, 1; CsCl, 6; pH 7.4.
0Na+/0Ca2+ solution (mM): LiCl, 140; glucose, 10; HEPES, 10; 1,2-
Di(2-aminoethoxy)ethane-NNN’N’ -tetra-acetic acid (EGTA), 0.75;
MgCl2, 1; pH 7.4.
2.9.4 Solutions used for isolating mixed-membrane prepa-
ration
Solution-A (mM): Sucrose, 300; 1,4-Piperazinediethanesulfonic acid
(PIPES), 20; Sodium Fluoride (NaF), 1; Sodium Orthovanadate
(Na3VO4), 1; pH 7.4 with KOH.
Solution-B (mM): Sucrose, 400; HEPES, 5; NaF, 1; Na3VO4, 1; pH
7.2 with 1M Tris-Base.
2.9.5 Solutions used in Western blotting
Tris-Buffered Saline with Tween-20 (TBS-T) (mM): Tris HCl, 38;
NaCl, 149; Tween-20, 0.05%.
Milk blocking buffer (w/v): Skimmed milk powder (Marvel, Chivers
Ireland Ltd, Ireland), 3 or 5% in TBS-T.
Tris-Glycine running buffer (mM): Tris-base, 25; Glycine, 192; SDS,
3.5.
166
Tris-Glycine transfer buffer (mM): Tris-base, 20; Glycine, 150; Methanol,
10%.
Tris-HCl−pH 8.8 (M): Tris-base, 1.5; pH to 8.8 with 1N HCl
Tris-HCl−pH 6.8 (M): Tris-base, 0.5; pH to 6.8 with 1N HCl
Membrane stripping solution (M): SDS, 0.35; 0.5 M Tris-HCL pH
6.8, 0.03; β-mercaptoethanol, 0.6%.
Ponceau S stain (w/v): Ponceau S Acid red, 2%; Trichloroacetic acid,
30%; Sulphosalicylic acid, 30%.
Amido Black stain (w/v): Amido Black, 0.1%; Methanol, 45%; Acetic
acid, 10%.
Amido Black Destaining Buffer (v/v): Methanol, 45%; Acetic acid,
10%.
Læmmli sample buffer, ×4 (w/v): SDS, 8%; Glycerol, 40%; β-mercaptoethanol,
20%; Bromophenol blue, 0.008%; Tris-HCl, 0.25 M.
2.10 Statistical analysis
Statistical comparison of data was performed using Student’s t test when only two
experimental groups were tested. One-way or two-way analysis of variance (ANOVA)
with post hoc testing using Newman-Keuls multiple comparison test, were utilised
when more than two groups were tested. All statistical analysis was performed on
Prism™ software (Version 4, Graphpad Software Inc. CA, USA). For all analyses,
a p < 0.05 was considered significant. The results in the following chapters are ex-
pressed as Mean ± standard error of the mean (SEM) of n observations (Mean±SEM
[n]; p-value).
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Chapter 3
Effects of clenbuterol treatment on
a normal rat heart
3.1 Introduction
The experiments described in this chapter were designed to test the hypothesis that
Chronic administration of clenbuterol alters myocardial structure and
function and affects calcium handling in a normal rat heart.
Short and long term effects of chronic clenbuterol administration on physiological
parameters (BP, ECG), myocardial structure and function, dynamics of ventricular
cardiomyocyte Ca2+ cycling, action potential and Ca2+ handling protein expression
were studied.
3.2 Materials & Methods
Experimental design and drug delivery: Randomly selected adult, male Lewis
rats (mean body weight (g): 318.6±2.4 [66]) were treated with either saline or
clenbuterol (2 mg/Kg body weight) by osmotic minipumps for a period of 1, 3,
9 or 28 days as shown in Fig 3.1. For specifications of osmotic minipumps see
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Table 2.1 (Page 108). A minimum of 6 animals per group were used for all
experiments. The concentration of clenbuterol in the minipump was adjusted
to deliver the required dose of clenbuterol. Details of surgical implantation
and drug dosage are described on Page 108.
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Fig. 3.1: Experimental protocol for testing the short-term and long-term effects of
chronic clenbuterol administration in normal rat hearts. (BP - blood pressure, ECG -
electrocardiography, TTE - Transthoracic Echocardiography, BW - body weight, HW
- heart weight, TL - tibial length.)
BP and ECG monitoring in conscious animals: Telemetry devices were im-
planted intra-abdominally (as described on Page 110) at the time of minipump
insertion, only in animals treated for 28 days (saline, n=6 and clenbuterol,
n=6) (Fig 3.1). All animals tolerated the surgical procedures well with no
mortality.
Assessment of in-vivo myocardial structure and function: At the end of the
experimental period (1, 3, 9 or 28 days), all animals were weighed. Echocardio-
169
graphy was performed to assess in-vivo cardiac function under 1.5% isoflurane
anæsthesia, in a blinded fashion by Dr Tom Smolenski. All measurements
were made from 2D short axis, M-mode images as shown in Fig. 2.5 (Page
116) and Table 2.2 (Page 117).
Assessment of cardiac hypertrophy ex-vivo: All animals were weighed at the
time of minipump implantation and at the end of the experimental period to
monitor gain in body weight. At the end of the experimental period (Fig 3.1)
hearts were excised, weighed and tibial length recorded.
Analysis of blood pressure data: A continuous 1 hour period of telemetry data
was analysed oﬄine. Noisy segments of recorded traces were visually confirmed
and eliminated from data analysis. Data was averaged from the full 1 hour
period and taken as representative value for the day. Blood pressure data
was analysed with Dataquestr A.R.T., Analysis 3.1 software (DSI™, USA).
Systolic BP was taken as the highest point and diastolic BP as the lowest
point on the arterial pressure waveform trace. Mean BP was calculated as
Mean BP = diastolic BP +
1
3
(sytolic BP− diastolic BP) (3.1)
Analysis of ECG data: A continuous 1 hour period of telemetry data was anal-
ysed oﬄine using Physiostatr ECG Analysis 4.01, (DSI™, USA). Noisy seg-
ments of recorded traces were visually confirmed and eliminated from data
analysis.
The R-wave amplitude, recorded in precordial and limb leads, is known to
correlate with LV hypertrophy (less accurate than precordial leads) in hu-
mans (J. E. Norman & Levy 1995; Molloy et al. 1992). Therefore the R-wave
amplitude, which was recorded from a Einthoven Lead II configuration, was
measured for voltage differences that may be representative of LV hypertrophy.
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PR interval, which represents the time between the onset of atrial depolariza-
tion and the onset of ventricular depolarization, was measured from the start
of the P-wave to start of Q-wave. The QT interval was taken as the time
between the start of the Q wave and the end of the T wave. QT interval
represents the time for both ventricular depolarization and repolarization to
occur, and therefore roughly estimates the duration of the longest ventricu-
lar action potential as the duration varies transmurally (Bers 2001). Cardiac
action potential duration shortens in response to increasing pacing frequency
(Ravens & Wettwer 1998). Similarly, at higher heart rates QT interval de-
creases (Hayes et al. 1994). Therefore the QT interval was corrected for heart
rate by Bazett’s method (Hayes et al. 1994; Baillard et al. 2000; Dias da Silva
et al. 2002; James et al. 2007)
QTcB (s) =
QT (s)√
RR interval (s)
(3.2)
However as the Bazett’s QT correction method has been developed for assess-
ing slower heart rates as in humans (HR∼70), it may not be applicable to
rats with a much higher heart rate (HR∼300) (Hayes et al. 1994). Therefore,
the QT interval was also corrected for heart rate using a method described by
Mitchell et al. (1998). This is based on the observation that the QT interval
co-varies linearly, compared to RR interval. The average RR interval for this
strain of male Lewis rats was calculated from 20 min, continuous ECG record-
ing of control rats on day 28, post-surgery to avoid the confounding effects of
surgical stress on baseline heart rate. The calculated average RR interval for
this strain of male Lewis rats was 199.63 ms (average HR∼300 bpm). The RRo
(observed RR interval in milliseconds) was normalized to 199.63 and expressed
as unitless multiples (RR199.63). The relationship between QTo (observed QT
interval) and QTcM (QT interval corrected for heart rate by Mitchell et al.
method) is governed by the following equation
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QTo = QTcM× RRy199.63 (3.3)
Taking the natural logarithms of each side of this relationship, the formula
can be expressed as
ln(QTo) = ln(QTcM) + y ln(RR199.63) (3.4)
which is similar to the slope-intercept equation of a straight line. Thus the
slope value (0.7457) of the linear relationship between the log-transformed QTo
and RR199.63 defined the exponent to which the RR199.63 interval ratio should
be raised to correct QT for heart rate as shown in Fig 3.2. The QTcM was
determined by the following formula for all animals over a continuous 1 hour
period, and taken as the representative value for the day.
QTcM =
QTo
RR0.7457199.63
(3.5)
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Fig. 3.2: Determination RR-exponent for correction of QT interval for heart rate. The
graph shows all data points from control rats over a continuous 20 min period on Day 28
following saline minipump implantation. The slope value of the linear regression line
shown was 0.7457 and was used as the RR-exponent for correction QT interval for all
animals.
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Assessment of cardiomyocyte structure and function: All cellular and pro-
tein expression experiments were performed only on the group of animals
treated for 28 days. Only LV cardiomyocytes were isolated for cellular ex-
periments as described on Page 123. Cell size was determined by 2D planime-
try of digital images, as described on Page 126. Cardiomyocytes were loaded
with Indo-1 (see Page 134 for details) and cytoplasmic [Ca2+] dynamics as-
sessed by analysis Ca2+ transient kinetics as described in Fig 2.15 (Page 140).
SR Ca2+ content was assessed by rapid application of 20 mM caffeine as shown
in Fig 2.16 A (Page 142). The amplitude of the caffeine-induced Ca2+ tran-
sient was taken as the index of the total Ca2+ available in the SR. The decay of
the caffeine-induced Ca2+ transient, in the presence of caffeine was attributed
to extrusion by NCX only. This is based on the assumption of negligible rela-
tive contribution of plasmalemmal Ca2+ATPase and mitochondrial-uniporter,
to Ca2+ fluxes in rat cardiomyocytes (Varro et al. 1993b; Bassani et al. 1994;
Bers 2001; Maier et al. 2003). The NCX-mediated Ca2+ extrusion was there-
fore taken as the decay time constant (τ) of a mono-exponential curve fitted
on the decay phase of the caffeine-induced Ca2+ transient (see Page 141).
Action potential measurements: The action potential of isolated cardiomyocytes
were measured by the current clamping method using high-resistance (15-
30 MΩ) electrode micropipettes, as described on Page 147. These experiments
were performed by Dr. C. M. N. Terracciano.
Ca2+ handling protein expression: Some hearts were snap frozen and only the
LV samples were used for assessing changes in protein expression by western
blotting. For details of protein extraction, protein concentration estimation,
protein electrophoresis and blotting, see Page 157. The expression levels of of
SERCA2a, NCX, phospholamban, CaV1.2(α1C) and calsequestrin were stud-
ied. For details of antibody concentrations used, see Table 2.4 (Page 164).
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The optical density values of the desired protein were standardized to β-tubulin
reactivity on the same blot.
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3.3 Results
3.3.1 Effects of clenbuterol on blood pressure and ECG
Blood pressure changes
On the 1st post-operative day, there was depression in systolic (mmHg: Saline 120.9±
3.2 [6], Clenbuterol 107.0±2.2 [5]; p < 0.01), diastolic (mmHg: Saline 90.1±2.7 [6],
Clenbuterol 79.1 ± 1.7 [5]; p < 0.01) and mean BP (mmHg: Saline 104.9 ± 3.2 [6],
Clenbuterol 92.8 ± 1.6 [5]; p < 0.01), which were significant up to the 3rd post-
operative day. Subsequently, all differences were reduced by the end of 1 week (Fig.
3.3 A-C), with no differences thereafter. These transient and early changes must
be interpreted with caution as they occur in the early postoperative period when
the animals are recovering from the stress of surgery. These results indicate that
clenbuterol has a transient hypotensive effect but does not affect BP in the long
term.
ECG changes
Heart rate: Baseline heart rate was consistently elevated in the clenbuterol treated
group compared to the saline group, throughout the 4 week period (Fig.
3.4 A). The heart rates in both groups were markedly elevated in the immedi-
ate post-operative period and returned to stable values at the end of 1 week. It
is unlikely to be a compensatory physiological response to clenbuterol-induced
hypotension as the the BP changes were transient. It is possibly due to
non-selective β1-AR stimulation and/or increased norepinephrine release from
the sympathetic nerve terminals by stimulating presynaptic β2-AR (Burniston
et al. 2005). Further experiments would be required to clarify this point.
PR interval: was unaffected over the 4 week period suggesting chronic clenbuterol
administration did not affect atrioventricular conduction (Fig. 3.4 B).
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R-wave amplitude: was briefly increased (day 3-4) in the clenbuterol treated
group but thereafter, there were no differences between the groups (Fig.
3.4 C). Although clenbuterol-induced LV hypertrophy was confirmed by echocar-
diography and morphometric measurements (described below), it was not de-
tectable on a single lead ECG. It is possible that R-wave amplitude measured
from an Einthoven Lead II configuration (representing the normal cardiac con-
duction axis) may not be appropriate in the presence of LV hypertrophy when
the heart may lie more horizontal (Kralova et al. 2008). R-amplitude mea-
sured from Lead I configuration and chest leads may be more appropriate in
this setting (Kralova et al. 2008).
QT interval: The observed QT interval (QTo) was consistently elevated in the
clenbuterol-treated group compared to the saline treatment (Fig 3.4 D).
As there was a significant tachycardia in the clenbuterol-treated group (Fig
3.4 A), the QT interval was corrected for heart rate by Bazett’s (QTcB) and
Mitchell’s (QTcM) methods (Fig 3.4 E, F). Depsite correction for heart rate,
there was a prolongation of QT interval in the clenbuterol-treated group. This
may be due to the prolonged APD of LV cardiomyocytes in the clenbuterol
treated group (described on Page 188).
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Fig. 3.3: Changes in sytolic, diastolic and mean blood pressure (A, B and C) over a 4 week
period during treatment with clenbuterol. (* = p<0.05, ** = p<0.01, *** = p<0.001)
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3.3.2 Effects of clenbuterol on LV size and function
Effects of clenbuterol on LV size and function in-vivo.
Echocardiography showed a significant and symmetrical (unchanged LVAW/LVPW)
increase in LV wall thickness, from Day 3 onwards and present until Day 28, in
the clenbuterol-treated group (Table 3.1). There was mild LV dilation seen only
on Day 1 with normal LV dimensions thereafter. Clenbuterol increased fractional
shortening and LVEF from Day 1-9 but normalized LV function thereafter, indicat-
ing preserved LV function. The estimated LV mass (see Table 2.2, Page 117 for
details) was increased at all time points confirming an early onset and persistent
cardiac hypertrophy following clenbuterol treatment. These results suggest chronic
clenbuterol treatment induces LV hypertrophy with preserved LV function.
Morphometric measurements to assess cardiac hypertrophy ex-vivo.
For a direct assessment of cardiac mass, hearts were excised and weighed. The heart
weight was normalized to body weight as well as tibial length because clenbuterol
affects skeletal muscle mass (Rothwell & Stock 1988; von Deutsch et al. 2000). Rats
treated with clenbuterol gained more body weight by 4 weeks compared with saline-
treated rats (weight gain between week 0 and week 4 (g): Clenbuterol 111± 11 [10],
Saline 89 ± 10 [8]; p < 0.001) (Table 3.2). Total heart weight was greater in
clenbuterol treated group at all time points (Table 3.2). The heart weight-to-body
weight ratio was increased up to Day 9 but unchanged at Day 28, possibly because
of a proportional increase in body weight in the rats treated with clenbuterol (Table
3.2). As there was no difference found in tibial length between the two groups, the
heart weight was normalized to tibial length which confirmed clenbuterol-induced
cardiac hypertrophy at all time points (Table 3.2).
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Table 3.1: Time-course of clenbuterol-induced echocardiographic changes. All measurements were made from M-mode images acquired from 2D short-
axis view at mid-papillary level. [n] indicates number of animals per group. (∗p < 0.05, ∗ ∗ p < 0.01, ∗ ∗ ∗p < 0.001 Saline vs Clenbuterol at the same
time point)
Day 1 Day 3 Day 9 Day 28
Measurement Saline Clenbuterol Saline Clenbuterol Saline Clenbuterol Saline Clenbuterol
LVAW d (cm) 0.15±0.01 [6] 0.15±0.01 [6] 0.13±0.01 [5] 0.17±0.01 [6]* 0.14±0.01 [6] 0.15±0.01 [6] 0.19±0.01 [8] 0.22±0.01 [9]*
LVAW s (cm) 0.3±0.01 [6] 0.33±0.01 [6] 0.24±0.02 [5] 0.3±0.01 [6]* 0.24±0.01 [6] 0.33±0.01 [6]*** 0.31±0.02 [8] 0.37±0.02 [9]
LVPW d (cm) 0.16±0.01 [6] 0.17±0.01 [6] 0.15±0.01 [5] 0.17±0.01 [6] 0.13±0.01 [6] 0.16±0.01 [6]* 0.19±0.01 [8] 0.22±0.01 [9]*
LVPW s (cm) 0.27±0.01 [6] 0.3±0.02 [6] 0.26±0.01 [5] 0.35±0.01 [6]*** 0.23±0.01 [6] 0.28±0.01 [6] 0.32±0.01 [8] 0.34±0.01 [9]
LVEDD (cm) 0.78±0.03 [6] 0.87±0.03 [6]* 0.79±0.03 [5] 0.82±0.03 [6] 0.84±0.01 [6] 0.85±0.02 [6] 0.76±0.03 [8] 0.76±0.02 [9]
LVESD (cm) 0.37±0.01 [6] 0.36±0.01 [6] 0.43±0.03 [5] 0.35±0.03 [6] 0.48±0.01 [6] 0.37±0.03 [6]** 0.35±0.04 [8] 0.31±0.03 [9]
LVAW % thickening 105±12 [6] 123±9 [6] 94±21 [5] 80±14 [6] 67±9 [6] 117±13 [6]** 70±9 [8] 68±5 [9]
LVPW % thickening 81±15 [6] 83±17 [6] 75±11 [5] 105±10 [6] 85±11 [6] 82±14 [6] 70±10 [8] 55±9 [9]
% FS 51.5±2.6 [6] 58.4±1.5 [6]* 46.1±3.1 [5] 58.2±1.8 [6]** 42.8±1.1 [6] 57.1±2.8 [6] ** 54.7±4.1 [8] 59.6±2.5 [9]
LVAW/LVPW 0.98±0.09 [6] 0.9±0.04 [6] 0.87±0.08 [5] 1±0.09 [6] 1.14±0.06 [6] 0.99±0.09 [6] 1.0±0.08 [8] 1.0±0.08 [9]
LV mass (g) 1.25±0.03 [6] 1.42±0.04 [6]** 1.22±0.04 [5] 1.47±0.08 [6]* 1.25±0.02 [6] 1.4±0.04 [6]** 1.44±0.04 [8] 1.69±0.05 [9]**
LVEF (M-mode) 86.5±1.9 [6] 91.3±0.9 [6]* 81.8±2.8 [5] 91.2±1.1 [6]** 78.8±1.2 [6] 90.2±1.8 [6]*** 87.7±2.6 [8] 91.7±1.4 [9]
LVAW d - LV anterior wall thickness in diastole, LVAW s - LV anterior wall thickness in systole, LVPW d - LV posterior wall thickness in diastole, LVPW s - LV posterior wall thickness in systole, LVEDD -
LV end diastolic diameter, LVESD - LV end systolic diameter, LVAW % thickening - LV anterior wall percentage thickening, LVPW % thickening - LV posterior wall percentage thickening, % FS - percentage
fractional shortening, LVAW/LVPW - ratio of LV anterior and posterior wall thickness, LVEF - LV ejection fraction.
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Table 3.2: Time-course of clenbuterol-induced changes in morphometric measurements. [n] indicates number of animals per group. (HW-Heart
Weight, BW-Body Weight, TL-Tibial Length) (∗p < 0.05, ∗ ∗ p < 0.01, ∗ ∗ ∗p < 0.001 Saline vs Clenbuterol at the same time point)
Day 1 Day 3 Day 9 Day 28
Measurement Saline Clenbuterol Saline Clenbuterol Saline Clenbuterol Saline Clenbuterol
HW (g) 1.07±0.04 [6] 1.34±0.07 [6]** 1.09±0.02 [6] 1.29±0.03 [6]*** 1.11±0.03 [6] 1.21±0.03 [6]* 1.13± 0.04 [8] 1.37±0.04 [10]***
Body weight (g) 323±5 [6] 323±4 [6] 339±6 [6] 319±7 [6] 370±7 [6] 370±7 [6] 367±4 [8] 427±4 [10]***
Tibial length (mm) 43.45±0.13 [6] 43.25±0.16 [6] 43.45±0.23 [6] 43.08±0.18 [6] 43.70±0.15 [6] 42.92±0.3 [6] 45± 0.2 [8] 45±0.1 [10]
HW/BW (g/g×1000) 3.29±0.11 [6] 4.14±0.23 [6]** 3.2±0.05 [6] 4.04±0.07 [6]*** 2.99±0.02 [6] 3.27±0.06 [6]*** 3.1±0.1 [8] 3.2±0.08 [10]
HW/TL (g/mm×1000) 24.52±0.96 [6] 30.92±1.7 [6]** 24.97±0.3 [6] 29.9±0.63 [6]*** 25.28±0.52 [6] 28.23±0.66 [6]*** 25.12±0.8 [8] 31.01±0.8 [10]***
182
Cellular hypertrophy
Cell size was assessed by planimetry. Myocytes from clenbuterol treated rats showed
an increase in cell width (µm: Clenbuterol 40±1.1 [45], Saline 37±0.8 [40]; p < 0.05)
and surface area (µm2: Clenbuterol 3930.08±107.16 [45], Saline 3607.78±108.72 [40];
p < 0.05) without any change in cell length (µm: Clenbuterol 132.28 ± 1.9 [45],
Saline 128.81 ± 2.46 [40]; p = NS) (Fig. 3.5). These findings confirm cardiomy-
ocyte hypertrophy and may contribute to the increased whole heart weight seen in
clenbuterol-treated hearts.
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Fig. 3.5: Morphometric assessment of isolated cardiac myocytes (at resting sarcomere length)
from the left ventricle showed increased cell area and cell width in the clenbuterol treated group
(n=45) compared with saline (n=40). Despite variability in cell dimension in both groups,
in the clenbuterol treated myocytes larger dimensions were more frequent than in the control
group, suggesting cellular hypertrophy. No difference was found in cell length between the
groups.
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3.3.3 Effects of clenbuterol on EC coupling
Characteristics of Ca2+ transients
Cytoplasmic Ca2+ cycling was assessed by measuring Indo-1 fluorescence ratio. The
amplitude of Indo-1 transients from clenbuterol-treated group was significantly in-
creased compared with control at all frequencies ((ratio units): 0.5 Hz: Clenbuterol
1.18± 0.08 [38], Saline 0.8± 0.04 [36]; p < 0.05; 1 Hz: Clenbuterol 1.14± 0.08 [38];
Saline 0.8±0.06 [36]; p < 0.05; 2 Hz: Clenbuterol 0.9±0.07 [38]; Saline 0.6±0.02 [36];
p < 0.01) (Fig. 3.6 A). However diastolic and systolic Indo-1 fluorescence, time-
to-peak fluorescence, time-to-50% (T50) and 90% (T90) decay of fluorescence were
not different between the groups (Table 3.3). The Indo-1 fluorescence transient
amplitude−frequency relationship, normally negative at these frequencies in rat my-
ocardium, remained negative after administration of clenbuterol (Fig. 3.6 B).
Sarcoplasmic reticulum Ca2+ content
The SR Ca2+ content, assessed by rapid application of 20 mM caffeine, was sig-
nificantly increased in the myocytes from clenbuterol-treated group compared with
saline treatment ((ratio units): Clenbuterol 2.87 ± 0.2 [23], Saline 1.88 ± 0.2 [20];
p < 0.05) (Fig. 3.7).
NCX-mediated Ca2+ extrusion
The NCX-mediated Ca2+ extrusion, assessed as the decay time constant (τ) of
the caffeine-induced Ca2+ transient, was not different between the two groups ((s):
Saline 1.86±0.28 [11], Clenbuterol 1.59±0.29 [14], p = NS).
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Table 3.3: Effects of clenbuterol on twitch-Ca2+ transients (r.u. - Indo-1 fluorescence ratio units, [ ] represents number of cells studied).
0.5 Hz 1 Hz 2 Hz
Saline Clenbuterol p-value Saline Clenbuterol p-value Saline Clenbuterol p-value
Diastolic ratio (r.u.) 0.79±0.02 [36] 0.80±0.02 [38] NS 0.78±0.02 [36] 0.79±0.02 [38] NS 0.82±0.02 [36] 0.83±0.03 [38] NS
Systolic ratio (r.u.) 0.88±0.02 [36] 0.91±0.03 [38] NS 0.87±0.02 [36] 0.90±0.03 [38] NS 0.88±0.02 [36] 0.92±0.03 [38] NS
Time-to-peak (ms) 188±3 [36] 194±3 [38] NS 186±3 [36] 191±3 [38] NS 164±2 [36] 168±2 [38] NS
Amplitude (r.u.) ×10 0.83±0.04 [36] 1.18±0.08 [38] <0.05 0.81±0.06 [36] 1.14±0.08 [38] <0.05 0.60±0.02 [36] 0.89±0.07 [38] <0.01
T50 decay (ms) 181±9 [36] 186±6 [38] NS 178±6 [36] 185±6 [38] NS 142±2 [36] 142±2 [38] NS
T90 decay (ms) 433±28 [36] 470±25 [38] NS 422±13 [36] 431±15 [38] NS 274±4 [36] 271±3 [38] NS
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Fig. 3.6: Ca2+ transients recorded using Indo-1 fluorescence at 0.5, 1 and 2 Hz (A). Cells
were field-stimulated using a pair of platinum electrodes. In the clenbuterol treated group, the
amplitude of Ca2+ transients was increased at all frequencies without changes in decline of
fluorescence. The Indo-1 ratio-frequency relationship was also unchanged (B) (∗p < 0.05, ∗ ∗
p < 0.01, ∗ ∗ ∗p < 0.001 Saline vs Clenbuterol).
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Fig. 3.7: SR Ca2+ content was monitored by changes in Indo-1 fluorescence induced by rapid
application of 20 mM caffeine. Caffeine application was preceded by a train of stimulation at
1 Hz followed by 1 s rest. In the clenbuterol treated group, caffeine elicited a larger Indo-1
transient suggesting a larger SR Ca2+ content compared with control.
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Fig. 3.8: Action potentials recorded from cardiac myocytes isolated from clenbuterol-treated
(clen) and control animals (saline) (left). Cells were stimulated at 1 Hz using a pulse of 1.2
nA current (5 ms). Action potentials were recorded using high resistance microelectrodes in
current clamp. The bar graph on the right shows that in myocytes from the clenbuterol-treated
group, action potential duration was increased.
3.3.4 Effects of clenbuterol on action potential duration
Action potential duration was increased in the myocytes from clenbuterol treated
rats compared with saline treatment (APD90 (ms): Clenbuterol 204±30 [11], Saline
117±14 [7]; p < 0.05) (Fig. 3.8). These results may also account for the prolonged
QT interval, seen on ECG, in the clenbuterol treated group (Fig 3.4 D-F).
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3.3.5 Effects of clenbuterol on Ca2+ handling protein ex-
pression
Western blotting showed a significant increase in SERCA2a (normalized ratio units:
Clenbuterol 0.11 ± 0.02 [10], Saline 0.04 ± 0.007 [8]; p < 0.05), phospholamban
(normalized ratio units: Clenbuterol 2.14± 0.18 [10]; Saline 0.6± 0.1 [8]; p < 0.001)
and NCX (normalized ratio units: Clenbuterol 0.68± 0.11 [10]; Saline 0.2± 0.03 [8];
p < 0.01) protein levels in the clenbuterol group compared with control. There was
no change in the expression of calsequestrin or the cardiac subunit of the L-type
Ca2+ channels, CaV1.2(α1C) (Fig. 3.9).
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Fig. 3.9: Western blots of Ca2+ handling proteins. There was a 277% increase in SERCA2a,
357% in phospholamban and 342% in NCX protein levels in the clenbuterol group compared
with control. There was no change in the expression of calsequestrin and CaV1.2(α1C) (OD
= Optical Density units). All proteins expression levels were normalized to the β-tubulin ex-
pression levels on the same blot. The arrows indicate 25 and 5 kD subunits of phospholamban.
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3.4 Discussion
The experiments described in this chapter show that chronic administration of clen-
buterol alters myocardial structure and function and affects calcium handling in
normal rat hearts.
3.4.1 Physiological effects of chronic clenbuterol treatment
The transient depression of BP seen in this study is in agreement with other studies
in the literature that report a drop in BP after acute application of clenbuterol, at
various doses (0.25 mg/Kg, Jones et al. (2004); 0.3 mg/Kg, Culmsee et al. (2007);
0.03-3.0 mM/Kg, Burniston et al. (2006b)). All these studies only report BP changes
only up to 3 hours following clenbuterol application. This may be a consequence
of β2-AR mediated, nitric oxide-dependent and independent mechanisms of vasodi-
lation (Ferro et al. 2004; Murray 1990). Physiological parameters during the first
post-operative week must be interpreted with caution as the animals may still be
stressed from the surgical procedures, with variable catecholamine levels and re-
sponses. Some studies also report an increased mean BP in anæsthetized and pithed
rats, following chronic clenbuterol treatment (Kazanietz et al. 1986, 1990). How-
ever, BP recorded in conscious animals may be a more accurate representation of
true physiological state. Therefore based on the results presented in this chapter,
clenbuterol does not affect blood pressure regulation during chronic administration.
It is possible that continued exposure to β2-AR agonist clenbuterol, results in de-
sensitization (Harden 1983) of the β2-AR with normalization of BP.
Clenbuterol administration resulted in a consistently elevated heart rate up to
4 weeks of treatment. Although it can be argued that the initial rise in heart rate
may be a compensatory phenomenon, secondary to transient arterial hypotension,
it is more likely that the sustained tachycardia may be due to chronic β-adrenergic
stimulation. The gradual reduction of heart rate during the first 1 week following
surgery in both groups may be attributable to recovery from surgical stress.
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In atria, stimulation of both β1- and β2-AR can evoke maximal increases in force
of contraction (in-vitro on isolated tissues) and heart rate (in-vivo in healthy sub-
jects), whereas in ventricles, only stimulation of β1-AR causes maximal increases in
force of contraction, while stimulation of β2-AR causes only submaximal increases
(Brodde et al. 2006; Brodde & Michel 1999). In guinea pig atria, clenbuterol-induced
tachycardia is mainly attributable to β2-AR stimulation, although there is a con-
tribution from β1-AR stimulation, suggesting a complex interplay between the β-
adrenoceptors (Mazzanti et al. 2007). Burniston et al. (2006b) and Jones et al.
(2004) have reported clenbuterol-induced tachycardia following acute administra-
tion, both in conscious and anæthetised animals. Although there is no evidence
that this is a β1-AR mediated effect, Burniston et al. (2006b) have suggested its
likelihood based on previous studies of clenbuterol-induced, β1-AR activation result-
ing in myocardial apopototis (Burniston et al. 2005). Studies from our laboratory
(Siedlecka et al. 2008) suggest that clenbuterol may have a direct and distinctive
β2-Gi-mediated, mode of action on isolated rat cardiomyocytes compared to other
β2-AR agonists. It is more likely that the clenbuterol-induced tachycardia may be
due to non-selective β1-AR stimulation and/or increased norepinephrine release from
the sympathetic nerve terminals by stimulating presynaptic β2-AR (Burniston et al.
2005).
Clenbuterol-induced tachycardia is well known in humans, following clinical (Di
Gioacchino et al. 1987; Meinen et al. 1988; Birks et al. 2006) and toxic doses (Hoff-
man et al. 2001; Barbosa et al. 2005; Daubert et al. 2007), treatable by specific β1-AR
blockade (Birks et al. 2006; Hoffman et al. 2001). It is possible that the mode of
action of clenbuterol varies in different species based on the relative distribution of
the β-AR sub-type. Further experiments would be required to clarify these points.
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3.4.2 Electrophysiological and electrocardiographic changes
from clenbuterol treated animals.
The results described in this Chapter show prolongation of action potential dura-
tion at single cell level, which may partly account for the sustained elevation of QT
interval, in the clenbuterol-treated group. The duration of the action potential is
a complex interplay of depolarizing and repolarizing currents (Tomaselli & Marban
1999). Increased SR Ca2+ content in clenbuterol-treated myocytes may partly be
explained by the action potential duration prolongation (Terracciano et al. 1997).
Increased Ca2+ entry via L-type Ca2+ channnels by β2-AR stimulation (not mea-
sured in this study) can be one of the causes for larger SR Ca2+ content (Zhang et al.
2001b). Increased peak I Ca,L density can be associated with slower inactivation of
the maximal I Ca,L and this may also lead to a prolonged action potential duration
(Keung 1989; Kleiman & Houser 1988). Although changes in the expression levels of
α1C-subunit of the L-type Ca
2+ channels were not seen in this study, the phospho-
rylation status of these channels, which may affect their open probability (Schroder
et al. 1998), needs further investigation. The role of various K+-channel currents
that are involved in repolarization has also not been addressed.
The sustained prolongation of QT interval in the clenbuterol-treated group sug-
gests an increased global ventricular depolarization and repolarization time. Re-
polarization is a complex electrical process resulting from a multitude of trans-
membrane ion currents having different timings, different kinetics and operating in
different layers of the myocardium. This may be partially explained by prolongation
of ventricular myocyte action potential in the clenbuterol-treated animals. However
the significance of QT prolongation is currently debated. QT interval prolongation
has been shown to increase risk of arrhythmias but, paradoxically, QT interval pro-
longation can also be an effective antiarrhythmic strategy and is in fact the goal of
class III antiarrhythmic drugs (Anderson 2006). In humans, QT interval prolonga-
tion (Elming et al. 2003, 2002b; Moss 1999; Elming et al. 2002a) and QT interval
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variability (Piccirillo et al. 2007; Couderc et al. 2007; Iacoviello et al. 2007) are asso-
ciated with an increased risk of ventricular arrhythmias and death. Recent evidence
from ex-vivo rabbit heart studies suggest prolongation of APD without variabil-
ity or triangulation (duration of Phase 3 repolarization) is not proarrhythmic but
significantly antiarrhythmic (Hondeghem et al. 2001). Prolonged APD associated
with variability, followed by prolonged APD associated with triangulation, are the
most important proarrhythmic factors (Hondeghem et al. 2001). Although not anal-
ysed, it would be desirable to assess the incidence of ventricular arrhythmias in the
clenbuterol treated rats with prolonged QT interval.
3.4.3 Cardiac Hypertrophy induced by β-adrenoceptor ag-
onists
Cardiac hypertrophy in clenbuterol-treated rats was observed by echocardiographic
assessment of LV dimensions and also confirmed by increased whole heart weight
at all time points. Heart weight was normalized to both tibial length and to body
weight to allow uniform comparison between groups and account for differences
in body mass. The ratio of heart weight-to-tibial length significantly increased in
clenbuterol treated animals at all time points. However, the ratio of heart weight-
to-body weight, which was increased up to day 9 in the clenbuterol treated group,
was not different at 4 weeks. This is due to the greater body of the clenbuterol
treated animals at 4 weeks, which may be due to skeletal muscle hypertrophy (Babij
& Booth 1988; Claeys et al. 1989; Maltin et al. 1987).
It could be argued that after the increase in body mass, a proportional increase
in cardiac output and blood flow is expected; the myocyte hypertrophy observed
could therefore be the consequence of pressure or volume overload rather than a
direct effect of clenbuterol. Also clenbuterol-induced tachycardia may be a factor
in inducing cardiac hypertrophy (Shizukuda et al. 1998; Yamamoto et al. 1996;
Kajstura et al. 1995). However, studies in cultured cardiomyocytes have shown that
clenbuterol can directly induce hypertrophy (Bhavsar et al. 2002). It is possible
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that the cardiac hypertrophy seen this in this study was also generated by a direct
mechanism of induction of hypertrophy mediated by clenbuterol. However further
studies would be required to investigate the contribution of these factors in the
development of hypertrophy.
The effects of clenbuterol on interstitial cells, extra-cellular matrix and vascular
tissue (which form a smaller component of the heart) have not been addressed in
the present study. Wong et al. (1997) have shown that clenbuterol administration in
conjunction with pressure overload by aortic banding in rats increases LV mass by
producing cardiomyocyte hypertrophy with less fibrosis and collagen content (Wong
et al. 1998a) than banding alone. It is therefore likely that the increased heart weight
is mainly due to the hypertrophy of the cardiomyocyte population, as confirmed by
isolated cardiomyocyte planimetry (Fig 3.5). Further studies would be required to
investigate if clebuterol has any effect on the interstitial cells, extra-cellular matrix
and vascular tissue in a normal heart.
Chronic nonspecific β-adrenergic stimulation is a well known cause of cardiac
hypertrophy and failure (Alderman & Harrison 1971; Taylor & Tang 1984). Stein
et al. (1996) have shown that cardiac hypertrophy induced by the non-selective β-
agonist isoproterenol reduced positive inotropic and lusitropic effects in papillary
muscles, which were accompanied by downregulation of PLB and SERCA2a pro-
tein expression. Burniston et al. have shown a dose-dependent, β1-AR mediated,
clenbuterol-induced myocardial apoptosis, necrosis and collagen content in the heart
and skeletal muscle of the rat after clenbuterol administration (Burniston et al. 2002,
2005, 2006a). The findings in this thesis indicate that β2-AR subtype-specific stim-
ulation may result in a phenotypically different cardiac hypertrophy with preserved
LV function (‘physiological’ hypertrophy). Although no histological analysis or as-
sessment of apoptosis was performed, any degree of possible apoptosis may not be
functionally relevant. Further studies would be required to elucidate this point.
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3.4.4 Differential effects of β1 and β2 stimulation and down-
stream signalling compartmentalisation
Cardiac tissue expresses at least two subtypes of β-adrenoceptors (AR), the β1
and β2 subtypes. The β1-AR is considered the more abundant receptor in most
species with an expression of 75 ∼ 85% compared with β2-AR (Xiao 2001). Stim-
ulation of individual subtype can have opposing functional and survival effects. In
the heart, selective β1-AR stimulation activates exclusively the Gs-adenylyl cyclase-
cAMP cascade, leading to protein kinase-A (PKA)-dependent phosphorylation of a
set of regulatory proteins involved in cardiac E-C coupling and energy metabolism,
including L-type Ca2+ channels, the SR membrane protein phospholamban and my-
ofilament proteins (troponin I and C) leading to improved inotropic function (Xiao
2001). In contrast β2-AR stimulation activates both Gs and Gi pathways. Gi stim-
ulation activates the Gi–Gβγ–phosphatidylinositol 3-kinase (PI3K)-protein kinase
B (PKB) pathway, which not only compartmentalizes and negates the concurrent
Gs–adenylyl cyclase (AC)–cAMP–PKA signaling but also exerts an anti-apoptotic
effect with improved survival in cardiomyocytes (Xiao 2001). This survival benefit
produced by chronic β2-AR stimulation, including clenbuterol, has been shown to
reduce apoptosis in a rat model of chronic heart failure (Ahmet et al. 2004, 2005;
Xydas et al. 2006a). β1-AR stimulation can therefore be pro-apoptotic and β2-AR
stimulation be anti-apoptotic (Chesley et al. 2000; Ahmet et al. 2005, 2004; Ponicke
et al. 2003; Communal et al. 1999; Zhu et al. 2001). Ahmet et al. (2004) have also
shown that administration of β2-AR agonists after myocardial infarction in rats re-
duced the extent of left ventricular dilation, infarct expansion and ejection fraction
decline. Treatment with metoprolol (β1-AR blocker) was less effective than the β2-
AR agonists in improving ejection fraction. Apoptosis was also reduced to a greater
extent by the β2-AR agonists than by metoprolol.
It has been reported in another study that administration of a single, larger
dose of clenbuterol (5 vs 2 mg/kg used in this study) causes cardiac necrosis in rats
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(Burniston et al. 2005, 2002). We did not perform direct quantification of cellular
necrosis or apoptosis in our study, but we did not observe functional impairment of
the heart. This functional impairment was not observed in previous studies where
clenbuterol was used chronically (Wong et al. 1998a). This suggests that the extent
of clenbuterol-induced necrosis, if present in the conditions used in our study, may
not be relevant for cardiac function.
3.4.5 Ca2+ regulation in cardiomyocytes from clenbuterol
treated animals
The mechanisms involved in the increased SR Ca2+ content without increased di-
astolic [Ca2+] levels are unclear. In this study clenbuterol induced several changes
in Ca2+ regulation such as increased Ca2+ transient amplitude, increased SR Ca2+
content and increased expression of the SERCA2a, PLB and NCX proteins. The
increased Ca2+ transients support larger contractions and can be explained by the
increased SR Ca2+ content. Increased SR Ca2+ content (possibly due to increased
SERCA2a abundance and activity) associated with prolonged action potentials (Ter-
racciano et al. 1997) may be responsible for this effect. NCX and PLB overexpres-
sion observed in clenbuterol treated hearts could also be involved (Sipido et al. 2002;
Terracciano et al. 1998; Zhang et al. 2001a). Increased Ca2+ entry can be another
reason for the larger SR Ca2+ content. Although the L-type Ca2+ current was not
measured in this study, the protein expression of the α1C-subunit of the L-type Ca
2+
channel was unchanged. However, the Ca2+ current may be increased on application
of clenbuterol because of a cAMP-dependent activation of the channels, possibly via
a Gs pathway, as shown for other β2-AR agonists (Zhang et al. 2001b).
Clenbuterol treatment increased the Ca2+ transient amplitude without affecting
the Ca2+ release or decay times indicating that concomitant effects on the mech-
anisms involved in Ca2+ release from the SR may also be present but were not
investigated in this study. The maintained rate of Ca2+ decline is consistent with
β2-adrenergic stimulation (Xiao & Lakatta 1993) and could be useful to maintain
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diastolic function.
Although an increased LV contractility was seen at Days 1-9, following clen-
buterol treatment, there was no difference in LV function after 4 weeks in clenbuterol-
treated rats (Table 3.1). The mechanisms underlying improved LV contractility in
the early treatment period have not been addressed in this thesis. They may include
β-AR mediated inotropism, altered myofilament sensitivity to Ca2+ and alteration
in systemic factors (such as peripheral vascular resistance, preload and afterload).
Further studies would be required to confirm these points.
More studies in diseased hearts (e.g. heart failure) are required to assess whether
cardiac function in-vivo would be affected by clenbuterol administration. This issue
has been addressed in Chapter 5.
In conclusion, the results from this Chapter confirm the hypothesis that chronic
administration of clenbuterol in rats induces cardiac hypertrophy (at organ and cel-
lular levels) with maintained contractile function and affects cardiomyocyte Ca2+
cycling. It is associated with prolonged QT interval (possibly due to prolonged
action potential duration), increased Ca2+ transient amplitude, increased SR Ca2+
content, increased expression of SERCA2a, phospholamban, and NCX. These find-
ings suggest that clenbuterol could have beneficial effects in preventing or reversing
cardiac atrophy secondary to mechanical unloading. This hypothesis has been tested
in Chapters 4 & 5.
198
Chapter 4
Effects of clenbuterol treatment
and mechanical unloading on the
structural and functional
properties of non-failing rat hearts
4.1 Introduction
The experiments described in this chapter were designed to test the following hy-
potheses:
• Mechanical left ventricular unloading and the consequent left ven-
tricular atrophy results in altered whole-heart and cellular function
in non-failing/normal rat hearts.
• Clenbuterol treatment during mechanical unloading of a non-failing/normal
rat heart improves whole-heart and cellular function.
Long and short term effects of mechanical unloading of non-failing/normal rat
hearts, with and without clenbuterol administration, on whole-heart function, cell
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size, EC coupling, electrophysiological properties and Ca2+ cycling protein expres-
sion were studied.
4.2 Materials & Methods
Animal models: Heterotopic abdominal heart transplantation in rats was used as
a model of mechanical unloading, as described on Page 103. Briefly the heart
was removed from the donor rat following cardioplegic arrest. The donor aorta
was anastomosed to the recipient abdominal aorta and the donor pulmonary
artery to the recipient inferior vena cava. Male Lewis rats (200-300g) were
used for all experiments.
Experimental groups: To test the effects of chronic mechanical unloading, rat
hearts were mechanically unloaded for 5 weeks. Only LV cardiomyocytes were
isolated from the transplanted hearts (UN) and recipient hearts (REC) used
as control (Fig 4.1 A). However, there were extensive and dense fibrotic
adhesions between the transplanted heart and abdominal organs increasing
the technical difficulty of explanting the unloaded heart and successfully iso-
lating cardiomyocytes. Therefore hearts were also unloaded for only 1 week
(Fig 4.1 B), which reduced the extent of fibrotic adhesions and improved
the technical ease and success of explanting the unloaded heart. During het-
erotopic abdominal heart transplantation, the recipient rat received an os-
motic minipump (Model 2001, Alzetr, USA) containing clenbuterol (Clen) or
saline (Sal) subcutaneously, as described on Page 108. Telemetry transmitters
were used for recording the ECG changes from heterotopically transplanted
hearts in some animals (n=11). After 7 days, both transplanted (UN+Sal
or UN+Clen) and recipient hearts (REC+Sal or REC+Clen) were removed
and studied. The recipient hearts, which were in the same neuro-hormonal
environment as the transplanted hearts, were used as control (Fig 4.1 B).
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as control
•ECG analysis
•LV cardiomyocyte isolation
•cell size
•epifluorescence & sarcomere shortening
•electrophysiology
•myofilament sensitivity to Ca2+
•Ca2+ handling protein expression by western blotting
Langendorff perfusion and LV function assessment (ex-vivo) by intraventricular balloon
Het abdo Tx + Clenbuterol ±
Telemetry device on Tx heart
A. B.
Fig. 4.1: Experimental protocols used to study effects of chronic mechanical unloading of a normal heart (A) and the effects of clenbuterol during
mechanical unloading of a normal rat heart (B). (Het abdo Tx - heterotopic abdominal heart transplantation, UN-unloaded heart, REC-recipient
heart, Sal-Saline, Clen-Clenbuterol)
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Ex-vivo LV function assessment: LV function of the transplanted and recipi-
ent hearts was assessed by measuring the ex-vivo pressure-volume relationship
using an intra-ventricular balloon as described on Page 118. Briefly, an intra-
ventricular balloon was inserted in the LV cavity, via the mitral valve, through
a left atriotomy. The isovolumic, pressure-volume relationship was assessed at
spontaneous heart rate without external pacing. All animals were heparinized
(1000 IU) before removal of the heart which was perfused with normal Tyrode
solution at 37℃ on a Langendorff apparatus.
ECG monitoring and analysis: Telemetry transmitters (Model TA10EA-F20, Phys-
ioTel™) were used for recording the ECG changes from heterotopically trans-
planted hearts in the abdomen. For details of surgical procedure, see Page 111.
ECG data was recorded by scheduled sampling protocol and 1 min/hour of
data was recorded over a 7 day period. Data was recorded from recovery fol-
lowing surgery for implantation of telemetry device and osmotic minipump
(containing saline or clenbuterol), until sacrifice.
ECG data was analysed for heart rate changes using ecg-Auto, version 2.5.0.3
software (EMKA Technologies, France). Heart rate was calculated from the
RR interval of all complexes within a 1 minute period, every 6 hours over the
7 day period of continuous ECG recording. A customized library of QRS com-
plexes were created for each animal by visual identification from the respective
ECG recording. Differences in average heart rate between groups was assessed
by Student’s t-test.
Cardiomyocyte Studies: Following explantation of recipient and transplanted
hearts (see Page 107) only LV myocytes were isolated by enzymatic diges-
tion (see Page 123). Cardiomyocytes were stored at room temperature and all
cellular experiments were performed within 7-8 hours of cell isolation.
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Cardiomyocyte size assessment: 2-dimensional area of digital images of car-
diomyocytes was assessed using the method described on Page 126.
Sarcomere shortening: These experiments were performed using the setup
shown in Fig 2.14, Page 138. For details of data acquisition (Page 127) and
analysis (Page 140, Fig 2.15) see Chapter 2.
Cytoplasmic Ca2+ measurement: Indo-1 fluorescence ratio was used to monitor
changes in [Ca2+]i using the setup shown in Fig 2.14, Page 138. For details of
data acquisition (Page 134) and analysis (Page 139, Fig 2.15), see Chapter 2.
SR Ca2+ content was assessed by rapid application of 20 mM caffeine in nor-
mal Tyrode solution (see Page 141) using the protocol shown in Fig 2.16 B
(Page 142).
Assessment of myofilament sensitivity to calcium: The cardiomyocyte myofil-
ament sensitivity to Ca2+ was assessed using a technique described by Bailey
et al. (1997). For a detailed explanation of the technique, see Page 144.
Measurement of action potential: Cardiomyocytes were superfused with nor-
mal Tyrode solution and studied using switch clamping. These experiments
were performed by Dr. C. M. N. Terracciano as described on Page 147.
The pipette resistance was 30 MΩ, and the pipette-filling solution contained
(in mM) KCl, 2000; HEPES, 5; EGTA, 0.1; pH, 7.2. Action potentials (AP)
were measured in current-clamp mode at stimulation of 1, 3, and 5 Hz using a
1 ms, 1.2-1.4 nA pulse. Traces were averaged with reference to the stimulation
signal, and the time to 50% (APD50) and 90% repolarization (APD90) were
taken as a measure of the AP duration for comparison between groups.
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Measurement of L-type calcium current properties: These experiments were
performed by Dr. C. M. N. Terracciano. For a detailed explanation of
the setup and technique, see Page 149. I Ca,L was measured using the same
hardware configuration as for AP, but in voltage-clamp mode. Current-voltage
(I-V) relationships for I Ca,L were built using 450 ms depolarization steps from
a holding potential of −40 mV (range: −45 mV to +50 mV, in 5 mV in-
crements). The measured current is nifedipine-sensitive and 4-aminopyridine-
insensitive, hence attributable to I Ca,L. To study time-dependent inactivation,
a bi-exponential of the I Ca,L measured at 0 mV was fitted to the decay, and
fast and slow components of I Ca,L inactivation identified (τfast and τslow).
Ca2+ handling protein expression: Some hearts were snap frozen and only the
LV samples were used for assessing changes in protein expression by western
blotting. For details of protein extraction, protein concentration estimation,
protein electrophoresis and blotting, see Page 157. The expression levels of
key Ca2+ cycling proteins (SERCA2a, NCX, phospholamban, phosphorylated
phospholamban (P-16), CaV1.2(α1C), calsequestrin and RyR2) were studied
to assess the contribution their abundance to changes seen in Ca2+ cycling.
For assessing changes in the protein expression of phospholamban, phosphory-
lated phospholamban (P-16; phosphorylated by protein kinase (PK) A, G or C
at Serine 16 position (Colyer 1998)) and RyR2, a separate set of animals were
used. The hearts were perfused in-vivo with ice-cold normal Tyrode solution
containing NaF, 1 mM and Na3VO4, 1 mM before snap-freezing the LV. The
addition of NaF and Na3VO4 was to prevent dephosphorylation of proteins.
These three proteins were estimated from the mixed membrane fraction of the
LV as described on Page 158. For details of antibody concentrations used see
Table 2.4, Page 164. The optical density values of the desired protein were
standardized to GAPDH reactivity or total protein reactivity on the same blot.
Statistical analysis: Statistical comparison of data was performed using Student’s
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t-test when only two experimental groups were tested. One-way analysis of
variance (ANOVA) with post hoc testing using Newman- Keuls multiple com-
parison test, were utilized when more than two groups were tested. All statisti-
cal analysis was performed on Prism™ software (Version 4, Graphpad Software
Inc. CA, USA). For all analyses p < 0.05 was considered significant.
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4.3 Results I - Effects of chronic mechanical un-
loading of rat hearts for 5 weeks
4.3.1 Effects of prolonged unloading on cell size
2D cell cross-sectional area, length and width of LV cardiomyocytes were assessed
by planimetry. The UN hearts were visually smaller (Fig 4.2 A) after 5 weeks of
mechanical unloading. The hearts were not weighed as all the transplanted hearts
had fibrotic adhesions which preclude accurate weight measurements. The isolated
LV cardiomyocytes had a 35% reduction in cell cross-sectional area, 15% in cell
length and 20% cell width (Fig 4.2 B, C). These results confirm that heterotopic
abdominal transplantation produces unloading-induced atrophy at a cellular level.
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Fig. 4.2: Pictures of an UN and REC heart showing reduction in heart size (A). Panel of
representative LV cardiomyocytes from REC (left) and UN (right) demonstrating unloading-
induced cardiomyocyte atrophy (B) with reduction in 2D cell cross-sectional area, cell length
and cell width (C).
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4.3.2 Effects of prolonged unloading on EC coupling
Cardiomyocyte contractility was assessed during 1 Hz field stimulation, by monitor-
ing real time changes of the sarcomere length. Cardiomyocytes from UN hearts had
smaller sarcomere shortening amplitude (shortening amplitude (µm): UN 0.08±0.01 [37],
REC 0.11±0.01 [38]; p <0.01) (Fig 4.3 A, B). The sarcomere relaxation was also
delayed (T50 (ms): UN 182±15.8 [37], REC 148±6.5 [38]; p <0.05) compared to
REC hearts (Fig 4.3 A, B). The time to peak shortening was unchanged (TTP
(ms) UN 95±4.6 [37], REC 92±3.2 [38]; p = NS). These results suggest impaired
cardiomyocyte contractility and relaxation in UN hearts.
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Fig. 4.3: Representative traces of simultaneously acquired Indo-1 transients (top) and sar-
comere shortening traces (bottom) from UN (black) and REC (grey) cardiomyocytes (A). UN
cardiomyocytes had smaller shortening amplitude, despite normal Indo-1 transient amplitude,
with delayed relaxation and decay of Indo-1 fluorescence (B).
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Cytoplasmic [Ca2+] was assessed by measuring Indo-1 fluorescence ratio. Indo-1
transient amplitude ((ratio units): UN 0.13±0.01 [37], REC 0.11±0.01 [38]; p =
NS) and time to peak fluorescence ((ms): UN 36±1.3 [37], REC 39±1.4 [38]; p =
NS) were unchanged with a delayed decay of fluorescence (T50 decay (ms): UN
168± 9.8 [37], REC 131±3.4 [38]; p < 0.001), suggesting delayed Ca2+ removal
from the cytoplasm (Fig 4.3 A, B). These results indicate preserved Ca2+ release
mechanisms with impaired cytoplasmic Ca2+ removal in UN cardiomyocytes.
Caffeine-induced Ca2+ transients from UN cardiomyocytes had similar amplitude
((ratio units): UN 0.17±0.01 [22], REC 0.17±0.02 [25]; p = NS) (Fig 4.4 C)
and decay time constant, τ ((s): UN 1.03±0.09 [22], REC 0.95±0.06 [24]; p =
NS) (Fig 4.4 D) compared to REC, suggesting an unchanged SR Ca2+ content
and NCX contribution to Ca2+ extrusion. However the SERCA contribution to
Ca2+ extrusion (assessed as κSERCA = κTwitch – κNCX) was reduced in UN compared
to REC ((% contribution): UN 84.3±0.79 [22], REC 89.8±0.67 [24]; p < 0.001)
(Fig 4.4 E). These results suggest a defective SR Ca2+ uptake contributing to the
observed delayed cytoplasmic Ca2+ removal in UN cardiomyocytes.
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Fig. 4.4: Protocol used for assessing SR Ca2+ content by rapid application of 20 mM caffeine
(A). Cells were stimulated at 1 Hz for 20-30 s (black transients) to achieve steady-state SR
Ca2+ content. Stimulation was stopped and 20 mM caffeine immediately applied to release SR
Ca2+ (grey transient). Protocol used to calculate relative contribution of SR Ca2+ uptake to
Ca2+ removal (B), the time constant (τ) of the field stimulated transient (black) and caffeine-
induced transient (grey) were assessed by fitting monoexponential curves (grey and black).
The SR Ca2+ content (C) and τ of NCX-mediated Ca2+ extrusion (D) were unchanged with
a reduction of SR Ca2+ uptake contribution to Ca2+ removal in UN cardiomyocytes (E).
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4.3.3 Effects of prolonged unloading on myofilament sensi-
tivity to calcium
Myofilament sensitivity to Ca2+ was assessed by sarcomere length / Indo-1 ra-
tio relationship from simultaneously recorded Indo-1 fluorescence and sarcomere
length changes of LV cardiomyocytes. Following mechanical unloading, the sarcom-
ere shortening-Indo-1 transient hysteresis loops showed that less contractility was
produced for the same level of fluorescence, suggesting reduced myofilament sensi-
tivity to Ca2+ in UN cardiomyocytes (Fig 4.5).
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Fig. 4.5: Less contractility was produced for the same level of fluorescence in UN cardiomy-
ocytes suggesting a lower myofilament sensitivity to Ca2+.
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4.4 Results II - Effects of clenbuterol during chronic
mechanical unloading of rat hearts for 1 week
4.4.1 Effects of mechanical unloading and clenbuterol treat-
ment on heart rate
ECG data from the unloaded heart were analysed for heart rate changes over 1 week
of continuous recording to assess the effect of clenbuterol on a denervated heart. Av-
erage heart rate over a 1 minute period, every 6 hours was calculated for each group.
Clenbuterol treatment during mechanical unloading of a normal heart, significantly
increased baseline average heart rate between days 1–4 compared to saline treat-
ment. There was no significant difference between the groups thereafter (Fig 4.6).
These results suggest that clenbuterol may have a early, transient effect on heart
rate in denervated and unloaded heart, but no influence in the long-term.
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Fig. 4.6: Heart rate changes in the denervated, unloaded heart were assessed by direct
ECG recording from the transplanted heart, over a 1 week period. Clenbuterol treatment
significantly increased the baseline heart compared to saline treatment between days 1-4, with
no difference between the groups thereafter. (* p < 0.05, ** p < 0.01 UN+Sal vs UN+Clen)
211
4.4.2 Effects of mechanical unloading and clenbuterol treat-
ment on ex-vivo left ventricular pressure-volume re-
lationship
LV function of normally loaded recipient and mechanically unloaded transplanted
hearts, treated with clenbuterol or saline, were assessed by ex-vivo pressure-volume
relationship studies with an intra-ventricular balloon (number of hearts per group;
REC+Sal=7, REC+Clen=8, UN+Sal=7, UN+Clen=9).
There was no difference in ex-vivo baseline heart rate between the groups (Fig 4.7 A).
Clenbuterol treatment of normal recipient hearts (REC+Clen) did not alter their
ex-vivo LV function (Fig 4.7). This finding is in contrast to improved LV func-
tion (assessed by echocardiography) seen after clenbuterol treatment of normal rat
hearts in Chapter 3 (Table 3.1, Page 181). It would be interesting to know if the in-
creased surgical stress the recipient animal is exposed alters the clenbuterol-induced
functional improvement.
UN+Sal had a rapid rise in diastolic pressure compared to REC+Sal, for the
same LV volumes (Fig 4.7 C). Also the +dP/dT at higher filling volumes was
reduced (Fig 4.7 E). There was no significant decrease in developed pressure or
−dP/dT. These findings suggest that mechanically unloaded hearts had reduced
compliance, consistent with unloading-induced atrophy, and impaired systolic con-
tractility.
UN+Clen had higher systolic pressure (Fig 4.7 B) and +dP/dT (Fig 4.7 E) for
the same filling volumes, compared to UN+Sal. There was no difference in diastolic
pressure rise (Fig 4.7 C). For the same LV volumes, UN+Clen had the highest
developed pressure (Fig 4.7 D) and +dP/dT (Fig 4.7 E) compared to all other
groups. There was no significant difference in −dP/dT between any groups. These
findings suggest that clenbuterol treatment during mechanical unloading normalized
impaired systolic contractility.
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Fig. 4.7: LV function of normally loaded recipient and mechanically unloaded transplanted hearts, treated with clenbuterol or saline, was assessed
by ex-vivo pressure-volume relationship studies with an intra-ventricular balloon. Changes in heart rate (A), systolic pressure (B), diastolic pressure
(C), developed pressure (D), +dP/dT (E) and −dP/dT (F) between each group are shown. (* p < 0.05, REC+Sal vs UN+Sal; † p < 0.05, UN+Sal
vs UN+Clen; § p < 0.05, §§ p < 0.01, REC+Sal vs UN+Clen).
213
R
E
C
+S
al
R
E
C
+C
le
n
U
N
+S
al
U
N
+C
le
n
0
1000
2000
3000
4000
5000
6000
*
**
***
*
C
e
ll
 a
re
a
 (
µµ µµ
m
2
)
Fig. 4.8: LV cardiomyocytes showed an increase in cell surface area after clenbuterol treat-
ment of normally loaded recipient hearts. Clenbuterol treatment also limited unloading-
induced cardiomyocyte atrophy (number of cells per group: REC+Sal=76, REC+Clen=105,
UN+Sal=75, UN+Clen=93).
4.4.3 Effects of mechanical unloading and clenbuterol treat-
ment on cell size
2D cell cross-sectional area of LV cardiomyocytes from all experimental groups was
assessed by planimetry. Clenbuterol treatment induced ∼8% cardiomyocyte hyper-
trophy in the recipient hearts (cell area (µm2): REC+Clen 3510±79 [105], REC+Sal
3265±70 [76]; p < 0.05) (Fig 4.8).
Mechanical unloading reduced cell area by ∼20% (cell area (µm2): UN+Sal
2672±84 [75], REC+Sal 3265±70 [76]; p < 0.001). Clenbuterol treatment dur-
ing mechanical unloading limited this cell area reduction to 10% (cell area (µm2):
UN+Clen 2974±80 [93], UN+Sal 2672±84 [75]; p < 0.001) (Fig 4.8). These find-
ings suggest that clenbuterol treatment induces cardiomyocyte hypertrophy in a
normally loaded heart and limits unloading-induced atrophy in a mechanically un-
loaded heart.
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4.4.4 Effects of mechanical unloading and clenbuterol treat-
ment on EC coupling
Cardiomyocyte contractility was assessed by monitoring real time changes of the
sarcomere length during field-stimulation. Clenbuterol treated recipient hearts had
shorter resting sarcomere length with unchanged contractility and relaxation (Fig 4.9 A,
Table 4.1). Mechanically unloaded hearts had shorter resting sarcomere length, un-
changed shortening amplitude, delayed time-to-peak contraction and delayed T50 re-
laxation (Fig 4.9 B, Table 4.1), suggesting impaired systolic and diastolic con-
tractile function. Clenbuterol treatment, during mechanical unloading, normalized
time-to-peak contraction and T50 relaxation (Fig 4.9 C, Table 4.1). These results
suggest that clenbuterol does not affect contractile function of a normal heart but
normalizes contractile dysfunction following mechanical unloading.
Cytoplasmic [Ca2+] was assessed by measuring Indo-1 fluorescence ratio. Clen-
buterol treatment increased the Ca2+ transient amplitude of the normally loaded
recipient cardiomyocytes, without affecting diastolic Ca2+ level, Ca2+ release or de-
cay (Fig 4.9 A, Table 4.1). The SR Ca2+ content and Indo-1 decay in caffeine
were unaffected. The SR fractional Ca2+ release was increased (Table 4.1) which
may contribute to the increased amplitude stimulation-induced Ca2+ transient.
Mechanical unloading increased the Ca2+ transient amplitude, SR Ca2+ content
and SR fractional Ca2+ release (Fig 4.9 B, Table 4.1). The time-to-peak Ca2+
release and T50 decay were delayed (Fig 4.9 B, Table 4.1). These findings suggest
impaired Ca2+ cycling after mechanical unloading despite an increased SR Ca2+
content.
Clenbuterol treatment during mechanical unloading normalized delayed time-
to-peak Ca2+ release without affecting the increased Ca2+ transient amplitude or
delayed stimulation-induced transient decay (Fig 4.9 C, Table 4.1), suggesting
normalized Ca2+ release mechanisms. SR Ca2+ content and SR fractional Ca2+
release remained increased, compared to normally loaded control hearts (Table 4.1).
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The delayed caffeine-induced Ca2+ transient decline was normalized, suggesting an
improved NCX contribution to Ca2+ extrusion (Fig 4.9 C, Table 4.1).
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A. B. C.
Fig. 4.9: Representative traces of simultaneously acquired Indo-1 transients (top panel) and sarcomere shortening (bottom panel) from all groups.
Clenbuterol treatment of a normally loaded recipient heart did not affect sarcomere shortening despite increased Indo-1 transient amplitude (A).
Mechanical unloading produced contractile and relaxation dysfunction associated with increased Indo-1 transient amplitude and delayed T50 decay
(B). Clenbuterol treatment during mechanical unloading, normalized contractile and relaxation dysfunction and was associated with faster TTP Indo-1
transients (C). Inset showing faster time-to-peak Indo-1 transients in UN+Clen. All data are shown in Table 1.
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Table 4.1: Contractile and Ca2+ handling parameters in experimental groups. (data in [ ] indicates number of cells studied) (∗p < 0.05, ∗∗p <
0.01, ∗∗∗p < 0.001 vs REC+Sal; †p < 0.05, ††p < 0.01, †††p < 0.001 UN+Sal vs UN+Clen)
REC+Sal REC+Clen UN+Sal UN+Clen
1 Hz Sarcomere shortening
Baseline SL (µm) 1.76±0.01 [91] 1.74±0.01 [118] * 1.71±0.01 [67] *** 1.69±0.01 [93] ***
Amplitude (µm) 0.08±0.005 [91] 0.08±0.004 [118] 0.08±0.005 [67] 0.08±0.005 [93]
Time to peak (ms) 87±2 [91] 82±2 [96] 97±5 [67] * 79±3 [70] †††
T50 relaxation (ms) 72±4 [90] 60±2 [95] 89±8 [69] * 69±5 [70] †
1Hz Calcium transient
Baseline (Indo-1 ratio units) 0.37±0.01 [90] 0.36±0.01 [115] 0.38±0.01 [67] 0.36±0.01 [88]
Amplitude (Indo-1 ratio units) 0.09±0.003 [90] 0.11±0.004 [115] *** 0.12±0.005 [67] ** 0.11±0.005 [88] **
Time to peak (ms) 32±1 [90] 32±1 [92] 38±2 [67] *** 35±1 [65] ††
T50 decay (ms) 96±4 [49] 91±4 [40] 111±6 [48] * 114±5 [34] *
Caffeine induced Ca2+ transient
SR Ca2+ content (Indo-1 ratio units) 0.14±0.01 [25] 0.13±0.01 [31] 0.18±0.01 [27] ** 0.17±0.01 [17] **
Indo-1 decay τ(s) 1.01±0.06 [26] 0.92±0.05 [33] 1.08±0.07 [28] 0.86±0.07 [20] *
Fractional Ca2+ release (%) 58±4 [25] 73±3 [31] ** 72±2 [27] ** 79±4 [19] **
NCX contribution to Ca2+ extrusion (%) 14±1 [25] 12±1 [33] 14±1 [28] 17±2 [20] †
Myofilament sensitivity to Ca2+
Slope value (µm/ratio unit) 2.22±0.32 [42] 1.93±0.21 [57] 1.67±0.24 [37] 1.59±0.19 [41]
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4.4.5 Effects of 1-week mechanical unloading and clenbuterol
treatment on myofilament sensitivity to calcium
Myofilament sensitivity to Ca2+ was assessed by sarcomere length-[Ca2+]i relation-
ship from simultaneously recorded Indo-1 fluorescence changes and sarcomere short-
ening of LV cardiomyocytes. The sarcomere shortening-Ca2+ transient hysteresis
loops showed no change between the groups (Table 4.1). These findings suggest
that following 1 week of clenbuterol treatment, with or without mechanical unload-
ing, myofilament sensitivity to Ca2+ is not affected. This may be a time-dependent
phenomenon as 5-weeks of mechanical unloading leads to depressed myofilament
sensitivity to Ca2+ (Fig 4.5).
4.4.6 Electrophysiological changes after mechanical unload-
ing and clenbuterol treatment
Action potential duration was assessed in current-clamp mode and I Ca,L measured
as described above. Mechanical unloading prolonged APD50 (Fig 4.10 A) but
not APD90 (Fig 4.10 B), suggesting a broader plateau of the AP. Clenbuterol
treatment, of a normally loaded or unloaded heart, did not affect the AP properties.
There was no change in the I-V relationship and peak current density (Fig 4.10 C)
or τfast (Fig 4.10 D) and τslow (Fig 4.10 E) components of I Ca,L inactivation
between the groups.
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Fig. 4.10: Mechanical unloading delayed APD50 (A) without affecting APD90 (B). Clen-
buterol treatment, with or without mechanical unloading, did not affect APD. The I-V rela-
tionship (C) and inactivation (D, E) of I Ca,L was unchanged between the groups.
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4.4.7 Effects of mechanical unloading and clenbuterol treat-
ment on calcium handling protein expression
Western blotting was performed as described above, to assess changes in Ca2+ cycling
protein expression. RyR2 and CaV1.2(α1C) protein expression levels were tested
as they are key mediators of SR Ca2+ release in cardiomyocyte EC coupling (Bers
2001, 2002). RyR2 expression was reduced after clenbuterol treatment of a normally
loaded heart (Fig 4.11). Mechanical unloading further reduced RyR2 expression
(Fig 4.11) which may contribute to the delayed time-to-peak of the Ca2+ transient
(Fig 4.9 B, Table 4.1). Clenbuterol treatment, during mechanical unloading, lim-
ited the unloading-induced reduction of RyR2 expression (Fig 4.11). This may con-
tribute to the faster time-to-peak Ca2+ release of stimulation-induced Ca2+ transient
seen following clenbuterol treatment (Fig 4.9 C, Table 4.1). There was no change
in the expression of CaV1.2(α1C) protein levels between the groups (Fig 4.11) which
is in accordance with the unchanged I Ca,L properties (Fig 4.10 C, D, E).
The expression levels of calsequestrin, which is an SR Ca2+ binding luminal pro-
tein that can regulate SR Ca2+ release (Gyorke & Terentyev 2008), were tested to
account for the changes seen in SR Ca2+ content and release following mechani-
cal unloading. There were no differences in calsequestrin expression between the
groups (Fig 4.11), suggesting no contribution from changes in its abundance to the
increased SR Ca2+ content and delayed Ca2+ release observed in unloaded hearts.
SERCA2a, NCX, phospholamban (and its PK-A, G or C phosphorylated form,
P-16) protein expression levels were studied as they are key mediators of Ca2+
removal from the cytoplasm (Bers 2001, 2002). There was no change in SERCA2a
expression levels between the groups (Fig 4.11). There was a reduction in NCX
expression levels after clenbuterol treatment of a normally loaded hearts (Fig 4.11).
Mechanical unloading further reduced NCX expression levels, which may contribute
to the delayed Ca2+ removal from the cytoplasm (Fig 4.9 B, Table 4.1). The
combination of mechanical unloading and clenbuterol treatment did not affect the
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unloading-induced reduction of NCX protein expression levels (Fig 4.11). It is
possible that the improved NCX-mediated contribution to Ca2+ extrusion from the
cytoplasm in unloaded hearts treated with clenbuterol (Table 4.1) could be due
to factors that regulate NCX activity, such as [Na+]i (Bers et al. 2006; Pieske &
Houser 2003) and phosphorylation (Wei et al. 2003). This hypothesis requires further
testing.
Total phospholamban expression was increased after clenbuterol treatment and
unloading (Fig 4.11). This increased phospholamban expression following mechan-
ical unloading, also reported by other groups (Ito et al. 2003; Minatoya et al. 2007),
may contribute to the delayed Ca2+ extrusion in the stimulation-induced Ca2+ tran-
sient (Table 4.1). This may occur by altering SERCA2a/PLB ratio, which is a
major determinant of cardiac contractile performance (Brittsan & Kranias 2000).
The phosphorylation state of PLB is also physiologically important in the regula-
tion of SERCA2a function because PLB inhibits SERCA2a in its unphosphorylated
state (Bers 2002). There was increased expression of phosphorylated phospholam-
ban (P-16) only in the unloaded hearts treated with clenbuterol (Fig 4.11), indicat-
ing an increased PK-A, C or G-induced phosphorylation of phospholamban (Bers
2001, 2002; Colyer 1998). This change would be expected to relieve phospholamban-
mediated inhibition of SERCA allowing faster decline in the twitch and Ca2+ tran-
sient (Bers 2002). However there was no improvement seen in the delayed T50 decay
of the stimulation-induced Ca2+ transient, despite faster T50 sarcomere relaxation
(Table 4.1), following unloading and clenbuterol treatment. Further studies would
be required to assess the relevance of this finding.
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Fig. 4.11: Representative western blots (A) and graphs of data (B) from all experimental
groups of CaV1.2(α1C), RyR2, SERCA2a, NCX, total phospholamban (PLB), phosphorylated
phospholamban (P-16), Calsequestrin and GAPDH. Clenbuterol reduced RyR2 expression
but limited unloading-induced reduction of RyR2 expression. Clenbuterol and mechanical
unloading reduced NCX and increased total phospholamban expression. P-16 expression was
increased only in the UN+Clen group indicating an increased PKA-induced phosphorylation
of phospholamban. There were no changes in calsequestrin expression between the groups.
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4.5 Discussion
The results described in this Chapter demonstrate that 5 weeks of mechanical un-
loading by heterotopic abdominal transplantation leads to cardiomyocyte atrophy
with defective contractility and relaxation. At the present time, this is the first
report showing a mechanistic link between myofilament sensitivity to Ca2+ and
contractile dysfunction following prolonged unloading in animal studies. Although
myofilament sensitivity to Ca2+ is best studied in permeabilized myocytes, the tech-
nique used to assess this parameter has been validated previously (Bailey et al.
1997). Whether these mechanisms also contribute to the functional properties of
the myocardium in patients treated with LVADs requires further testing. The de-
layed cardiomyocyte relaxation following mechanical unloading seen in this Chapter,
and reported by other groups (Ito et al. 2003; Minatoya et al. 2007), may be ex-
plained by reduced myofilament sensitivity to Ca2+ (Varian & Janssen 2007) and a
defective SR Ca2+ uptake, respectively.
The results described in this Chapter also demonstrate that 1 week of mechan-
ical unloading of a normal rat heart induces cardiomyocyte atrophy, detrimental
changes in contractility and relaxation at whole-heart and cardiomyocyte level. It
is associated with altered EC coupling, prolonged AP and altered expression and
phosphorylation of key Ca2+ cycling proteins. Administration of β2-AR agonist,
clenbuterol to a normally loaded heart induces cardiomyocyte hypertrophy with un-
altered whole-heart and cellular contractile and relaxation function, altered Ca2+
cycling protein expression. Administration of the β2-AR agonist, clenbuterol during
mechanical unloading of a non-failing rat heart limits unloading-induced cardiomy-
ocyte atrophy. Contractile and relaxation dysfunction at whole-heart and cellular
level are partially normalized by effects of clenbuterol on EC coupling, possibly due
to changes in Ca2+ cycling protein expression and phosphorylation.
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4.5.1 Unloading-induced atrophy
Myocardial atrophy is an important consequence of mechanical unloading and has
been demonstrated in both human (Xydas et al. 2006b; Maybaum et al. 2007) and
animal (Rakusan et al. 1997) studies. This is likely to be the main limiting factor for
improving myocardial recovery in treatment regimes using LVADs. A limitation of
the results in this Chapter is that data were collected from normal rat hearts. There-
fore in Chapter 5, the effects of mechanical unloading, with and without clenbuterol
treatment, of failing rats hearts have been tested.
Studies with shorter periods of unloading were not associated with contractile
dysfunction (Welsh et al. 2001; Ritter et al. 2000). Oriyanhan et al. (2007) have
recently shown a time-dependent reduction of hypertrophied cardiomyocyte size and
papillary muscle contractile function, following heterotopic abdominal transplanta-
tion of failing rat hearts, suggesting that prolonged unloading may have detrimental
functional consequences. Maybaum et al. (2007) have reported an improvement in
LV function (LVEF >40%) of heart failure patients following 30 days LVAD support.
However, longer duration (120 days) of LVAD support of failing hearts appeared to
deleteriously affect LV function despite regression of cardiomyocyte hypertrophy
(Maybaum et al. 2007). Xydas et al. (2006b) have reported maximum improve-
ment in LVEF at 60 days, with no further improvement thereafter in failing hearts
supported by LVAD.
In a study from Harefield Hospital, the β2-AR agonist clenbuterol was used
to prevent myocardial atrophy in patients treated with LVADs (Yacoub 2001; Birks
et al. 2006) (see Page 84). Clenbuterol has been proposed to limit unloading-induced
atrophy and improve explantation rate for ‘bridge to recovery’ (Yacoub 2001; Birks
et al. 2006). The results described in this chapter show that clenbuterol limits
unloading-induced atrophy at cellular level during mechanical unloading of a nor-
mal or non-failing rat hearts. It is known that despite 50% reduction in cell size
following mechanical unloading of failing hearts with LVAD, specific changes in EC
coupling (shortening of action potential duration, increased SR Ca2+ content, faster
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inactivation of I Ca,L current), and not regression of cellular hypertrophy, are associ-
ated with clinical recovery (Terracciano et al. 2004). This suggests that there may
be functional more than structural changes that determine the point where positive
effects of unloading-induced reverse remodelling become deleterious. The associated
pharmacological therapy in Birks et al. (2006), may act on functional parameters to
improve myocardial function. More investigations into the molecular mechanisms
responsible for the unloading-induced myocardial remodelling are required to design
new combined therapeutic approaches during LVAD treatment.
4.5.2 Mechanical unloading and excitation-contraction cou-
pling
The results in this Chapter confirm impaired cardiomyocyte contractility and relax-
ation following 5 weeks or 1 week unloading normal or non-failing rat hearts. Other
groups have reported only an impairment of diastolic function with intact systolic
function following 5 weeks of mechanical unloading (Ito et al. 2003; Minatoya et al.
2007). This discrepancy could be due to differences in the methods to assess con-
tractility (sarcomere shortening vs cardiomyocyte or papillary muscle shortening)
(Delbridge & Roos 1997). The results in this Chapter also show that following
5 weeks of mechanical unloading, there was reduced amplitude of sarcomere short-
ening, in the presence of unaltered Ca2+ transient amplitude, suggesting defective
myofilament sensitivity to Ca2+ (Fig 4.3).
Ito et al. (2003) and Minatoya et al. (2007) have shown impaired relaxation and
decay of [Ca2+]i at baseline in the 5-week unloaded hearts (similar to this thesis),
combined with a reduction of contractile reserve at higher work states obtained by
increasing [Ca2+]o. This finding further highlights the detrimental effects of unload-
ing. The same authors have also reported that the reduced contractility at higher
work states was due to impaired capacity to augment peak systolic [Ca2+]i with
unchanged peak systolic [Ca2+]i - fractional cell shortening relationship. However
they did not test whether myofilament sensitivity to Ca2+ was affected. The re-
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sults in this Chapter confirm reduced myofilament sensitivity to Ca2+ after 5 weeks
unloading (Fig 4.5). However, shorter periods of unloading (1 week), were not
associated with alterations in myofilament sensitivity to Ca2+, despite an increased
Ca2+ transient amplitude (Table 4.1).
After 5 weeks of mechanical unloading, Ca2+ cycling was altered with defective
removal of [Ca2+]i during twitch contraction (Fig 4.3 A, B). The SR Ca
2+ con-
tent and Ca2+ removal of caffeine-induced transient (attributable to NCX-mediated
Ca2+ extrusion) were unaltered, with reduced contribution of SR Ca2+ uptake to
Ca2+ removal (Fig 4.4 E). Given the reduction in SR Ca2+ uptake rate, the SR
Ca2+ content should be reduced. In UN myocytes there was no difference in the
amplitude of the caffeine-induced Ca2+ transient suggesting a similar SR Ca2+ con-
tent compared with control myocytes. Although this was not directly measured in
this study at 5 weeks of unloading, it is possible that changes in action potential
duration in UN myocytes may occur. The prolonged action potential may reduce
Ca2+ extrusion via NCX and maintain the SR Ca2+ content despite a reduction in
SR Ca2+ uptake (Terracciano et al. 1997). This hypothesis requires further testing.
After 1 week of mechanical unloading, Ca2+ cycling was also altered but with
a larger and delayed stimulation-induced Ca2+ transient amplitude and defective
removal of [Ca2+]i (Table 4.1). Ritter et al. (2000) have also reported an increased
stimulation-induced Ca2+ transient amplitude after 5 days of mechanically unloading
normal mouse hearts. They concluded that a reduction in cell volume with main-
tenance of internal surface membrane areas, and/or a decrease in concentration of
cellular Ca2+ buffers, may contribute to the increase in the Ca2+ transient.
The increased SR Ca2+ content and SR fractional Ca2+ release, reported in this
Chapter after 1 week of mechanical unloading (Table 4.1), may contribute to the
increased stimulation-induced Ca2+ transient amplitude. It is possible that the pro-
longation of action potential following 1 week of mechanical unloading (Fig 4.10),
may reduce Ca2+ extrusion via NCX and maintain the SR Ca2+ content as sug-
gested above (Terracciano et al. 1997). This hypothesis requires further testing.
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The faster Ca2+ release of stimulation-induced Ca2+ transient seen after clenbuterol
treatment during mechanical unloading could be due to the increased RyR expres-
sion (Fig 4.11) but further studies would be required to confirm this relationship.
The delayed caffeine-induced Ca2+ transient decline observed after mechanical
unloading was normalized by clenbuterol, suggesting an improved NCX contribution
to Ca2+ extrusion (Fig 4.9 C, Table 4.1). Although, clenbuterol did not alter the
NCX protein abundance (Fig 4.11), this improvement may be due to factors that
regulate NCX activity, such as [Na+]i (Bers et al. 2006; Pieske & Houser 2003) and
phosphorylation (Wei et al. 2003). These hypotheses requires further testing.
In rodent cardiomyocytes, the main mechanisms for restoring diastolic [Ca2+]i
are SR Ca2+ reuptake (∼80%) and NCX-mediated Ca2+ extrusion (∼20%), with
minimal contribution (<1%) from sarcolemmal Ca2+-ATPase and mitochondrial uni-
porter (Maier et al. 2003; Bers 2001). This suggests that in UN myocytes there is a
reduced contribution from the SR Ca2+ uptake. This may be explained by reduced
SERCA2a expression (Oriyanhan et al. 2007; Tsuneyoshi et al. 2005b), increased
phospholamban expression (Fig 4.11), or altered phosphorylation of phospholam-
ban (Ito et al. 2003; Minatoya et al. 2007; Fig 4.11), thus inhibiting SERCA2a
function and SR Ca2+ reuptake following mechanical unloading.
4.5.3 Myofilament sensitivity to calcium
The [Ca2+]i - sarcomere length relationship was assessed by a technique described
by Bailey et al. (1997), which confirmed a reduced myofilament sensitivity to [Ca2+]i
after 5 weeks (Fig 4.5 D), but not 1 week (Table 4.1) of mechanical unloading.
These results suggest that depression in myofilament sensitivity to Ca2+ is a time-
dependent change. One possible limitation of this approach is that calibration of
the fluorescence signals was not performed to quantify cytoplasmic [Ca2+]. While
this can be a possible source of error, the relationship between Indo-1 fluorescence
ratio and cytoplasmic [Ca2+] is sufficiently linear in the range of measurements
reported (20% to 80% of Ca transients) (Bassani et al. 1995a; Levi et al. 1996),
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to allow comparisons between groups. It would be interesting to study if cells of
similar cross-section across groups also display reduced myofilament sensitivity to
Ca2+ thus increasing the reliability of this technique.
The possible reasons for the reduced myofilament responsiveness to changes in
[Ca2+]i include contractile protein isoform shifts and / or their phosphorylation
states (Minatoya et al. 2007; Tsuneyoshi et al. 2005b). This might offer a new
therapeutic target for improving cardiomyocyte contractile function to improve the
‘bridge to recovery’ rate following LVAD support.
In conclusion, the results described in this Chapter demonstrate that chronic
mechanical unloading of normal hearts leads to time-dependent cardiomyocyte at-
rophy with defective contractility and relaxation due to reduced myofilament sen-
sitivity to Ca2+ and a defective SR Ca2+ uptake. Shorter periods of mechanically
unloading normal hearts also induces cardiomyocyte atrophy, contractile dysfunc-
tion at whole-heart and cardiomyocyte level. It is associated with deranged EC
coupling, prolonged AP and altered expression and phosphorylation of key Ca2+
cycling proteins. Clenbuterol treatment during mechanical unloading of a normal
heart limits unloading-induced cardiomyocyte atrophy, normalizes contractile and
relaxation dysfunction at whole-heart and cellular level by altered EC coupling due
to changes in Ca2+ cycling protein expression and phosphorylation.
The results in this Chapter confirm the hypotheses that, (i) mechanical left
ventricular unloading and the consequent left ventricular atrophy results in altered
function at whole-heart and cellular levels in a normal or non-failing rat heart (ii)
clenbuterol treatment during mechanical unloading of a normal or non-failing rat
heart improves whole-heart and cellular function. The effects of clenbuterol treat-
ment during mechanical unloading of a failing heart rat with contractile dysfuntion
have been tested in the next Chapter.
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Chapter 5
Effects of clenbuterol treatment
and mechanical unloading on the
structural and functional
properties of a failing rat hearts
The experiments described in this chapter were designed to test the hypothesis that
Clenbuterol has an additional benefit when combined with mechanical
unloading in the treatment of a failing rat heart.
In this Chapter, the role and possible mechanisms of clenbuterol in enhancing reverse
remodelling during mechanical unloading (using abdominal heart transplantation) in
a murine chronic heart failure model (induced by left coronary artery ligation) have
been investigated. Specifically, the effects of clenbuterol on whole-heart function,
heart rate, incidence of ventricular arrhythmias, cell size, EC coupling, myofilament
sensitivity to Ca2+ and cellular electrophysiological properties were studied.
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5.1 Materials & Methods
Animal models: Rat model of chronic post-infarction cardiomyopathy was used
as it is a well established, reproducible model of dysfunction (Loennechen et al.
2002; Ahmet et al. 2004). Heterotopic abdominal heart transplantation in rats
was used as a model of mechanical unloading, as described on Page 103.
Induction of heart failure: Heart failure (HF) was induced by permanent left
coronary artery (LCA) ligation as previously described (Loennechen et al.
2002; Ahmet et al. 2004). Sham operated animals underwent left thoracotomy
and the needle was passed under the LCA and removed without ligation. For
details of the surgical procedure, see Page 101.
Monitoring development of heart failure: Changes in LV function were as-
sessed by echocardiography over a period of 4-6 weeks. Echocardiography
was performed under 1.5% isoflurane anæsthesia to ensure constant depth of
anæsthesia in all animals. Transthoracic echocardiography was performed us-
ing a 15 MHz probe on an Acuson Sequoia™ 256 system (Acuson, CA, USA)
to obtain parasternal short-axis views at the level of the mid-papillary muscle
(see Page 113). Ejection fraction (EF) was calculated from the systolic and
diastolic 2-dimensional cross-sectional LV areas, as described in Table 2.2,
Page 117.
Experimental groups: To test the effect of clenbuterol in HF, Sham and HF an-
imals received an osmotic minipump (Model 2001, Alzetr, USA) containing
clenbuterol (2 mg/Kg body weight/day) or normal saline (Sal) for 7 days
(Sham+Sal, HF+Sal or HF+Clen), implanted subcutaneously (see Page 108).
To test the effects of mechanical unloading (UN), the failing hearts were het-
erotopically transplanted (Ono & Lindsey 1969) into the abdomen of control
Lewis rats and the recipients then received an osmotic minipump containing
clenbuterol or Sal for 7 days (HF+UN+Sal or HF+UN+Clen). Briefly, the
failing heart was removed from the donor rat following cardioplegic arrest and
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Fig. 5.1: Experimental protocol used to study clenbuterol and mechanical unloading
in a rat model of chronic post-infarction cardiomyopathy
the donor aorta was anastomosed to the recipient abdominal aorta and the
donor pulmonary artery to the recipient inferior vena cava. For details of the
surgical procedure, see Page 103.
Ex-vivo LV function assessment: LV function of the transplanted heart was as-
sessed by measuring the pressure-volume relationship ex-vivo using an intra-
ventricular balloon as described on Page 118. All animals were heparinized
(1000 IU) before removal of the heart which was perfused with normal Tyrode
solution at 37℃ on a Langendorff apparatus. Hearts were paced with platinum
electrodes on the right ventricle to maintain a heart rate of 300 bpm.
ECG monitoring and analysis: Subcutaneously implanted telemetry transmit-
ters (Model TA10EA-F20, PhysioTel™) were used for recording the ECG
changes from some rats with heart failure, treated with clenbuterol (HF+Clen,
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n=7) or saline (HF+Sal, n=7) over a 1 week period. For a detailed descrip-
tion of surgical implantation procedure, see Page 112. Data was recorded
continuously over a 7 day period, starting from recovery following surgery for
implantation of telemetry device and osmotic minipump (containing saline or
clenbuterol), until sacrifice.
ECG data were analysed for heart rate changes and incidence of ventricular
arrhythmias using ecg-Auto, version 2.5.0.3 software (EMKA Technologies,
France). Heart rate was calculated from the average heart rate of only sinus
beats, from a 5 minute period, every 6 hours over the 1 week period of con-
tinuous ECG recording. Ventricular arrhythmia analysis was performed on a
1 hour continuous ECG recording, every 6 hours, giving 4 time points over a
24 hour period. A customized library of ventricular premature beats (VPB)
was created for each animal by visual identification from the respective ECG
recording (Fig 5.2). A VPB was defined as a discrete and identifiable prema-
ture QRS complex which was premature in relation to the P-wave, according
to Convention 13 of The Lambeth Conventions (Walker et al. 1988). The VPBs
in the entire analysis period were identified by the ecg-Auto software based on
a ‘shape recognition’ algorithm that correlated test complexes with those in
the ECG library. Two (couplets) and three (triplets) consecutive VPBs, which
do not constitute ventricular tachycardia, were termed as salvos, according to
Convention 14 of The Lambeth Conventions (Walker et al. 1988). Ventricular
tachycardia (VT) was defined as a run of 4 or more consecutive VPBs, accord-
ing to Convention 14 of The Lambeth Conventions (Walker et al. 1988). Data
are represented as number of events per hour of assessment, over the 1 week
period.
Cardiomyocyte Studies: Following explantation of recipient and transplanted
hearts (see Page 107) only LV myocytes were isolated by enzymatic diges-
tion (see Page 123). Cardiomyocytes were stored at room temperature and all
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Fig. 5.2: Representative library of 15 polymorphic VPBs used for arrhythmia recog-
nition.
cellular experiments were performed within 7-8 hours of cell isolation.
Cardiomyocyte size assessment: Cardiomyocytes were examined using an Olym-
pus IX-71 inverted microscope with a ×60 objective. Digital images of the
cardiomyocytes were acquired and the projected 2-dimensional area for each
cell was measured using ImageJ software (NIH, USA). For a detailed explana-
tion of the planimetry procedure, see Page 126.
Sarcomere shortening: These experiments were performed using the setup
shown in Fig 2.14, Page 138. For details of data acquisition (Page 127) and
analysis (Page 140, Fig 2.15) see Chapter 2.
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Cytoplasmic Ca2+ measurement: Indo-1 fluorescence ratio was used to mon-
itor changes in [Ca2+]i using the setup shown in Fig 2.14, Page 138. For
details of data acquisition (Page 134) and analysis (Page 139, Fig 2.15), see
Chapter 2.
SR Ca2+ content was assessed by rapid application of 20 mM caffeine in nor-
mal Tyrode solution (see Page 141) using the protocol shown in Fig 2.16 B
(Page 142).
Assessment of myofilament sensitivity to calcium: The cardiomyocyte myofil-
ament sensitivity to Ca2+ was assessed using a technique described by Bailey
et al. (1997). For a detailed explanation of the technique, see Page 144.
Measurement of action potential: Cardiomyocytes were superfused with nor-
mal Tyrode solution and studied using switch clamping. These experiments
were performed by Dr. C. M. N. Terracciano and Dr. M. A. Stagg. For
a detailed explanation of the technique, see Page 147. The pipette resistance
was 30 MΩ, and the pipette-filling solution contained (in mM) KCl, 2000;
HEPES, 5; EGTA, 0.1; pH, 7.2. Action potentials (AP) were measured in
current-clamp mode at stimulation of 1, 3, and 5 Hz using a 1 ms, 1.2-1.4
nA pulse. Traces were averaged with reference to the stimulation signal, and
the time to 90% repolarization (APD90) was taken as a measure of the AP
duration for comparison between groups.
Measurement of sodium-calcium exchanger current density: These experi-
ments were performed by Dr. J. Lee. For a detailed explanation of the tech-
nique, see Page 154. The pipette-filling solution contained (in mM) CsCl, 45;
HEPES, 20; MgCl2, 11; Na2ATP, 10; CsOH, 100; EGTA, 50; CaCO3, 25;
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pH, 7.2. [Ca2+]i calculated to be ∼200 nmol/l, as previously described (Quinn
et al. 2003). The I NCX was taken as the 5 mM Ni
2+-sensitive component of the
current, which was normalized to the whole-cell capacitance for cross-group
comparisons. Data were analyzed using Clampfit software (Axon Instruments,
CA, USA).
Measurement of L-type calcium current properties: These experiments were
performed by Dr. M. A. Stagg. For a detailed explanation of the setup
and technique, see Page 149. I Ca,L was measured using the same hardware
configuration as for AP, but in voltage-clamp mode. All I Ca,L data were
analyzed using Clampfit© software (Axon Instruments, CA, USA).
Ca2+ cycling and β2-AR coupled, Gαi protein expression: Some hearts were
snap frozen and only the LV samples were used for assessing changes in pro-
tein expression by western blotting. For details of protein extraction, protein
concentration estimation, protein electrophoresis and blotting, see Page 157.
The hearts were perfused in-vivo with ice-cold normal Tyrode solution con-
taining NaF, 1 mM and Na3VO4, 1 mM before snap-freezing the LV to prevent
dephosphorylation of proteins. Tissue samples were collected only from the
basal, anteroseptal region of the LV, as shown in Fig 5.3.
The expression levels of NCX, troponin I, phosphorylated troponin I (β-AR
stimulation-mediated, protein kinase (PK)A and PKC phosphorylation at Ser-
ine 23/24 sites, (Ward et al. 2002; Noland et al. 1995; Gaponenko et al. 1999))
were studied to assess the effects of clenbuterol and mechanical unloading on
key Ca2+ cycling and myofilament protein expression. Gαi protein expression,
which is known to increase in murine heart failure and correlate closely with
severity of impaired cardiac function (Shi et al. 1995), was studied to assess
the effects of selective β2-AR stimulation and mechanical unloading in heart
failure.
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Fig. 5.3: Protocol of LV sample collection for western blotting
For details of antibody concentrations used see Table 2.4, Page 164. The
optical density values of the desired protein were standardized to total protein
reactivity on the same blot.
Gene expression analysis: These experiments were performed by Dr. L. E. Felkin
and Dr. P. J. R. Barton. Total RNA was extracted from frozen LV tis-
sue samples (6 hearts per group) using the standard Trizol protocol (Cata-
logue No. 15596-026, Invitrogen, UK), purified using RNeasy™ mini-columns
with DNase treatment (Catalogue No. 74104 and 79254 respectively, Qia-
gen, UK) and quantified using Ribogreen RNA binding dye (Catalogue No.
R11490, Invitrogen). Real time-PCR was performed as described previously
(Felkin et al. 2006). Primers and standard Taqman probes for α- and β-
myosin heavy chain (MHC) were designed in-house using Primer Express v.1
5 (α-MHC: Forward primer: 5’-caaactcatggccacactcttct-3’, reverse primer:
5’-ggaaggatgagcctttcttcttg-3’, probe: 5’-FAM-ccactgtcaccggtatcagcagaagcata
-3’. β-MHC: Forward primer: 5’-agctcctaagtaatctgtttgccaa-3’, reverse primer:
5’-aaaggatgagcctttctttgct-3’, probe 5’-FAM-cttgtctacaggtgcatcagctccagcat-3’).
Data were analysed using the Comparative Ct method (User Bulletin 2, Cata-
logue No. P/N4303859, Applied Biosystems, UK) with target gene expression
normalized to 18S ribosomal RNA levels (Catalogue No. 4310893E, Applied
237
Biosystems) and are given as mean relative expression levels±SEM.
Statistical analysis: Statistical comparison of data was performed using one-way
analysis of variance followed by Newman-Keuls post-hoc test for individual
significant differences or Student’s t-test where appropriate. All statistical
analyses were performed using Prism 4 software (GraphPad Software, Inc.)
and p<0.05 was considered significant. Data are expressed as mean±SEM [n]
unless otherwise specified.
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5.2 Results
5.2.1 Effects of clenbuterol on LV function of failing hearts
in-vivo
LV function of failing and sham operated animals, treated with clenbuterol or saline,
was assessed in-vivo by echocardiography. LCA ligation produced LV dysfunction
after 4-6 weeks at whole-heart level characterized by reduced LVEF, reduced LV
fractional shortening, LV wall thinning and LV chamber dilation on echocardiogra-
phy (Fig 5.4 B, D; Table 5.1). Clenbuterol treatment of failing hearts increased
LVEF by 16%, increased LV fractional shortening by 6% and improved thickening
of the viable posterior wall by 20% (Fig 5.4 B, D; Table 5.1). These results
indicate that clenbuterol affects LV function of failing hearts.
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Fig. 5.4: Echocardiography results: Representative 2D (top) and M-mode (bottom) echocar-
diography traces at mid-papillary level of a normal control heart (A), a failing heart treated
with saline showing akinetic anterior scar and reduced contractility and thinning of posterior
wall (B). A failing heart treated with clenbuterol shows improved posterior wall contractility
with unchanged anterior scar movement (C). Sham operated and heart failure animals treated
with saline showed no change in LVEF but clenbuterol treatment of failing hearts improved
LVEF by ∼18% (D). Data are shown in Table 5.1. (*** p < 0.001 HF vs HF+Clen)
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Table 5.1: Echocardiographic parameters measured in experimental groups (data in [ ] indicates number of hearts studied) (* p < 0.05, ** p < 0.01,
*** p < 0.001 vs Sham; †† p < 0.01, † † † p < 0.001 HF vs HF+Clen).
Sham Sham+Sal HF HF+Sal HF HF+Clen
LV ejection fraction (%) 79.0±1.4 [12] 81.1±1.9 [11] 35.9±2.4 [11]*** 41.7±1.8 [10]*** 35.9±2 [16]*** 52.1±1.4 [16]*** †††
LV fractional shortening (%) 44.7±1.8 [12] 48.3±2.1 [10] 18.9±1.6 [11]*** 18.0±1.3 [9]*** 18.9±0.9 [15]*** 24.7±1.1 [16]*** ††
LV diameter (cm)
diastole 0.71±0.02 [12] 0.73±0.02 [11] 0.98±0.02 [11]*** 0.98±0.01 [9]*** 0.96±0.02 [15]*** 1.02±0.03 [16]***
systole 0.31±0.01 [12] 0.32±0.01 [11] 0.25±0.01 [11]** 0.27±0.02 [9] 0.25±01 [15]*** 0.30±0.01 [16]†††
LV anterior wall thickness (cm)
diastole 0.17±0.01 [12] 0.16±0.01 [11] 0.10±0.01 [11]*** 0.10±0.01 [9]*** 0.13±0.01 [15]*** 0.12±0.01 [16]
systole 0.29±0.01 [12] 0.30±0.01 [11] 0.12±0.01 [11]*** 0.11±0.01 [9]*** 0.14±0.01 [15]*** 0.15±0.01 [16]***
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5.2.2 Effects of clenbuterol on heart rate and incidence of
ventricular arrhythmias in failing hearts in-vivo.
ECG data was analysed from 1 week of continuous recording. Heart rate was calcu-
lated from the average heart rate of only sinus beats , from a 5 minute period, every
6 hours over the 1 week period of continuous ECG recording. Clenbuterol treatment
of animals with heart failure significantly increased baseline average heart rate be-
tween day 1–4 but there was no statistical difference between the groups thereafter
(Fig 5.5). These results suggest that clenbuterol may have a early, transient effect
on heart rate in failing hearts but no influence in the long-term.
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Fig. 5.5: Clenbuterol treatment of failing hearts significantly increased baseline heart rate
between day 1–4 but there was no significant difference between the groups thereafter.
(* p < 0.05)
Ventricular arrhythmia analysis was performed on a 1 hour continuous ECG
recording, every 5 hours, giving 4 time points over a 24 hour period. There was
high variability between the groups in the incidence of isolated VPBs (Fig 5.6 A;
Fig 5.7 A) with no statistically significant difference. However, there were no
salvos (couplets & triplets) (Fig 5.6 B, C; Fig 5.7 B, C) or non-sustained VT
(Fig 5.6 D, E; Fig 5.7 D) in the clenbuterol treated failing hearts. These results
suggest that despite the high variability between groups, clenbuterol did not increase
the incidence of ventricular arrhythmias at rest, in heart failure.
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Fig. 5.6: Representative traces of isolated VPBs (A), couplet (B), triplet (C) and monomor-
phic, non-sustained VT (D & E).
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Fig. 5.7: There was a large variability between in the incidence of isolated VPBs (A) be-
tween groups with no statistically significant difference. However there were no couplets (B),
triplets (C) or non-sustained VT in clenbuterol treated failing hearts (D) (4 animals per group
were studied).
5.2.3 Effects of clenbuterol on ex-vivo LV function
LV function of normally loaded and mechanically unloaded failing hearts, treated
with clenbuterol or saline, was assessed by ex-vivo pressure-volume relationship stud-
ies. LCA ligation reduced LV developed pressure and dP/dTmax (Fig 5.8 A, B).
Clenbuterol treatment or mechanical unloading alone did not affect these parame-
ters but the combination of both clenbuterol treatment and mechanical unloading of
failing hearts improved LV dP/dTmax (Fig 5.8 C, D). These results indicate that
the combination of clenbuterol and mechanical unloading enhances LV functional
recovery of failing hearts.
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Fig. 5.8: Pressure-volume relationship of sham operated and heart failure groups showing a
reduced LV developed pressure (A) and dP/dTmax (B) of failing hearts treated with saline.
The combination of clenbuterol treatment and mechanical unloading improved dP/dTmax (D)
but did not affect the LV developed pressure (C). Number of hearts per group: Sham+Sal=5,
HF+Sal=7, HF+Clen=8, HF+UN+Sal=7, HF+UN+Clen=8 (* p < 0.05, ** p < 0.01, ***
p < 0.001 HF+Sal vs Sham+Sal; § p < 0.05 HF+UN+Sal vs HF+UN+Clen).
5.2.4 Effects of clenbuterol on the unloading-induced cell
size reduction
2D cell surface area, length and width of LV cardiomyocytes from all experimental
groups were assessed by planimetry. After LCA ligation, cardiomyocyte hypertrophy
developed, as shown by an increase in cell surface area, length and width (Fig 5.9).
Clenbuterol treatment alone did not further increase cell size. Mechanical unloading
alone reduced cell size to normal values but clenbuterol treatment during unload-
ing limited this effect (Fig 5.9). These results indicate that clenbuterol limits
unloading-induced cell size reduction and supports the rationale of its use to limit
unloading-induced myocardial atrophy.
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Fig. 5.9: Heart failure induced myocyte hypertrophy, indicated by an increased cell area (A),
width (B) and length (C). Clenbuterol treatment limited unloading-induced normalization
of cell area by retaining cell length. Number of cells studied per group: Sham+Sal=173,
HF+Sal=106, HF+Clen=105, HF+UN+Sal=181, HF+UN+Clen=232 (** p < 0.01, *** p <
0.001).
5.2.5 Effects of clenbuterol on cardiomyocyte contractility
Cardiomyocyte contractility was assessed during field-stimulation by real time changes
of the sarcomere length. Sarcomere shortening and relaxation were impaired after
LCA ligation (Fig 5.10 A, Table 5.2) and were unaffected by mechanical un-
loading alone (Fig 5.10 C, Table 5.2). Clenbuterol treatment alone or in com-
bination with mechanical unloading improved sarcomere shortening and relaxation
(Fig 5.10 B, D, Table 5.2). These results indicate that mechanical unloading
alone did not affect the depressed cardiomyocyte contractility but clenbuterol com-
bined with mechanical unloading enhanced functional recovery.
5.2.6 Effects of clenbuterol on calcium cycling
Cytoplasmic [Ca2+] was assessed by measuring Indo-1 fluorescence ratio. Cardiomy-
ocyte Ca2+ cycling, following LCA ligation, was characterized by delayed Ca2+
release and extrusion. However, the Ca2+ transient amplitude was paradoxically
increased (Fig 5.10 A, Table 5.2). The increased Ca2+ transient amplitude was
accompanied by increased SR Ca2+ content with delayed removal in caffeine-induced
Ca2+ transient (Table 5.2) suggesting a reduced NCX contribution to Ca2+ extru-
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sion from the cytoplasm. Clenbuterol treatment alone did not affect Ca2+ transient
amplitude or SR Ca2+ content but normalized the delayed stimulation-induced and
caffeine-induced Ca2+ transient decline (Fig 5.10 B, Table 5.2). Mechanical un-
loading alone did not affect the Ca2+ transient kinetics or SR Ca2+ content but
induced a faster decline of the caffeine-induced Ca2+ transient (Table 5.2). The
combination of clenbuterol treatment and mechanical unloading of HF normalized
Ca2+ handling at cytoplasmic and SR levels (Fig 5.10 D, Table 5.2). These results
indicate that the combination of clenbuterol and mechanical unloading normalized
cardiomyocyte Ca2+ cycling.
5.2.7 Effects of clenbuterol on myofilament sensitivity to
calcium
Myofilament sensitivity to Ca2+ was assessed by sarcomere length-[Ca2+]i relation-
ship from simultaneously recorded Indo-1 fluorescence changes and sarcomere short-
ening of LV cardiomyocytes. The sarcomere shortening-Ca2+ transient hysteresis
loops showed that less contractility was produced for the same [Ca2+]i following
LCA ligation, suggesting reduced myofilament sensitivity to Ca2+ (Fig 5.11 E, Ta-
ble 5.2). Clenbuterol treatment alone or in combination with mechanical unloading
normalized this parameter. Mechanical unloading did not affect the depressed my-
ofilament sensitivity to Ca2+ (Fig 5.11 E, Table 5.2).
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Fig. 5.10: Simultaneously acquired sarcomere shortening and Indo-1 transients showing defective EC coupling in heart failure (A). Clenbuterol
treatment, with and without mechanical unloading, improved myocyte contractility and Ca2+ transient kinetics (B-D). Arrows highlight statistically
significant differences between groups (data shown in Table 5.2).
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Table 5.2: Contractile and Ca2+ handling parameters in experimental groups. (data in [ ] indicates number of cells studied) (∗p < 0.05, ∗∗p <
0.01, ∗∗∗p < 0.001, HF+Sal vs Sham+Sal; †p < 0.05, ††p < 0.01, †††p < 0.001 vs HF+Sal; §p < 0.05, §§p < 0.01, §§§p < 0.001, HF+UN+Sal vs
HF+UN+Clen)
Sham+Sal HF+Sal HF+Clen HF+UN+Sal HF+UN+Clen
1 Hz Sarcomere shortening
Baseline SL (µm) 1.70± 0.02 [46] 1.66± 0.01 [68]∗ 1.71± 0.01 [69]†† 1.66± 0.01 [38] 1.71± 0.01 [50]†† §
Amplitude (µm) 0.08± 0.01 [46] 0.07± 0.01 [68]∗ 0.1± 0.01 [69]††† 0.07± 0.01 [38] 0.1± 0.01 [50]††† §§§
Time to peak (ms) 86.9± 3.3 [46] 102.6± 2.6 [68]∗∗∗ 84.9± 2.3 [69]††† 97.8± 2.7 [38] 71.9± 1.7 [50]††† §§§
T50 relaxation (ms) 70.5± 5.7 [42] 91.2± 6.1 [65]∗ 53.6± 2.4 [68]††† 90.0± 6.2 [38] 46.0± 2.2 [50]††† §§§
1Hz Calcium transient
Baseline (Indo-1 ratio units) 0.31± 0.01 [45] 0.33± 0.01 [67]∗∗ 0.33± 0.01 [69] 0.31± 0.01 [38] 0.32± 0.01 [48]
Amplitude (Indo-1 ratio units) 0.12± 0.01 [45] 0.15± 0.01 [67]∗∗ 0.14± 0.01 [69] 0.14± 0.01 [38] 0.11± 0.01 [48]††† §§
Time to peak (ms) 33.1± 1.1 [45] 36.4± 0.6 [67]∗∗ 34.6± 0.7 [69] 34.9± 1.1 [38] 31.2± 0.7 [47]††† §§
T50 decay (ms) 70.9± 1.5 [45] 75.4± 1.4 [66]∗ 68.5± 1.1 [69]††† 74.3± 1.9 [38] 62.5± 1.4 [48]††† §§§
Indo-1 decay τ (ms) 76.4± 2.9 [45] 88.2± 3.4 [66]∗ 65.8± 2.2 [69]††† 83.1± 3.8 [38] 58.5± 1.3 [48]††† §§§
Caffeine induced Ca2+ transient
SR Ca2+ content (Indo-1 ratio units) 0.11± 0.01 [29] 0.14± 0.01 [43]∗∗ 0.14± 0.004 [41] 0.14± 0.01 [26] 0.11± 0.01 [34]† §
Indo-1 decay τ (s) 1.21± 0.08 [22] 1.44± 0.06 [42]∗ 1.21± 0.07 [35]†† 1.20± 0.07 [23]† 1.14± 0.07 [26]††
Myofilament sensitivity to Ca2+
Slope value (µm/ratio unit) 2.23±0.27 [35] 1.65±0.12 [66]∗ 2.36±0.18 [69] †† 1.42±0.13 [38] 2.13±0.2 [52]† §
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Fig. 5.11: Simultaneously acquired sarcomere shortening and Indo-1 transient traces (A)
were used to generate hysteresis loops (B) showing the relationship of sarcomere length (SL)
and cytoplasmic Ca2+ concentration, measured by Indo-1 (r.u - ratio units). The slope of a
regression line, fitted through the linear portion of the loop (C, D), was used as a measure of
myofilament sensitivity to Ca2+. Clenbuterol treatment improved the depressed myofilament
sensitivity to Ca2+ in heart failure, with and without mechanical unloading (data shown in
Table 5.2). (* p < 0.05, ** p < 0.01, *** p < 0.001)
5.2.8 Effects of clenbuterol on action potential prolongation
APD was assessed in current-clamp mode as described above. Following LCA liga-
tion, electrophysiological studies demonstrated increased action potential duration
at all frequencies compared to sham-operated controls (Fig 5.12 A). Clenbuterol
treatment did not affect the prolonged action potential duration. Mechanical un-
loading alone further prolonged the action potential duration at higher stimulation
frequency (APD90 at 5Hz (ms): HF+Sal 44.7±3.0 [51], HF+UN+Sal 63.0±4.8 [26];
p < 0.01) (Fig 5.12 A). The combination of clenbuterol treatment and mechanical
unloading normalized the prolonged action potential duration in HF at all frequen-
cies (Fig 5.12 A). These results indicate that clenbuterol combined with mechanical
unloading enhances recovery of deranged action potential properties.
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Fig. 5.12: Action potential duration was prolonged in heart failure and unaffected by clen-
buterol treatment (A). Mechanical unloading of failing hearts further prolonged action po-
tential duration at higher stimulation frequency which was normalized by clenbuterol treat-
ment. Clenbuterol normalized the unloading-induced reduction of I NCX (B). Inset showing
the voltage-clamp protocol used.
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5.2.9 Effects of clenbuterol on sodium-calcium exchanger
current
Clenbuterol normalized the delayed stimulation-induced and caffeine-induced Ca2+
transient decline suggesting an improved NCX contribution to Ca2+ extrusion from
the cytoplasm. Therefore I NCX was measured to test if clenbuterol affected the
biophysical properties of NCX. The I NCX was unchanged at all voltages tested in
cardiomyocytes from hearts following LCA ligation and unaffected by clenbuterol
treatment alone (Fig 5.12 B). Mechanical unloading reduced I NCX but this cur-
rent was partially restored by clenbuterol treatment (at +80 mV (pA/pF): HF+Sal
1.7±0.2 [30], HF+UN+Sal 0.9±0.1 [25], HF+UN+Clen 1.6±0.3 [21]; HF+Sal vs
HF+UN+Sal, p < 0.01; HF+Sal vs HF+UN+Clen, p = NS) (Fig 5.12 B). These
results indicate that clenbuterol partially prevents the reduction of NCX activity
associated with mechanical unloading.
5.2.10 Effects of clenbuterol on L-type calcium current
HF reduced peak I Ca,L (Fig 5.13 B) and resulted in slower inactivation times
(Fig 5.13 E, F) which may partially account for delayed Ca2+ release of the Ca2+
transient and the prolonged APD90 respectively. Clenbuterol treatment alone or
in combination with mechanical unloading did not affect the I Ca,L properties. Me-
chanical unloading alone of failing hearts did not affect the peak I Ca,L but normal-
ized slower I Ca,L inactivation times seen in HF (τfast (ms): Sham+Sal 7.2±0.6 [43],
HF+UN+Sal 5.5±0.4 [23]; p < 0.05; τslow (ms): Sham+Sal 31.2±2.0 [43], HF+UN+Sal
27.3±2.0 [23]; p < 0.05) (Fig 5.13 E, F). These results indicate that clenbuterol
does not affect L-type calcium current.
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Fig. 5.13: I Ca,L activation and inactivation properties were studied using the protocols A
and B respectively. Heart failure reduced peak I Ca,L as shown by I-V relationship (B) pro-
longed inactivation times (E, F) which were unaffected by clenbuterol treatment. Mechanical
unloading normalized the prolonged inactivation times with no additional affect by clenbuterol
treatment. The conductance / conductancemax relationship of all groups was unchanged (D).
(* p < 0.05, ** p < 0.01)
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5.2.11 Effects of clenbuterol and mechanical unloading on
Ca2+ cycling and β2-AR coupled, Gαi protein expres-
sion
Clenbuterol normalized the delayed stimulation-induced and caffeine-induced Ca2+
transient decline suggesting an improved NCX contribution to Ca2+ extrusion from
the cytoplasm. Also, clenbuterol combined with mechanical unloading improves
NCX activity, demonstrated by a partially restored I NCX . To clarify the contri-
bution of NCX protein abundance on the above observations, NCX protein expres-
sion was assessed by western blotting. NCX protein abundance was unaffected in
heart failure but reduced during clenbuterol treatment (Fig 5.14 A). Mechanical
unloading alone of failing hearts further reduced NCX protein levels. However,
clenbuterol treatment of failing hearts combined with mechanical unloading, lim-
ited the unloading-induced reduction (Fig 5.14 A). These results suggest that the
improved NCX contribution to Ca2+ extrusion from the cytoplasm, seen after clen-
buterol treatment of failing hearts, is possibly due to other mechanisms such as
altered phosphorylation state of NCX (Wei et al. 2003), [Na+]i (Bers et al. 2006;
Pieske & Houser 2003) and SR Ca2+ uptake. The unloading-induced reduction in
NCX protein abundance, improved by clenbuterol treatment (Fig 5.14 A), may
explain the similar trend in NCX activity, assessed by I NCX (Fig 5.12 B).
Clenbuterol treatment alone or in combination with mechanical unloading nor-
malized depressed myofilament sensitivity to Ca2+ (Fig 5.11 E, Table 5.2). To
identify the mechanisms underlying this observation, protein expression levels of
troponin I, a key regulator of myofilament sensitivity to Ca2+ (LeWinter 2005),
were studied by western blotting. There was a reduction in troponin I in heart fail-
ure which was further reduced after mechanical unloading, unaffected by clenbuterol
treatment (Fig 5.14 B). However, there was increased abundance of phosphorylated
troponin I following clenbuterol treatment, with and without mechanical unloading
(Fig 5.14 C). Troponin I, an inhibitory subunit of troponin, can be phosphorylated
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in response to β-AR stimulation by PKA and PKC at Serine 23/24 sites (Ward et al.
2002). This phosphorylation stimulates a conformational change of the regulatory
domain of troponin C, reduces association between troponin I and troponin C, and
reduces myofilament sensitivity to Ca2+ by reducing the Ca2+-binding affinity of
troponin C (Ward et al. 2002; Noland et al. 1995; Gaponenko et al. 1999). These
results suggest this mechanism is unlikely to be important in the improved myofil-
ament sensitivity to Ca2+ seen in this study (Table 5.2). It is likely that other
mechanisms, like phosphorylation of myosin light chain 2 (MLC2) which can coun-
teract the negative effect of troponin I phosphorylation on myofilament sensitivity
to Ca2+ (Lamberts et al. 2007), may be responsible for the improvement seen after
clenbuterol treatment.
Under normal conditions β1-AR stimulation activate exclusively the Gs pathway
and stimulation of cardiac β2-AR activates both Gs and pertussis toxin (PTX)-
sensitive Gi pathways (Kuschel et al. 1999a; Chen-Izu et al. 2000; Xiao et al. 2004).
Gαi protein expression, which is known to increase in murine heart failure and corre-
late closely with severity of impaired cardiac function (Shi et al. 1995), was studied
to assess the effects of selective β2-AR stimulation and mechanical unloading in heart
failure. Clenbuterol treatment normalized the unloading-induced reduction of Gαi
expression levels (Fig 5.14 D). These results suggest that clenbuterol treatment
improves Gαi expression levels in unloaded myocardium of failing hearts. Although
not tested in the present study, it is possible that this may have beneficial effects of
Gi-mediated signaling in failing hearts (Xiao 2001; Xiao et al. 2004).
5.2.12 Effects of clenbuterol on myosin heavy chain isoform
changes
Heart failure (Gupta 2007) and mechanical unloading (Oriyanhan et al. 2007) are
known to induce a shift in the expression of MHC isoforms. This can be a reason for
changes in the myofilament sensitivity to Ca2+. Gene expression of α- and β-MHC
were measured by RT-PCR. There was a reduction in α-MHC RNA expression in
254
A. B.
C. D.
NCX
S
ha
m
+S
al
H
F+
S
al
H
F+
C
le
n
H
F+
U
N
+S
al
H
F+
U
N
+C
le
n
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
**
***
***
NS
***
n
o
rm
a
li
s
e
d
 t
o
 t
o
ta
l 
p
ro
te
in
re
a
c
ti
v
it
y
 (
ra
ti
o
 u
n
it
s
)
Troponin I
S
ha
m
+S
al
H
F+
S
al
H
F+
C
le
n
H
F+
U
N
+S
al
H
F+
U
N
+C
le
n
0.0
0.1
0.2
0.3 ***
**
NS
n
o
rm
a
li
s
e
d
 t
o
 t
o
ta
l 
p
ro
te
in
re
a
c
ti
v
it
y
 (
ra
ti
o
 u
n
it
s
)
phosphorylated Troponin I
S
ha
m
+S
al
H
F+
Sa
l
H
F+
C
le
n
H
F+
U
N
+S
al
H
F+
U
N
+C
le
n
0.0
0.1
0.2
0.3
0.4
0.5
0.6
**
***
*
*
n
o
rm
a
li
s
e
d
 t
o
 t
o
ta
l 
p
ro
te
in
re
a
c
ti
v
it
y
 (
ra
ti
o
 u
n
it
s
)
S
ha
m
+S
al
H
F+
Sa
l
H
F+
C
le
n
H
F+
U
N
+S
al
H
F+
U
N
+C
le
n
0.0
0.1
0.2
0.3
0.4
0.5
*
*
Gα i
NS
NS
n
o
rm
a
li
s
e
d
 t
o
 t
o
ta
l 
p
ro
te
in
re
a
c
ti
v
it
y
 (
ra
ti
o
 u
n
it
s
)
Fig. 5.14: Effects of clenbuterol treatment and mechanical unloading on Ca2+ cycling and
β2-AR coupled, Gαi protein expression. (* p < 0.05, ** p < 0.01, *** p < 0.001)
heart failure, which was further reduced by mechanical unloading ((relative mRNA
expression): Sham+Sal 1.58±0.14 [6], HF+Sal 0.93±0.06 [6]; p < 0.01; HF+UN+Sal
0.31±0.13 [5] vs HF+Sal; p < 0.001). β-MHC expression was unchanged in heart
failure and mechanical unloading. The ratio of α-MHC/β-MHC confirmed a re-
duction in relative α-MHC expression in heart failure and mechanical unloading
((relative mRNA expression): Sham+Sal 2.05±0.31 [6], HF+Sal 0.83±0.25 [6];
p < 0.05; HF+UN+Sal 0.14±0.05 [5] vs HF+Sal; p < 0.05). Clenbuterol treatment
had no further effect on the relative α-MHC isoform expression changes ((relative
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mRNA expression): HF+Sal vs HF+Clen 0.63±0.12 [5]; p = NS; HF+UN+Sal vs
HF+UN+Clen 0.15±0.05 [4]; p = NS). This suggests that improved myofilament
sensitivity to Ca2+ seen after clenbuterol treatment is unlikely to be due to changes
in MHC isoform expression.
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5.3 Discussion
The results described in this Chapter demonstrate that depressed whole-heart and
cellular contractile function observed in heart failure can be improved by chronic ad-
ministration of β2-AR agonist clenbuterol. At whole heart level in-vivo, clenbuterol
improves LVEF and, when combined with mechanical unloading, it also improves
ex-vivo dP/dTmax. At a cellular level, depressed sarcomere contractility is restored
to normal values in heart failure by clenbuterol treatment, with or without mechan-
ical unloading. Clenbuterol affects cell size, EC coupling, ion channel function and
action potential properties but the cellular functional improvement can be ascribed
particularly to the normalization of myofilament sensitivity to Ca2+. Mechanical
unloading alone has no effects on the depressed sarcomere shortening or whole heart
function.
5.3.1 β2-AR agonists and ECG changes
The results from ECG analysis of failing hearts indicate that clenbuterol may have a
transient effect on heart rate in failing rat hearts. However physiological parameters
during the early post-operative period must be interpreted with caution as the ani-
mals may still be stressed from the surgical procedures, with variable catecholamine
levels. The results described in Chapter 3 show a sustained elevation in baseline
heart rate of rats with normal heart function, treated with clenbuterol throughout
the 4 week period (Fig. 3.4 A, Page 179). It is possible that clenbuterol may have
no further effect on heart rate in heart failure with pre-existing tachycardia due to
an over-active sympathetic system and elevated catecholamine levels (Anker et al.
1997; Macefield et al. 1999).
Clenbuterol-induced tachycardia is well known in humans, following clinical (Di
Gioacchino et al. 1987; Meinen et al. 1988; Birks et al. 2006) and toxic doses (Hoff-
man et al. 2001; Barbosa et al. 2005; Daubert et al. 2007), treatable by specific β1-AR
blockade (Birks et al. 2006; Hoffman et al. 2001). It is possible that the mode of
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action of clenbuterol may vary in different species based on the relative distribution
of the β-AR sub-type.
A meta-analysis of randomized controlled studies in patients with obstructive air-
ways disease suggests that there may be increased risk of adverse cardiac events in
this population following administration of β2-AR agonists (Salpeter 2004). Orally
administered salbutamol to patients with advanced congestive heart failure was as-
sociated with ventricular tachycardia and atrial fibrillation (Mettauer et al. 1985).
Cazzola et al. (1998) reported that β2-AR agonists may increase the incidence of
cardiac arrhythmias in patients with preexisting cardiac arrhythmias. However, the
results from this study indicate that clenbuterol did not have any significant effect
on the incidence of arrhythmias, despite the high variability between the groups.
Although the incidence of arrhythmias were not different between the groups when
the animals were at rest, it would be interesting to know if there was a difference
during stressed states, such as exercise with a high catecholamine levels (Cerrone
et al. 2005; Liu et al. 2006; Wehrens et al. 2003).
5.3.2 β2-AR agonists and heart failure
Heart failure causes derangements of β-AR signalling pathways (Lohse et al. 2003).
There is evidence that the β2-AR–Gi subtype specific stimulation has cardioprotec-
tive effects and beneficial functional consequences in rodent ischaemic cardiomyopa-
thy and may also be enhanced when combined with β1-AR blockade (Ahmet et al.
2004, 2005; Xydas et al. 2006a). The results in this Chapter demonstrate whole-
heart and cellular function improvement with the β2-AR agonist clenbuterol without
mechanical unloading. Xydas et al. (2006a) have shown an improvement in ex-vivo
end diastolic pressure-volume relationship in failing hearts treated for 9 weeks with
clenbuterol compared to β1-AR blocker metoprolol. In a study from this laboratory,
it has been shown that acute application of clenbuterol on isolated ventricular car-
diomyocytes predominantly activates the β2-AR–Gi pathway (Siedlecka et al. 2008).
The results in this Chapter show that chronic clenbuterol treatment normalized
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the unloading-induced reduction of Gαi protein expression levels (Fig 5.14 D). Al-
though not tested in the present study, this may explain the cardioprotective effects
observed.
The role of β2-AR stimulation during mechanical unloading is also complex.
While mechanical unloading is known to restore β-AR responsiveness and density
in heart failure (Ogletree-Hughes et al. 2001) and increase β2-AR mRNA expression
(Tsuneyoshi et al. 2005a), it has been shown that adenoviral gene transfer of a β2-AR
transgene in unloaded rabbit hearts further improved myocardial function (Tevaearai
et al. 2002). The results described in this Chapter further support the use of β2-AR
stimulation during mechanical unloading to improve myocardial function.
The ability of clenbuterol to induce structural changes to the myocardium is
controversial. Burniston et al. (2005) have shown a dose-dependent, β1-AR medi-
ated, clenbuterol-induced myocardial apoptosis, necrosis and collagen content in the
heart and skeletal muscle of the rat after clenbuterol administration. Although the
β1-AR was not selectively blocked in this study, it is possible to predict that this
strategy would further improve the beneficial effects of clenbuterol during mechani-
cal unloading in heart failure. Based on the above rationale to maximize the β2-AR
mediated beneficial effects of clenbuterol during mechanical unloading, bisoprolol
a selective β1-AR blocker, is used in combination with clenbuterol in the patients
treated with LVADs (Birks et al. 2006). Other studies have shown that clenbuterol
administration has a beneficial effect on fibrosis and apoptosis. Wong et al. (1997)
have shown that clenbuterol administration in conjunction with pressure overload
by aortic banding in rats increases LV mass with less fibrosis and collagen content
(Wong et al. 1998a) than banding alone. George et al. (2006) report no change in
collagen content in heart failure patients treated with clenbuterol during mechanical
unloading by LVAD.
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5.3.3 Clenbuterol and unloading-induced myocyte atrophy
Myocardial atrophy is an important consequence of mechanical unloading and has
been demonstrated in both human (Maybaum et al. 2007) and animal (Rakusan
et al. 1997) studies. This is likely to be an important limiting factor for improving
myocardial recovery and forms the basis for use of clenbuterol in patients treated
with LVADs in order to improve explantation rate for ‘bridge to recovery’ (Yacoub
2001). The results described in Chapter 3 (Fig. 3.5) show that clenbuterol increases
cardiomyocyte size in normal hearts and, in Chapters 4 & 5 limits cell size reduc-
tion after mechanical unloading in normal (Fig 4.8) and failing hearts (Fig 5.9).
In contrast, Tsuneyoshi et al. (2005b) found that clenbuterol could not prevent at-
rophy during mechanical unloading of a normal rat heart for 2 weeks. This may
suggest that myocyte hypertrophy, induced by heart failure, may be a prerequisite
for the effects of clenbuterol during mechanical unloading. It should be noted that
cell size was assessed after unloading for 1 week. It is known that longer dura-
tion of unloading in failing human (Maybaum et al. 2007) and animal (Oriyanhan
et al. 2007) hearts can deleteriously affect whole-heart and cardiomyocyte function,
despite regression of myocyte hypertrophy. Testing whether clenbuterol administra-
tion is beneficial when used during longer periods of mechanical unloading of failing
hearts would be of interest. Clenbuterol may have an important role in providing
an early phase of protection, delaying the onset or preventing unloading-induced
atrophy. To elucidate these points, further studies are required.
Clenbuterol treatment during mechanical unloading limits cardiomyocyte atro-
phy by a preferential retention of cell length than width (Fig 5.9). This may indicate
a different form of hypertrophy induced by clenbuterol, which has been proposed
to be more “physiological” (Petrou et al. 1995; Ghorayeb et al. 2005; Kong et al.
2005; Wong et al. 1998a, 1997; Hon et al. 2001). In addition, in the unloaded my-
ocardium, there is the association with the atrophic response of the myocytes and
this can explain the morphological differences observed. More studies are required
to investigate this point.
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5.3.4 Clenbuterol and excitation-contraction coupling
Twitch Ca2+ transient amplitude and SR Ca2+ content are generally reduced in
human (Gwathmey et al. 1987) and animal models of heart failure (Li et al. 1995).
However some studies in animal models have also shown unchanged (Anand et al.
1997) or increased (Loennechen et al. 2002) Ca2+ transient amplitude with altered
contractility. Similar to the results described in this Chapter, Loennechen et al.
(2002) have shown an increased diastolic and systolic Ca2+ transient at 1, 4 and
13 weeks post-infarction in a rat model. Vahl et al. (1994) have demonstrated the
after-load dependence of the Ca2+ transient amplitude in human heart failure. They
attribute this to an increased dissociation of Ca2+ from the contractile proteins,
defective Ca2+ reuptake of the SR or an increased Ca2+ inflow via Ca2+ channels.
The differing results in Ca2+ transient kinetics in the above studies may depend on
the model of heart failure and experimental conditions. The paradoxical increased
Ca2+ transient amplitude and SR Ca2+ content with reduced sarcomere shortening
amplitude seen in this model of post-infarction cardiomyopathy may indicate an
intermediate stage in the development of heart failure with pathological hypertrophy,
reduced contractile function and defective myofilament sensitivity to Ca2+.
An increased Ca2+ transient may result from a reduced function of NCX and
consequent increased Ca2+ load of the SR in the presence of maintained SR Ca2+
uptake. The mechanisms by which NCX is involved in the improvement are un-
clear. It is possible that NCX has a compensatory rather than a causal role in
the improvement observed. Other Ca2+ regulatory mechanisms, such as SR Ca2+
uptake, and factors that regulate NCX activity, such as [Na+]i (Bers et al. 2006;
Pieske & Houser 2003) and phosphorylation (Wei et al. 2003), can be involved.
NCX mediated-Ca2+ extrusion was faster in unloaded myocytes with or without
clenbuterol. In the clenbuterol-treated group the biophysical properties of NCX
(assessed as I NCX) were directly affected. Some of these changes may be partly
explained by altered NCX protein abundance (Fig 5.14 A) but more studies are
required to investigate this point.
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The prolongation of the action potential in heart failure may also contribute to
the increased SR Ca2+ loading and increase the twitch Ca2+ transient amplitude
(Terracciano et al. 1997) as seen in our study. Mechanical unloading alone did not
affect the deranged cardiomyocyte contractility or Ca2+ cycling of failing hearts in
our study. This might be due to the short duration of unloading as suggested by Ito
et al. (2003).
There was a delayed time course of both twitch and caffeine-induced Ca2+ re-
moval in myocytes from failing hearts which were improved by clenbuterol treatment
alone and in combination with mechanical unloading (Table 5.2). A number of
factors can explain this behavior. In the group treated with clenbuterol alone the
NCX contribution to Ca2+ removal may be increased due to changes in intracellular
[Na+] as discussed above. In the group with clenbuterol and mechanical unloading
the shortening of the action potential and increased NCX current density could also
be important. Finally the contribution of the SR Ca2+ uptake, which has not been
addressed in this study, may also play an important role.
5.3.5 Clenbuterol and myofilament sensitivity to calcium
Abnormal myofilament function contributes significantly to contractile dysfunction
in chronic heart failure although its relative importance compared to altered Ca2+
homeostasis is currently debated (Day et al. 2007). In the heart failure model used
in this thesis, there was depressed myofilament Ca2+ sensitivity. Clenbuterol treat-
ment normalized this depressed myofilament Ca2+ sensitivity irrespective of whether
it was associated to mechanical unloading (Fig 5.11 E, Table 5.2). This may be a
key mechanism involved in the ability of clenbuterol to improve contractile function
at cellular level. The results in this Chapter suggest that improved myofilament
sensitivity to Ca2+ seen after clenbuterol treatment is not due to the effects of clen-
buterol on MHC expression (Section 5.2.12, Page 254) or phosphorylation states of
troponin-I (Fig 5.14 C). It is possible that clenbuterol affects other key mechanisms
like phosphorylation of MLC2 which can counteract the negative effect of troponin I
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phosphorylation on myofilament sensitivity to Ca2+ (Lamberts et al. 2007), abun-
dance and phosphorylation states of myosin binding protein-C (Tong et al. 2004;
Calaghan et al. 2000; Pohlmann et al. 2007), which may be responsible for the
improvement seen after clenbuterol treatment.
One possible limitation in the results described in this thesis is that myofilament
sensitivity to Ca2+ was estimated by assessing the relationship between sarcomere
shortening and Indo-1 fluorescence. Calibration of the fluorescence signals to quan-
tify cytoplasmic [Ca2+] was not performed. While this can be a possible source of
error, the relationship between Indo-1 fluorescence ratio and cytoplasmic [Ca2+] is
sufficiently linear in the range of measurements reported (20% to 80% of Ca tran-
sients) (Bassani et al. 1995a; Levi et al. 1996) to allow comparisons between groups.
The results in this Chapter show that clenbuterol affects cell size, EC coupling,
ion channel function and action potential properties and normalizes myofilament
sensitivity to Ca2+. The combination of all the above changes, rather than changes
in a single parameter, may lead to improved cellular and whole-heart function. The
temporal and causal relationship of the changes in relation to contractile functional
improvement is a challenging point that requires further studies.
In conclusion, the treatment of failing hearts with clenbuterol, alone or in combi-
nation with mechanical unloading, improves LV function at whole-heart and cellular
level.
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Chapter 6
Concluding remarks
The results described in this thesis show that chronic administration of clenbuterol
alters myocardial structure and function in normal / non-failing rat hearts, with
and without mechanical unloading. More specifically, chronic administration of
clenbuterol has significant physiological effects, induces altered Ca2+ regulation of
rat hearts that accompany organ and cellular hypertrophy.
The treatment of failing hearts with clenbuterol, alone or in combination with
mechanical unloading, improves LV function at whole-heart and cellular level by
effects on cell morphology, EC coupling and myofilament sensitivity to calcium.
Together, these findings provide the first direct evidence that treatment with the
β2-AR agonist clenbuterol, during mechanical unloading of failing hearts is beneficial
in countering some of the deleterious effects of mechanical unloading alone. These
findings support the use of clenbuterol in the strategy to improve recovery in heart
failure patients treated with LVADs and also begins to elucidate some of the possible
cellular mechanisms responsible for the improvement in LV function.
What are the main limitations of the thesis? Some of the limitations in in-
terpreting the results from this thesis and extrapolating to them to human
heart failure may be due to the differences in murine and human physiology
and disease pathogenesis. Also the choice of model of heart failure, degree
of heart failure, durations of clenbuterol treatment and mechanical unloading
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may also compound the difficulty in interpretation. The logic and rationale
underlying the experimental design, including practical considerations, have
discussed in detail on Page 98.
Although the improved ‘bridge-to-recovery’ rate using ‘combination therapy’
involves various other pharmacological agents (see Page 84), only the role of
clenbuterol has been tested in this thesis. Experiments testing all the phar-
macological agents were not undertaken due to practical constraints.
Despite the above limitations, these results provide the first direct evidence
that pathophysiology of failing hearts, especially during mechanical unloading,
can be altered by combined β2-AR agonist treatment.
What are the future experiments that might be helpful? Some of the inter-
esting findings and questions raised in the course of this thesis could be tested
in future experiments. Firstly, it would be interesting to study the effects of
clenbuterol during prolonged periods of unloading (>1 week) of failing hearts
which may be more representative of the clinical scenario.
Whether the improvements seen after clenbuterol treatment can be further en-
hanced by combining with β1-AR blockade, to minimize the deleterious effects
of chronic β1-AR stimulation, remains to be studied. Also, selective reduction
of clenbuterol-induced tachycardia by pharmacological sinus node inhibition
using ivabradine (Mulder et al. 2004) may also have additive benefits during
remodelling process in heart failure.
One of the key findings includes clenbuterol-induced improvement in myofila-
ment sensitivity to Ca2+ in chronically unloaded and failing hearts. However,
the exact mechanism by which this improvement occurs has not been studied.
One of the possible mechanisms may include phosphorylation of MLC2 which
can counteract the negative effect of troponin I phosphorylation on myofila-
ment sensitivity to Ca2+ (see Page 262). It would be interesting to study the
effects of clenbuterol on MLC2 expression and phosphorylation.
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It would be desirable to study the role of clenbuterol on failing hearts us-
ing large animal models of heart failure and mechanical unloading using im-
plantable mechanical circulatory assist devices.
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